Pfizer (PFE) 10-K 22 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2017	Feb. 20, 2018	Jul. 02, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	PFIZER INC.
Entity Central Index Key	78,003
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false
Trading Symbol	PFE
Entity Common Stock, Shares Outstanding		5,952,864,751
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 200

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016		Dec. 31, 2015
Income Statement [Abstract]
Revenues	[1]	$ 52,546	$ 52,824		$ 48,851
Costs and expenses:
Cost of sales	[1],[2]	11,240	12,329		9,648
Selling, informational and administrative expenses	[1],[2]	14,784	14,837		14,809
Research and development expenses	[1],[2]	7,657	7,872		7,690
Amortization of intangible assets	[1]	4,758	4,056		3,728
Restructuring charges and certain acquisition-related costs	[1]	487	1,724		1,152
Other (income)/deductions––net	[1]	1,315	3,655		2,860
Income from continuing operations before provision/(benefit) for taxes on income	[1],[3],[4],[5]	12,305	8,351		8,965
Provision/(benefit) for taxes on income	[1]	(9,049)	1,123		1,990
Income from continuing operations	[1]	21,353	7,229		6,975
Discontinued operations:
Income from discontinued operations––net of tax	[1]	(1)	16		17
Gain/(loss) on disposal of discontinued operations––net of tax	[1]	3	0		(6)
Discontinued operations––net of tax	[1]	2	17		11
Net income before allocation to noncontrolling interests	[1],[6],[7],[8]	21,355	7,246		6,986
Less: Net income attributable to noncontrolling interests	[1]	47	31		26
Net income attributable to Pfizer Inc.	[1]	$ 21,308	$ 7,215		$ 6,960
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 3.57	$ 1.18		$ 1.13
Discontinued operations––net of tax (in dollars per share)	[1]	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	3.57	1.18		1.13
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	3.52	1.17		1.11
Discontinued operations––net of tax (in dollars per share)	[1]	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 3.52	$ 1.17		$ 1.11
Weighted-average shares––basic	[1],[9]	5,970	6,089		6,176
Weighted-average shares––diluted	[1]	6,058	6,159	[9]	6,257	[9]
Cash dividends paid per common share (in dollars per share)	[1]	$ 1.28	$ 1.2		$ 1.12
[1]	Amounts may not add due to rounding.
[2]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.
[3]	2016 v. 2015––The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs.
[4]	2017 v. 2016––The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower certain asset impairments and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in international income was primarily due to the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower restructuring charges and certain acquisition-related costs, and lower certain asset impairments.
[5]	Income from continuing operations before provision/(benefit) for taxes on income. IH’s earnings in 2017 include dividend income of $266 million from our investment in ViiV. For additional information, see Note 4.
[6]	Amounts may not add due to rounding.
[7]	Amounts may not add due to rounding.
[8]	Amounts may not add due to rounding.
[9]	2017 shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 21,355	$ 7,246	$ 6,986
Foreign currency translation adjustments, net	[1]	1,116	(815)	(3,110)
Reclassification adjustments	[1],[5]	162	0	0
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total	[1]	1,278	(815)	(3,110)
Unrealized holding gains/(losses) on derivative financial instruments, net	[1]	(10)	(442)	204
Reclassification adjustments for (gains)/losses included in net income	[1],[6]	(520)	452	(368)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[1]	(530)	10	(165)
Unrealized holding gains/(losses) on available-for-sale securities, net	[1]	818	248	(846)
Reclassification adjustments for (gains)/losses included in net income	[1],[6]	(244)	(118)	796
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total	[1]	574	130	(50)
Benefit plans: actuarial losses, net	[1]	(212)	(1,888)	(37)
Reclassification adjustments related to amortization	[1],[7]	588	558	550
Reclassification adjustments related to settlements, net	[1],[7]	117	127	671
Other	[1]	(145)	195	199
Defined benefit Plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[1]	348	(1,009)	1,383
Benefit plans: prior service (costs)/credits and other, net	[1]	(2)	184	432
Reclassification adjustments related to amortization	[1],[7]	(184)	(173)	(160)
Reclassification adjustments related to curtailments, net	[1],[7]	(18)	(26)	(32)
Other	[1]	0	6	(3)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[1]	(203)	(8)	237
Other comprehensive income/(loss), before tax	[1]	1,468	(1,692)	(1,705)
Tax provision/(benefit) on other comprehensive income/(loss)	[1],[8]	(262)	(174)	528
Other comprehensive income/(loss) before allocation to noncontrolling interests	[1],[4]	1,730	(1,518)	(2,232)
Comprehensive income before allocation to noncontrolling interests	[1]	23,085	5,728	4,754
Less: Comprehensive income/(loss) attributable to noncontrolling interests	[1]	62	28	(1)
Comprehensive income attributable to Pfizer Inc.	[1]	$ 23,023	$ 5,701	$ 4,755
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	The foreign currency translation adjustments reclassified into Other (income)/deductions—net in the consolidated statement of income primarily result from sale of our 40% ownership investment in Teuto and the sale of our 49% equity share in Hisun Pfizer. See Note 2D. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment: Equity-Method Investments.
[6]	Reclassified into Other (income)/deductions—net and Cost of sales in the consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[7]	Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the consolidated statements of income. For additional information, see Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.
[8]	See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

Consolidated Statements of Com4

Consolidated Statements of Comprehensive Income (Parenthetical)	Nov. 10, 2017	Jun. 30, 2017	Dec. 31, 2016
Laboratorio Teuto Brasilero [Member]
Equity method investment, ownership percentage		40.00%	40.00%
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Equity method investment, ownership percentage	49.00%		49.00%

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	[1],[2]	$ 1,342	$ 2,595
Short-term investments	[1]	18,650	15,255
Trade accounts receivable, less allowance for doubtful accounts: 2017—$584; 2016—$609	[1]	8,221	8,225
Inventories	[1],[3]	7,578	6,783
Current tax assets	[1]	3,050	3,041
Other current assets	[1]	2,289	2,249
Assets held for sale	[1]	12	801
Total current assets	[1]	41,141	38,949
Long-term investments	[1]	7,015	7,116
Property, plant and equipment, less accumulated depreciation	[1],[4]	13,865	13,318
Identifiable intangible assets, less accumulated amortization	[1],[5]	48,741	52,648
Goodwill	[1]	55,952	54,449
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,855	1,812
Other noncurrent assets	[1]	3,227	3,323
Total assets	[1]	171,797	171,615
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2017—$3,546; 2016—$4,225	[1]	9,953	10,688
Trade accounts payable	[1]	4,656	4,536
Dividends payable	[1]	2,029	1,944
Income taxes payable	[1]	477	437
Accrued compensation and related items	[1]	2,196	2,487
Other current liabilities	[1]	11,115	11,023
Total current liabilities	[1]	30,427	31,115
Long-term debt	[1]	33,538	31,398
Pension benefit obligations, net	[1]	5,926	6,406
Postretirement benefit obligations, net	[1]	1,504	1,766
Noncurrent deferred tax liabilities	[1]	3,900	30,753
Other taxes payable	[1]	18,697	4,000
Other noncurrent liabilities	[1]	6,149	6,337
Total liabilities	[1]	100,141	111,776
Commitments and Contingencies	[1]
Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2017—-524; 2016—-597	[1]	21	24
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2017—-9,275; 2016—-9,230	[1]	464	461
Additional paid-in capital	[1]	84,278	82,685
Treasury stock, shares at cost: 2017—3,296; 2016—-3,160	[1]	(89,425)	(84,364)
Retained earnings	[1]	85,291	71,774
Accumulated other comprehensive loss	[1]	(9,321)	(11,036)
Total Pfizer Inc. shareholders’ equity	[1]	71,308	59,544
Equity attributable to noncontrolling interests	[1]	348	296
Total equity	[1],[6]	71,656	59,840
Total liabilities and equity	[1]	$ 171,797	$ 171,615
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, as well as an increase due to foreign exchange.
[4]	The increase in total property, plant and equipment is primarily due to capital additions and the impact of foreign exchange, partially offset by depreciation, reductions due to restructuring efforts and disposals.
[5]	The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to (i) amortization, (ii) measurement period adjustments related to Medivation (see Note 2A), as well as (iii) impairments of Developed technology rights (see Note 4), partially offset by (iv) assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (v) the assets recorded in connection with the EU and U.S. approvals of Besponsa and in connection with the U.S. approval of Bosulif (see Note 7E) and (vi) the assets recorded in connection with the approvals of Bavencio (see Note 2C).
[6]	Amounts may not add due to rounding.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	[1]	$ 584	$ 609
Short term borrowings, current portion of long term debt	[1]	$ 3,546	$ 4,225
Preferred stock, shares authorized	[1]	27,000,000	27,000,000
Preferred stock, shares issued	[1]	524	597
Common stock, par value (in dollars per share)	[1]	$ 0.05	$ 0.05
Common stock, shares authorized	[1]	12,000,000,000	12,000,000,000
Common stock, shares issued	[1]	9,275,000,000	9,230,000,000
Treasury stock, shares at cost	[1]	3,296,000,000	3,160,000,000
[1]	Amounts may not add due to rounding.

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions		Total		Shareholders’ Equity	Preferred Stock [Member]	Common Stock [Member]	Add’l Paid-In Capital [Member]	Treasury Stock [Member]		Retained Earnings [Member]	Accum. Other Comp. Loss [Member]	Non-controlling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2014	[1]				717	9,110,000,000		2,819,000,000
Beginning balance at Dec. 31, 2014	[1]	$ 71,622		$ 71,301	$ 29	$ 455	$ 78,977	$ (73,021)		$ 72,176	$ (7,316)	$ 321
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	6,986	[2],[3],[4]	6,960						6,960		26
Other comprehensive income/(loss), net of tax	[1]	(2,232)	[2]	(2,206)							(2,206)	(26)
Cash dividends declared:
Common stock	[1]	(7,141)		(7,141)						(7,141)
Preferred stock	[1]	(2)		(2)						(2)
Noncontrolling interests	[1]	(16)										(16)
Share-based payment transactions (in shares)	[1]					67,000,000		(1,000,000)
Share-based payment transactions	[1]	$ 1,946		1,946		$ 3	2,015	$ (72)
Purchases of common stock (in shares)		(182,000,000)	[5]					(182,000,000)	[1]
Purchases of common stock	[1]	$ (6,160)	[5]	(6,160)				$ (6,160)
Preferred stock conversions and redemptions (in shares)	[1]				(68)
Preferred stock conversions and redemptions	[1]	(5)		(5)	$ (3)		(3)	$ 1
Other	[1]			27			27					(27)
Ending balance (in shares) at Dec. 31, 2015	[1]				649	9,178,000,000		3,003,000,000
Ending balance at Dec. 31, 2015	[1]	64,998		64,720	$ 26	$ 459	81,016	$ (79,252)		71,993	(9,522)	278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	7,246	[2],[3],[4]	7,215						7,215		31
Other comprehensive income/(loss), net of tax	[1]	(1,518)	[2]	(1,514)							(1,514)	(3)
Cash dividends declared:
Common stock	[1]	(7,446)		(7,446)						(7,446)
Preferred stock	[1]	(2)		(2)						(2)
Noncontrolling interests	[1]	(10)										(10)
Share-based payment transactions (in shares)	[1]					52,000,000		(3,000,000)
Share-based payment transactions	[1]	$ 1,563		1,563		$ 3	1,672	$ (111)
Purchases of common stock (in shares)		(154,000,000)	[6]					(154,000,000)	[1]
Purchases of common stock	[1]	$ (5,000)	[6]	(5,000)				$ (5,000)
Preferred stock conversions and redemptions (in shares)	[1]				(52)
Preferred stock conversions and redemptions	[1]	(5)		(5)	$ (2)		(2)
Other	[1],[7]	13		13						13
Ending balance (in shares) at Dec. 31, 2016	[1]				597	9,230,000,000		3,160,000,000
Ending balance at Dec. 31, 2016	[1]	59,840	[8]	59,544	$ 24	$ 461	82,685	$ (84,364)		71,774	(11,036)	296
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	21,355	[2],[3],[4]	21,308						21,308		47
Other comprehensive income/(loss), net of tax	[1]	1,730	[2]	1,715							1,715	14
Cash dividends declared:
Common stock	[1]	(7,789)		(7,789)						(7,789)
Preferred stock	[1]	(1)		(1)						(1)
Noncontrolling interests	[1]	(9)										(9)
Share-based payment transactions (in shares)	[1],[9]					45,000,000		15,000,000
Share-based payment transactions	[1],[9]	$ 1,536		1,536		$ 2	1,597	$ (63)
Purchases of common stock (in shares)		(150,000,000)	[10]					(150,000,000)	[1]
Purchases of common stock	[1]	$ (5,000)	[10]	(5,000)				$ (5,000)
Preferred stock conversions and redemptions (in shares)	[1]				(73)
Preferred stock conversions and redemptions	[1]	(5)		(5)	$ (3)		(3)	$ 1
Other	[1]	0		0						0
Ending balance (in shares) at Dec. 31, 2017	[1]				524	9,275,000,000		3,296,000,000
Ending balance at Dec. 31, 2017	[1]	$ 71,656	[8]	$ 71,308	$ 21	$ 464	$ 84,278	$ (89,425)		$ 85,291	$ (9,321)	$ 348
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.
[6]	Represents shares purchased pursuant to the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.
[7]	Represents the $13 million cumulative effect of the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, for certain elements of the accounting for share-based payments. For additional information, see Notes to Consolidated Financial Statements––Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in Pfizer’s 2016 Financial Report.
[8]	Amounts may not add due to rounding.
[9]	2017 treasury shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement.
[10]	Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on February 2, 2017. See above for additional information.

Consolidated Statements of Equ8

Consolidated Statements of Equity (Parenthetical) shares in Millions, $ in Millions	Jan. 01, 2016USD ($)
Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]
Cumulative effect of the adoption of new accounting standard	$ 13

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 21,355		$ 7,246		$ 6,986
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[2]	6,269		5,757		5,157
Asset write-offs and impairments	[2]	634		1,613		1,119
Foreign currency loss related to Venezuela	[2],[5]	0		0		806
Loss on sale of HIS net assets	[2],[6]	55		1,712		0
TCJA impact	[2],[8]	(10,660)	[7]	0		0
Deferred taxes from continuing operations	[2]	(2,410)		(700)		(20)
Share-based compensation expense	[2]	840		691		669
Benefit plan contributions in excess of expense	[2]	(961)		(712)		(617)
Other adjustments, net	[2]	50		208		(152)
Other changes in assets and liabilities, net of acquisitions and divestitures:
Trade accounts receivable	[2]	259		(134)		21
Inventories	[2]	(357)		365		(199)
Other assets	[2]	(31)		(60)		236
Trade accounts payable	[2]	46		871		254
Other liabilities	[2]	(67)		(223)		664
Other tax accounts, net	[2]	1,446		(734)		(235)
Net cash provided by operating activities	[2]	16,470		15,901		14,688
Investing Activities
Purchases of property, plant and equipment	[2]	(1,956)		(1,823)		(1,397)
Purchases of short-term investments	[2]	(14,596)		(15,957)		(28,581)
Proceeds from redemptions/sales of short-term investments	[2]	10,307		29,436		40,064
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[2]	2,058		(4,218)		5,768
Purchases of long-term investments	[2]	(3,537)		(8,011)		(9,542)
Proceeds from redemptions/sales of long-term investments	[2]	3,594		11,254		6,929
Acquisitions of businesses, net of cash acquired	[2]	(1,000)		(18,368)		(16,466)
Acquisitions of intangible assets	[2]	(261)		(176)		(99)
Other investing activities, net	[2],[9]	650		51		344
Net cash used in investing activities	[2]	(4,741)		(7,811)		(2,980)
Financing Activities
Proceeds from short-term borrowings	[2]	8,464		7,472		5,557
Principal payments on short-term borrowings	[2]	(9,990)		(5,102)		(3,965)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less	[2]	1,401		(3,084)		2,717
Proceeds from issuance of long-term debt	[2]	5,274		10,976		0
Principal payments on long-term debt	[2]	(6,154)		(7,689)		(2,990)
Purchases of common stock	[2]	(5,000)		(5,000)		(6,160)
Cash dividends paid	[2]	(7,659)		(7,317)		(6,940)
Proceeds from exercise of stock options	[2]	862		1,019		1,263
Other financing activities, net	[2]	(233)		(196)		109
Net cash used in financing activities	[2]	(13,035)		(8,921)		(10,409)
Effect of exchange-rate changes on cash and cash equivalents	[2]	53		(215)		(1,000)
Net increase/(decrease) in cash and cash equivalents	[2]	(1,254)		(1,046)		298
Cash and cash equivalents, beginning	[2]	2,595	[10]	3,641		3,343
Cash and cash equivalents, end	[2]	1,342	[10]	2,595	[10]	3,641
Supplemental Cash Flow Information
Exchange of $1.1 billion net book value 6.50% U.K. pound denominated bonds maturing in 2038 for $1.8 billion of new 2.735% U.K. pound denominated bonds maturing in 2043, resulting in a net book loss of $747 million	[2],[11]	1,848		0		0
Receipt of ICU Medical common stock	[2],[9]	428		0		0
Promissory note from ICU Medical	[2],[9]	75		0		0
Exchange of Hospira subsidiary debt for Pfizer debt	[2],[12]	0		0		1,669
Cash paid (received) during the period for:
Income taxes	[2]	2,489		2,521		2,383
Interest	[2]	1,518		1,451		1,302
Interest rate hedges	[2]	$ (199)		$ (338)		$ (237)
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.3, but rather at the then SIMADI rate of 200, the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy.
[6]	In 2017, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[7]	2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A.
[8]	As a result of the enactment of the TCJA, Pfizer’s Provision/(benefit) for taxes on income was favorably impacted by approximately $10.7 billion, primarily reflecting the remeasurement of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information.
[9]	In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock initially valued at $428 million and a promissory note in the amount of $75 million which was repaid in full as of December 31, 2017 and included in Other investing activities for the year ended December 31, 2017. For additional information, see Note 2B. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment: Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH).
[10]	Amounts may not add due to rounding.
[11]	The $747 million is included in the net loss of $846 million upon the exchange and early retirement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Long-Term Debt for additional information.
[12]	In October 2015, Pfizer exchanged $1.7 billion debt of its then recently acquired subsidiary, Hospira, for virtually the same amount of Pfizer debt. See Note 7D. Financial Instruments: Long-Term Debt.

Consolidated Statements of Ca10

Consolidated Statements of Cash Flows (Parenthetical) shares in Millions

1 Months Ended

12 Months Ended

Dec. 31, 2017USD ($)

Dec. 31, 2017GBP (£)

Nov. 30, 2016USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2017GBP (£)

Feb. 03, 2017USD ($)shares

Nov. 21, 2016USD ($)

Jun. 30, 2016USD ($)

Oct. 31, 2015USD ($)

Sep. 03, 2015USD ($)

Loss on early retirement of debt

$ 999,000,000

$ 312,000,000

$ 999,000,000

[1]

$ 312,000,000

[1]

$ 0

[1]

Tax Benefit from Tax Cuts and Jobs Act of 2017

[3],[4]

10,660,000,000

[2]

$ 0

$ 0

Unsecured Debt [Member]

Debt instrument, face amount

$ 6,000,000,000

$ 5,000,000,000

Hospira [Member] | Unsecured Debt [Member]

Debt instrument, face amount

$ 1,700,000,000

$ 1,750,000,000

ICU Medical [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]

Shares of common stock received for disposal | shares

3.2

Value of common stock received for disposal

$ 428,000,000

Consideration receivable

$ 75,000,000

Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]

Loss on early retirement of debt

$ 846,000,000

Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member] | Senior Notes [Member]

Amount of debt exchanged

£ 833,000,000

$ 1,100,000,000

Interest rate, percentage

6.50%

6.50%

6.50%

Senior Unsecured U.K. Pound Debt, 2.735%, Due 2043 [Member] | Senior Notes [Member]

Interest rate, percentage

2.735%

2.735%

2.735%

Debt instrument, face amount

$ 1,800,000,000

$ 1,800,000,000

£ 1,375,882,000

U.K. Pound Denominated Debt [Member]

Loss on exchange of debt

$ 747,000,000

[1]

In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in 2016.

[2]

2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A.

[3]

Amounts may not add due to rounding.

[4]

As a result of the enactment of the TCJA, Pfizer’s Provision/(benefit) for taxes on income was favorably impacted by approximately $10.7 billion, primarily reflecting the remeasurement of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this 2017 Financial Report for terms used throughout the consolidated financial statements and related notes of this 2017 Financial Report. The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Taxes paid on intercompany sales transactions are deferred until recognized upon sale of the asset to a third party. We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 18 . Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. Our recent significant business development activities include: • On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical, a global device manufacturer, for up to approximately $900 million , composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. HIS includes IV pumps, solutions and devices. The operating results of HIS are included in the consolidated statement of income and EH’s operating results through February 2, 2017 and, therefore, our financial results, and EH’s operating results, for the year ended December 31, 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH’s operating results, for the year ended December 31, 2016 reflect 12 months of HIS global operations and for the year ended December 31, 2015 reflect four months of HIS U.S. operations and three months of HIS international operations. Assets and liabilities associated with HIS are presented as held for sale in the consolidated balance sheet as of December 31, 2016. • On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. for $1,045 million , composed of cash and contingent consideration. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH’s operating results, and cash flows for the year ended December 31, 2017 reflect approximately 11 months of the small molecule anti-infectives business acquired from AstraZeneca. • On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH’s operating results, and cash flows for the year ended December 31, 2017. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016 reflect approximately three months of Medivation operations. • On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion , net of cash acquired), plus $698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH’s operating results, and cash flows for the year ended December 31, 2017. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016 reflect approximately six months of Anacor operations. • On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which fell into Pfizer’s second fiscal quarter), Pfizer paid Allergan $150 million (pre-tax) for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 4 ). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement. • On September 3, 2015, we acquired Hospira for approximately $16.1 billion in cash ( $15.7 billion , net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Hospira. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2015 reflect four months of Hospira U.S. operations and three months of Hospira international operations. For additional information, see Note 2. B. Adoption of New Accounting Standards in 2017 We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our consolidated financial statements from adopting this standard. We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. There was no material impact to our consolidated financial statements from adopting this standard. C. Estimates and Assumptions In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income. Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. For information on estimates and assumptions in connection with the TCJA, see Notes to Consolidated Financial Statements–– Note 5A . Tax Matters: Taxes on Income from Continuing Operations. D. Acquisitions Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net . Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. E. Fair Value We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques: • Income approach, which is based on the present value of a future stream of net cash flows. • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. • Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence. Our fair value methodologies depend on the following types of inputs: • Quoted prices for identical assets or liabilities in active markets (Level 1 inputs). • Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs). • Unobservable inputs that reflect estimates and assumptions (Level 3 inputs). A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. F. Foreign Currency Translation For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss) . The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net . For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net , and we translate non-monetary items at historical rates. G. Revenues and Trade Accounts Receivable Revenue Recognition —We record revenues from product sales when the goods are shipped and title passes to the customer. At the time of sale, we also record estimates for a variety of revenue deductions, such as chargebacks, rebates, sales allowances and sales returns. When we cannot reasonably estimate the amount of future sales returns and/or other revenue deductions, we record revenues when the risk of product return and/or additional revenue deductions has been substantially eliminated. Deductions from Revenues–– Our gross product revenues are subject to a variety of deductions, that generally are estimated and recorded in the same period that the revenues are recognized, and primarily represent chargebacks, rebates and sales allowances to wholesalers, and, to a lesser extent, distributors like MCOs, retailers and government agencies with respect to our pharmaceutical products. Those deductions represent estimates of rebates and discounts related to gross sales for the reporting period and, as such, knowledge and judgment of market conditions and practice are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Specifically: • In the U.S., we record provisions for pharmaceutical Medicare, Medicaid, and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates. • Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds, and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals. • Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability. • Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit. • We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $4.9 billion and $4.3 billion as of December 31, 2017 and December 31, 2016 , respectively. The following table provides information about the balance sheet classification of these accruals: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,352 $ 1,154 Other current liabilities : Accrued rebates 2,674 2,261 Other accruals 512 509 Other noncurrent liabilities 385 357 Total accrued rebates and other accruals $ 4,923 $ 4,282 Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues . Collaborative Arrangements— Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded when our collaboration partners ship the product and title passes to their customer. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when our collaboration partners sell the product and title passes to their customers. All royalty payments to collaboration partners are included in Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net. Trade Accounts Receivable —Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. H. Cost of Sales and Inventories We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary. I. Selling, Informational and Administrative Expenses Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $3.1 billion in 2017 , $3.2 billion in 2016 and $3.1 billion in 2015 . Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs. J. Research and Development Expenses R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. R&D expenses related to upfront and milestone payments for intellectual property rights totaled $169 million in 2017 , $82 million in 2016 and $429 million in 2015 . For additional information, see Note 2C . K. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets Long-lived assets include: • Property, plant and equipment, less accumulated depreciation —These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws. • Identifiable intangible assets, less accumulated amortization —These acquired assets are recorded at fair value. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated. • Goodwill —Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized. Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate. We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Specifically: • For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate. • For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate. • For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value. Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. L. Restructuring Charges and Certain Acquisition-Related Costs We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other costs incurred in connection with a business acquisition are expensed as incurred . Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. M. Cash Equivalents and Statement of Cash Flows Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments . Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature. N. Investments and Derivative Financial Instruments Our investments are comprised of the following: trading funds and securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and ability to hold the investment to maturity) and private equity securities. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. • Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net. • Available-for-sale debt and equity securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized. • Held-to-maturity debt securities are carried at amortized cost. • Private equity securities are carried at equity method or at cost method. For equity investments where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in Other (income)/deductions—net . The excess of the cost of the investment over our share of the equity of the investee as of the acquisition date is allocated to the identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not include amounts of contingent consideration. Realized gains or losses on sales of investments are determined by using the specific identification cost method. We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Derivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A ), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7F ). A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. O. Tax Assets and Liabilities and Income Tax Contingencies Current tax assets primarily includes (i) tax effects associated with intercompany transfers of assets within our consolidated group, which are recognized in the consolidated statement of income when the asset transferred is sold to a third-party or recovered through amortization of the asset's remaining economic life; and (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations. Deferred tax assets and

Acquisitions, Sale of Hospira I

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment	12 Months Ended
	Dec. 31, 2017
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment	A. Acquisitions AstraZeneca’s Small Molecule Anti-Infectives Business (EH) On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). Under the terms of the agreement, we made an upfront payment of approximately $552 million to AstraZeneca upon the close of the transaction and an additional $3 million payment for a contractual purchase price adjustment in the second quarter of 2017. We also made a $50 million milestone payment in the second quarter of 2017, we made an additional milestone payment of $125 million in our first fiscal quarter of 2018 and we will make a deferred payment of $175 million to AstraZeneca in January 2019. In addition, AstraZeneca may be eligible to receive an additional milestone payment of $75 million if the related milestone is achieved prior to December 31, 2021, and up to $600 million if sales of Zavicefta™ exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta™ and ATM-AVI in certain markets for a period ending on the later of 10 years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately $250 million to $425 million . The total fair value of consideration transferred for AstraZeneca’s small molecule anti-infectives business was approximately $1,045 million , which includes $555 million in cash, plus the fair value of contingent consideration of $490 million (which is composed of the deferred payment, the $50 million milestone payment made in the second quarter of 2017, the $125 million milestone payment made in our first fiscal quarter of 2018 and the future expected milestone and royalty payments). In connection with this acquisition, we provisionally recorded $879 million in Identifiable intangible assets , primarily consisting of $660 million in Developed technology rights and $219 million in IPR&D . We also recorded $92 million in Other current assets related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, $92 million in Goodwill and $17 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized. Medivation, Inc. (IH) On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Of this consideration, approximately $365 million was not paid as of December 31, 2016, and was recorded in Other current liabilities. The remaining consideration was paid as of December 31, 2017 . Medivation is a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has a development-stage oncology asset in its pipeline, talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer. In connection with this acquisition, we recorded $12.2 billion in Identifiable intangible assets , primarily consisting of $8.1 billion of Developed technology rights with an average useful life of approximately 12 years and $4.1 billion of IPR&D, and recorded $6.1 billion of Goodwill, $4.0 billion of net income tax liabilities, and $259 million of assumed contingent consideration. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in Identifiable intangible assets of approximately $1.0 billion with a corresponding change to Goodwill and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The 2017 results include a decrease of approximately $38 million to Amortization of intangible assets which reflects the cumulative pre-tax impact of the measurement period adjustments to Identifiable intangible assets that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. Bamboo Therapeutics, Inc. (IH) On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for $150 million , plus potential milestone payments of up to $495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately $343 million , including cash of $130 million ( $101 million , net of cash acquired), contingent consideration of $167 million , consisting of milestone payments, and the fair value of Pfizer’s previously held equity interest in Bamboo of $45 million . We previously purchased a minority stake in Bamboo in the first quarter of 2016 for a payment of approximately $43 million . Upon acquiring the remaining interest in Bamboo in the third quarter of 2016, we recognized a gain of $2 million on our existing investment in Other (income)/deductions––net over the one-year allocation period . This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. Bamboo is a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we recorded $330 million of Identifiable intangible assets, consisting entirely of IPR&D. We also recorded $142 million of Goodwill and $94 million of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. Anacor Pharmaceuticals, Inc. (IH) On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion net of cash acquired), plus $698 million debt assumed. Anacor is a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA on December 14, 2016 under the trade name, Eucrisa. In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and recorded $4.9 billion in Identifiable intangible assets , primarily consisting of $4.8 billion of IPR&D , and recorded $646 million of Goodwill and $346 million of net income tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. Hospira, Inc. (EH) On September 3, 2015, we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for $90 per share in cash. The total fair value of consideration transferred for Hospira was approximately $16.1 billion in cash ( $15.7 billion , net of cash acquired). Hospira is a subsidiary of Pfizer and its commercial operations are included in the EH segment. Hospira’s principal business was the development, manufacture, marketing and distribution of generic acute-care and oncology injectables, biosimilars and integrated infusion therapy and medication management systems (see Note 2B below). Hospira’s broad portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. We believe our acquisition of Hospira has strengthened our EH business, as EH now has a broadened portfolio of generic and branded sterile injectables, marketed biosimilars and biosimilars in development. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: (MILLIONS OF DOLLARS) Amounts Recognized as of Acquisition Date Final Working capital, excluding inventories (a) $ 342 Inventories 1,901 PP&E 2,352 Identifiable intangible assets, excluding IPR&D (b) 8,290 IPR&D 1,030 Other noncurrent assets 362 Long-term debt (1,928 ) Benefit obligations (117 ) Net income tax accounts (c) (3,380 ) Other noncurrent liabilities (61 ) Total identifiable net assets 8,791 Goodwill 7,295 Net assets acquired/total consideration transferred $ 16,087 (a) Includes cash and cash equivalents, short-term investments, accounts receivable, other current assets, assets held for sale, accounts payable and other current liabilities. (b) Comprised of finite-lived developed technology rights with a weighted-average life of approximately 17 years ( $7.7 billion ) and other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ( $570 million ). (c) Final amounts recognized as of the acquisition date, included in Current tax assets ( $57 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $58 million ), Income taxes payable ( $5 million ), Noncurrent deferred tax liabilities ( $3.4 billion ) and Other taxes payable ( $101 million , including accrued interest of $5 million ). As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $565 million , of which $12 million was not expected to be collected. In the ordinary course of business, Hospira incurred liabilities for environmental, legal and tax matters, as well as guarantees and indemnifications. These matters may include contingencies. Except as specifically excluded by the relevant accounting standard, contingencies are required to be measured at fair value as of the acquisition date if the acquisition-date fair value of the asset or liability arising from a contingency can be determined. If the acquisition-date fair value of the asset or liability cannot be determined, the asset or liability would be recognized at the acquisition date if both of the following criteria are met: (i) it is probable that an asset existed or that a liability had been incurred at the acquisition date, and (ii) the amount of the asset or liability can be reasonably estimated. • Environmental Matters —In the ordinary course of business, Hospira incurred liabilities for environmental matters such as remediation work, asset retirement obligations and environmental guarantees and indemnifications. The contingencies for environmental matters are not significant to Pfizer’s financial statements. • Legal Matters —Hospira is involved in various legal proceedings, including product liability, patent, commercial, antitrust and environmental matters and government investigations, of a nature considered normal to its business. The contingencies arising from legal matters are not significant to Pfizer’s financial statements. • Tax Matters —In the ordinary course of business, Hospira incurred liabilities for income taxes . Income taxes are exceptions to both the recognition and fair value measurement principles associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model as previously used by Hospira. Net liabilities for income taxes approximate $3.4 billion as of the acquisition date, which included $109 million for uncertain tax positions. The net tax liability included the recording of additional adjustments of approximately $3.2 billion for the tax impact of fair value adjustments and approximately $719 million for income tax matters that we intend to resolve in a manner different from what Hospira had planned or intended. For example, because we planned to repatriate certain overseas funds, we provided deferred taxes on Hospira’s unremitted earnings for which no taxes had been previously provided by Hospira as it was Hospira’s intention to indefinitely reinvest those earnings. Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of Hospira includes the following: • the expected specific synergies and other benefits that we believe will result from combining the operations of Hospira with the operations of Pfizer; • any intangible assets that do not qualify for separate recognition, as well as future, as yet unidentified projects and products; and • the value of the going-concern element of Hospira’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately). Goodwill is not amortized and is not deductible for tax purposes. All of the goodwill related to the acquisition of Hospira is related to our EH segment (see Note 10 for additional information). Actual and Pro Forma Impact of Acquisition —The following table presents information for Hospira’s operations that are included in Pfizer’s consolidated statements of income beginning from the acquisition date, September 3, 2015 through Pfizer’s domestic and international year-ends in 2015 (see Note 1A ): (MILLIONS OF DOLLARS) December 31, 2015 Revenues $ 1,513 Net loss attributable to Pfizer Inc. common shareholders (a) (575 ) (a) Includes purchase accounting charges related to the provisional estimated fair values recognized as of the acquisition date for (i) the fair value adjustment for acquisition-date inventory that has been sold ( $378 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Hospira ( $161 million pre-tax); (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Hospira ( $34 million pre-tax ); and (iv) amortization expense related to the fair value adjustment of long-term debt acquired from Hospira ( $13 million income pre-tax), as well as restructuring and integration costs ( $556 million pre-tax). The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014: Unaudited Supplemental Pro Forma Consolidated Results (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) Year Ended December 31, 2015 Revenues $ 52,082 Net income attributable to Pfizer Inc. common shareholders 7,669 Diluted EPS attributable to Pfizer Inc. common shareholders 1.23 The unaudited supplemental pro forma consolidated results were prepared using the acquisition method of accounting and do not purport to reflect what the combined company’s results of operations would have been had the acquisition occurred on January 1, 2014, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors. The unaudited supplemental pro forma financial information includes various assumptions, including those related to the purchase price allocation of the assets acquired and the liabilities assumed from Hospira. The unaudited supplemental pro forma consolidated results reflect the historical financial information of Pfizer and Hospira, adjusted to give effect to the acquisition of Hospira as if it had occurred on January 1, 2014, primarily for the following pre-tax adjustments in 2015: • Elimination of Hospira’s historical intangible asset amortization expense (approximately $33 million ). • Additional amortization expense (approximately $342 million ) related to the fair value of identifiable intangible assets acquired. • Additional depreciation expense (approximately $52 million ) related to the fair value adjustment to PP&E acquired. • Adjustment related to the non-recurring fair value adjustment to acquisition-date inventory estimated to have been sold (the elimination of $364 million of charges). • Adjustment to decrease interest expense (approximately $18 million ) related to the fair value adjustment of Hospira debt. • Adjustment for non-recurring acquisition-related costs directly attributable to the acquisition (the elimination of $877 million of charges), reflecting non-recurring charges incurred by both Hospira and Pfizer which would have been recorded in 2014 under the pro forma assumption that the Hospira acquisition was completed on January 1, 2014. The above adjustments were adjusted for the applicable tax impact. The taxes associated with the adjustments related to the fair value adjustment for acquired intangible assets, PP&E, inventory and debt reflect the statutory tax rates in the various jurisdictions where the adjustments are expected to be incurred. The taxes associated with elimination of Hospira’s historical intangible asset amortization expense and the adjustment for the acquisition-related costs directly attributable to the acquisition were based on the tax rate in the jurisdiction in which the related deductible costs were incurred. Marketed Vaccines Business of Baxter International Inc. (IH) On December 1, 2014 (which fell in the first fiscal quarter of 2015 for our international operations), we acquired Baxter ’ s portfolio of marketed vaccines for a final purchase price of $648 million . The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. In connection with this acquisition, we recorded $376 million in Identifiable intangible assets, primarily consisting of $371 million in Developed technology rights. We also recorded $194 million of Inventories and $12 million in Goodwill . The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. B. Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical agreed to acquire all of our global infusion systems net assets, HIS, for approximately $1 billion in cash and ICU Medical common stock. HIS includes IV pumps, solutions, and devices. As a result of the performance of HIS relative to ICU Medical’s expectations, on January 5, 2017 we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately $900 million , composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. The revised transaction closed on February 3, 2017. At closing, under the terms of the revised agreement, we received 3.2 million newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately $428 million (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which are reported as available-for-sale equity securities at fair value in Long-term investments on the consolidated balance sheet as of December 31, 2017, a promissory note in the amount of $75 million , which was repaid in full as of December 31, 2017, and net cash of approximately $200 million before customary adjustments for net working capital, which is reported in Other investing activities, net on the consolidated statement of cash flows for the year-ended December 31, 2017. In addition, we are entitled to receive a contingent amount of up to an additional $225 million in cash based on ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. After receipt of ICU Medical shares, we own approximately 16% of ICU Medical. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months after the closing date. We recognized pre-tax losses of approximately $55 million in 2017 in Other (income)/deductions––net, representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell. For additional information, see Note 4 . While we have received the full purchase price excluding the contingent amount as of the February 3, 2017 closing, the sale of the HIS net assets was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, which represent a relatively small portion of the HIS net assets, we have continued to operate the net assets for the net economic benefit of ICU Medical, and we are indemnified by ICU Medical against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. Sales of the HIS net assets have occurred in certain of these jurisdictions as of December 31, 2017 and we expect the sale of the HIS net assets in the remaining jurisdictions to be fully completed by the first quarter of 2018. As such, and as we have already received all of the non-contingent proceeds from the sale and ICU Medical is contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes. In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale. At December 31, 2016 , we determined that the carrying value of the HIS net assets held for sale exceeded their fair value less estimated costs to sell, resulting in a pre-tax impairment charge of $1.7 billion , which is included in Other (income)/deductions––net (see Note 4 ). The decline in value resulted from lower expectations as to future cash flows to be generated by HIS, primarily as a result of an increase in competition for customer contracts and pricing factors that were not initially anticipated. Assets and liabilities associated with HIS are presented as held for sale in the consolidated balance sheet as of December 31, 2016 . The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities . The amounts associated with HIS, as well as other assets classified as held for sale consisted of the following: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Assets Held for Sale Inventories $ — $ 377 PP&E — 457 Identifiable intangible assets — 1,319 Goodwill — 119 Other assets — 152 Less: adjustment to HIS assets for net realizable value (a) — (1,681 ) Total HIS assets held for sale — 743 Other assets held for sale (b) 12 58 Assets held for sale $ 12 $ 801 Liabilities Held for Sale Accrued compensation and related items $ — $ 54 Other liabilities — 103 Total HIS liabilities held for sale $ — $ 157 (a) For 2016 , we recorded an adjustment to HIS assets for net realizable value of $1,681 million plus estimated costs to sell of $31 million for a total impairment on HIS net assets of $1,712 million . (b) Other assets held for sale consist primarily of PP&E and other assets. C. Research and Development and Collaborative Arrangements Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P. On November 1, 2016, we announced the discontinuation of the global clinical development program for bococizumab. During December 2016, $31.3 million was refunded to NovaQuest representing amounts NovaQuest prepaid for development costs (under the May 2016 agreement described below) that were not used for program expenses due to the discontinuation of the development program. No additional payments have been or are expected to be received from or paid to NovaQuest under this agreement, which was effectively terminated on November 18, 2016. In May 2016, our agreement with NovaQuest became effective, under which NovaQuest agreed to fund up to $250 million in development costs related to certain Phase III clinical trials of Pfizer’s bococizumab compound and Pfizer agreed to use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding was expected to cover up to 40% of the development costs and was to be received over five quarters during 2016 and 2017. As there was a substantive and genuine transfer of risk to NovaQuest, the development funding applicable to program expenses during 2016 was recognized as an obligation to perform contractual services and therefore has been recognized as a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for 2016 totaled $180.3 million . Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P. In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest will fund up to $200 million in development costs related to certain Phase III clinical trials of Pfizer’s rivipansel compound and Pfizer will use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding is expected to cover up to 100% of the development costs and will be received over approximately 12 quarters from 2016 to 2019. As there is a substantive and genuine transfer of risk to NovaQuest, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses totaled $72.1 million for 2017 and $46.6 million for 2016. Following potential regulatory approval, NovaQuest will be eligible to receive a combination of fixed milestone payments of up to approximately $267 million in total, based on achievement of first commercial sale and certain levels of cumulative net sales as well as royalties on rivipansel net sales over approximately eight years. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the rivipansel product and royalties on net sales will be recorded as Cost of sales when incurred. Research and Development Arrangement with RPI Finance Trust In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI will fund up to $300 million in development costs related to certain Phase III clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI’s development funding is expected to cover up to 100% of the costs primarily for the applicable clinical trials through 2021. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses totaled $75.6 million for 2017 and $44.9 million for 2016. If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to $250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as Cost of sales when incurred. Collaborative Arrangements In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product. The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Revenues —Revenues (a) $ 606 $ 659 $ 644 Revenue s—Alliance revenues (b) 2,927 1,746 1,312 Total revenues from collaborative arrangements 3,533 2,405 1,956 Cost of sales (c) (329 ) (315 ) (282 ) Selling, informational and administrative expenses (d) (54 ) (5 ) (287 ) Research and development expenses (e) 222 64 (330 ) Other income/(deductions)—net (f) 249 542 482 (a) Represents sales to our partners of products manufactured by us. (b) Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2017 reflects an increase in alliance revenues from Eliquis and Xtandi. The increase in 2016 reflects an increase in alliance revenues from Eliquis and the inclusion of Xtandi revenues resulting from the acquisition of Medivation in September 2016, partially offset by the expiration of the Rebif co-promotion collaboration at the end of 2015. (c) Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners. (d) Represents net reimbursements to our partners for selling, informational and administrative expenses incurred. (e) Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $15 million in 2017 , $15 million in 2016 and $310 million in 2015 (primarily related to our collaboration with OPKO, see below). 2017 and 2016 also include reimbursements related to our collaboration with Lilly (see below) of $147 million and $120 million , respectively. (f) Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our 36 month royalty arrangement on sales of Enbrel in the U.S. and Canada, partially offset by a full year

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	12 Months Ended
	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. We expect to incur costs of approximately $1 billion (not including costs of $215 million in 2015 associated with the return of acquired IPR&D rights as described in the Current-Period Key Activities section below) associated with the integration of Hospira. The majority of these costs are expected to be incurred for the three-year period post-acquisition. In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our global commercial structure reorganization, manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise. As a result of the evaluation performed in connection with our decision in September 2016 to not pursue, at that time, splitting IH and EH into two separate publicly-traded companies, we identified new opportunities to potentially achieve greater optimization and efficiency to become more competitive in our business. Therefore, in early 2017 , we initiated new enterprise-wide cost reduction/productivity initiatives, which we expect to substantially complete by the end of 2019. These initiatives will encompass all areas of our cost base and will include: • Optimization of our manufacturing plant network to support IH and EH products and pipelines. During 2017-2019, we expect to incur costs of approximately $800 million related to this initiative. Through December 31, 2017 , we incurred approximately $197 million associated with this initiative. • Activities in non-manufacturing related areas, which include further centralization of our corporate and platform functions, as well as other activities where opportunities are identified. During 2017-2019, we expect to incur costs of approximately $300 million related to this initiative. Through December 31, 2017 , we incurred approximately $151 million associated with this initiative. The costs expected to be incurred during 2017-2019, of approximately $1.1 billion for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation––asset restructuring. Of this amount, we expect that about 20% of the total charges will be non-cash. Current-Period Key Activities In 2017 , we incurred costs of $348 million associated with the 2017-2019 program, $319 million associated with the integration of Hospira and $137 million associated with all other acquisition-related initiatives. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Restructuring charges (a) : Employee terminations $ (34 ) $ 940 $ 489 Asset impairments (b) 190 142 254 Exit costs 21 74 68 Total restructuring charges 178 1,156 811 Transaction costs (c) 4 127 123 Integration costs (d) 305 441 219 Restructuring charges and certain acquisition-related costs 487 1,724 1,152 Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows (e) : Cost of sales 91 201 117 Selling, informational and administrative expenses — — — Research and development expenses — 7 5 Total additional depreciation––asset restructuring 91 207 122 Implementation costs recorded in our consolidated statements of income as follows (f) : Cost of sales 118 230 102 Selling, informational and administrative expenses 71 81 82 Research and development expenses 38 25 14 Other (income)/deductions––net — 3 5 Total implementation costs 227 340 203 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 805 $ 2,271 $ 1,478 (a) In 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In 2015, restructuring charges are largely associated with.cost-reduction and productivity initiatives not associated with acquisitions. In 2017 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities in 2017 are associated with the following: • IH ( $64 million income); EH ( $4 million income); WRD/GPD ( $80 million ); manufacturing operations ( $115 million ); and Corporate ( $51 million ). The restructuring activities in 2016 are associated with the following: • IH ( $272 million ); EH ( $158 million ); WRD/GPD ( $169 million ); manufacturing operations ( $368 million ); and Corporate ( $189 million ), The restructuring activities in 2015 , which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following: • IH ( $85 million ); EH ( $402 million ); WRD/GPD ( $80 million ); manufacturing operations ( $80 million ); and Corporate ( $164 million ). In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million , which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million , which is included in Asset impairments ; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million , which is included in Asset impairments ; and (iii) a payment to Celltrion of $20 million , which is included in Exit costs . (b) The asset impairment charges for 2017 are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for 2017 and 2016 are primarily associated with abandoned assets. The asset impairment charges for 2015 are primarily associated with our acquisition of Hospira. See (a) above for additional information. (c) Transaction costs represent external costs for banking, legal, accounting and other similar services, which in 2017 are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in 2016 are mostly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and the terminated transaction with Allergan and primarily include expenditures for banking, legal, accounting and other similar services. (d) I ntegration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2017 , integration costs primarily relate to our acquisitions of Hospira and Medivation, as well as a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 11 ). In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira. (e) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (f) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, January 1, 2016 $ 1,109 $ — $ 48 $ 1,157 Provision 940 142 74 1,156 Utilization and other (a) (502 ) (142 ) (86 ) (730 ) Balance, December 31, 2016 (b) 1,547 — 36 1,583 Provision (34 ) 190 21 178 Utilization and other (a) (474 ) (190 ) 9 (656 ) Balance, December 31, 2017 (c) $ 1,039 $ — $ 66 $ 1,105 (a) Includes adjustments for foreign currency translation. (b) Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million ). (c) Included in Other current liabilities ( $643 million ) and Other noncurrent liabilities ( $462 million ).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	12 Months Ended
	Dec. 31, 2017
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Interest income (a) $ (391 ) $ (470 ) $ (471 ) Interest expense (a) 1,270 1,186 1,199 Net interest expense 879 716 728 Foreign currency loss related to Venezuela (b) — — 806 Royalty-related income (c) (499 ) (905 ) (922 ) Certain legal matters, net (d) 240 510 975 Net gains on asset disposals (e) (343 ) (171 ) (232 ) Loss on sale and impairment on remeasurement of HIS net assets (f) 55 1,712 — Certain asset impairments (g) 395 1,447 818 Business and legal entity alignment costs (h) 71 261 282 Net losses on early retirement of debt (i) 999 312 — Other, net (j) (482 ) (227 ) 403 Other (income)/deductions––net $ 1,315 $ 3,655 $ 2,860 (a) 2017 v. 2016 ––Interest income decreased primarily driven by a lower investment balance. Interest expense increased, primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt. Capitalized interest expense totaled $72 million 2017 , $ 61 million in 2016 and $ 32 million in 2015 . (b) In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.3 , but rather at the then SIMADI rate of 200 , the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy. (c) Royalty-related income decreased in 2017 and 2016 , primarily due to lower royalty income for Enbrel of $470 million in 2017 , compared to 2016, and $54 million in 2016 , compared to 2015, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by increases in Xtandi royalty-related income of $176 million in 2017 , compared to 2016, and $63 million in 2016 , compared to 2015. (d) In 2017 , primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to court approval (for additional information, see Note 17A2 ), and a $79 million charge to reflect damages awarded by a jury in a patent matter. In 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, 2016 includes a settlement related to a patent matter. In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. (e) In 2017 , primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $451 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $281 million ; (iii) gross realized gains on sales of available-for-sale equity securities of $75 million ; (iv) a net loss of $120 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of $187 million ; (vi) gains on sales of investments in private equity securities of $80 million ; (vii) a gain on sale of property of $52 million ; (viii) a net loss of $30 million related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest; and (ix) a loss of $81 million related to the sale of our 49% equity share in Hisun Pfizer. Proceeds from the sale of available-for-sale securities were $5.1 billion in 2017. In 2016, primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $666 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $548 million ; (iii) a net loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of $84 million ; and (v) gains on sales of investments in private equity securities of $2 million . Proceeds from the sale of available-for-sale securities were $10.2 billion in 2016. In 2015, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $164 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $960 million ; (iii) net gain of $937 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of $90 million ; and (v) gains on sales of investments in private equity securities of $3 million . Proceeds from the sale of available-for-sale securities were $4.3 billion in 2015. (f) In 2017, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information . (g) In 2017 , primarily includes intangible asset impairment charges of $337 million , reflecting (i) $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) $124 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) $39 million related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) $26 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) $20 million related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with EH and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of $43 million for an impairment of our AM-Pharma B.V. long-term investment (see Note 2E ). In 2016, primarily includes intangible asset impairment charges of $869 million , reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ( $840 million ) and IH ( $29 million ). In addition, 2016 includes an impairment loss of $452 million related to Pfizer’s then 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a then recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. In 2015, primarily includes an impairment loss of $463 million related to Pfizer’s then 49% -owned equity-method investment in Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2D ) and intangible asset impairment charges of $323 million , reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: EH ( $294 million ), WRD ( $13 million ); and Consumer Healthcare ( $17 million ). The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. (h) Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (i) In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in 2016. (j) In 2017, includes, among other things, dividend income of $266 million from our investment in ViiV, and income of $62 million from resolution of a contract disagreement. In 2016, includes among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A ); and income of $116 million from resolution of a contract disagreement. In 2015, includes, among other things, (i) charges of $194 million related to the write-down of assets to net realizable value; (ii) charges of $159 million , reflecting the change in the fair value of contingent consideration liabilities; and (iii) income of $45 million associated with equity-method investees. The asset impairment charges included in Other (income)/deductions––net are based on estimates of fair value. The following table provides additional information about the intangible assets that were impaired during 2017 in Other (income)/deductions––net : Year Ended December 31, Fair Value (a) 2017 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– Developed technology rights (b) 50 — — 50 337 Total $ 50 $ — $ — $ 50 $ 337 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E. (b) Reflects intangible assets written down to fair value in 2017 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters

Tax Matters	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations The following table provides the components of Income from continuing operations before provision/(benefit) for taxes on income : Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 United States $ (6,879 ) $ (8,534 ) $ (6,809 ) International 19,184 16,886 15,773 Income from continuing operations before provision/(benefit) for taxes on income ( a), (b) $ 12,305 $ 8,351 $ 8,965 (a) 2017 v. 2016 –– The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower certain asset impairments and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in international income was primarily due to the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower restructuring charges and certain acquisition-related costs, and lower certain asset impairments. (b) 2016 v. 2015 –– The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs. The following table provides the components of Provision/(benefit) for taxes on income based on the location of the taxing authorities: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 United States Current income taxes: Federal $ 14,127 $ 342 $ 67 State and local 320 (52 ) (8 ) Deferred income taxes: Federal (25,964 ) (419 ) 300 State and local (268 ) (106 ) (36 ) Total U.S. tax provision (11,785 ) (235 ) 323 International Current income taxes 2,709 1,532 1,951 Deferred income taxes 28 (175 ) (284 ) Total international tax provision 2,737 1,358 1,667 Provision/(benefit) for taxes on income $ (9,049 ) $ 1,123 $ 1,990 In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including the impact on deferred tax assets and liabilities from the reduction in the corporate tax rate from 35% to 21% , the impact on valuation allowances and other state income tax considerations, the $15.2 billion repatriation tax liability on accumulated post-1986 foreign earnings for which we plan to elect payment over eight years through 2026 (with the first of eight installments due in April 2019) that is reported in Other taxes payable , and deferred taxes on basis differences expected to give rise to future taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a result of the TCJA, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial tax system. The estimated amounts recorded may change in the future due to uncertain tax positions. With respect to the aforementioned repatriation tax liability related to the TCJA repatriation tax, our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income , states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We have elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. However, given the complexity of these provisions, we have not finalized our analysis. We were able to make a reasonable estimate of the deferred taxes on the temporary differences expected to reverse in the future and provided a provisional deferred tax liability of approximately $1 billion as of December 31, 2017. The provisional amount is based on the evaluation of certain temporary differences inside each of our foreign subsidiaries that are expected to reverse as global intangible low-taxed income. However, as we continue to evaluate the TCJA’s global intangible low-taxed income provisions during the measurement period, we may revise the methodology used for determining the deferred tax liability associated with such income. We believe that we have made reasonable estimates with respect to each of the above items, however, all of the amounts recorded are provisional as we have not completed our analysis of the complex and far reaching effects of the TCJA. Further, we continue to consider our assertions on any remaining outside basis differences in our foreign subsidiaries as of December 31, 2017 and have not completed our analysis. Under guidance issued by the staff of the SEC, we expect to finalize our accounting related to the tax effects of the TCJA on deferred taxes, valuation allowances, state tax considerations, the repatriation tax liability, global intangible low-taxed income, and any remaining outside basis differences in our foreign subsidiaries during 2018 as we complete our analysis, computations and assertions. It is possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. We will revise these estimates during 2018 as we gather additional information to complete our tax returns and as any interpretation or clarification of the TCJA occurs through legislation, U.S. Treasury actions or other means. In 2017 , the Provision/(benefit) for taxes on income was impacted by the following: • estimated U.S. net tax benefits of $10.7 billion associated with the enactment of the TCJA (see discussion above), primarily reflecting: ◦ $22.8 billion tax benefit associated with the remeasurement of U.S. deferred tax liabilities on unremitted earnings of foreign subsidiaries (see Note 5C ); ◦ $1.6 billion tax benefit associated with the remeasurement of other U.S. deferred tax liabilities, primarily associated with intangibles (see Note 5C ); ◦ $12.9 billion tax expense related to the repatriation tax on deemed repatriated accumulated pre-2017 post-1986 earnings of foreign subsidiaries; ◦ $1.0 billion tax expense related to future taxes on global intangible low-taxed income (see Note 5C ); and ◦ approximately $100 million tax benefit primarily associated with certain tax initiatives; • U.S. tax expense of approximately $1.3 billion related to the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries; • tax benefit of approximately $370 million related to net losses on early retirement of debt; • tax benefits of approximately $150 million representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; and • the non-deductibility of a $307 million fee payable to the federal government as a result of the U.S. Healthcare Legislation. In 2016 , the Provision/(benefit) for taxes on income was impacted by the following: • U.S. tax expense of approximately $1.1 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in 2016 (see Note 5C ); • tax benefits of approximately $460 million , representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations; • benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position; • net tax benefits of $89 million , related to the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, requiring excess tax benefits or deficiencies of share-based compensation to be recognized as a component of the Provision/(benefit) for taxes on income (see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in Pfizer’s 2016 Financial Report); • the non-deductibility of a $312 million fee payable to the federal government as a result of the U.S. Healthcare Legislation; and • the permanent extension of the U.S. R&D tax credit, which was signed into law in December 2015. In 2015 , the Provision/(benefit) for taxes on income was impacted by the following: • U.S. tax expense of approximately $2.1 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in 2015 (see Note 5C ); • tax benefits of approximately $360 million , representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations; • the permanent extension of the U.S. R&D tax credit, which was signed into law in December 2015, as well as tax benefits associated with certain tax initiatives; • the non-deductibility of a foreign currency loss related to Venezuela; • the non-deductibility of a charge for the agreement in principle reached in February 2016 to resolve claims relating to Protonix; and • the non-deductibility of a $251 million fee payable to the federal government as a result of the U.S. Healthcare Legislation. In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision/(benefit) for taxes on income (see Note 2A ). B. Tax Rate Reconciliation The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows: Year Ended December 31, 2017 2016 2015 U.S. statutory income tax rate 35.0 % 35.0 % 35.0 % TCJA impact (a) (86.6 ) — — Taxation of non-U.S. operations (b), (c), (d) (17.0 ) (13.8 ) (9.6 ) Tax settlements and resolution of certain tax positions (e) (1.2 ) (5.5 ) (4.0 ) U.S. Healthcare Legislation (e) 0.9 1.3 0.9 U.S. R&D tax credit and manufacturing deduction (e) (0.7 ) (1.0 ) (1.0 ) Certain legal settlements and charges (e) 0.1 (2.9 ) 3.1 All other, net (f) (3.9 ) 0.3 (2.1 ) Effective tax rate for income from continuing operations (73.5 )% 13.4 % 22.2 % (a) For a discussion about the enactment of the TCJA, see Note 5A. (b) For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which includes the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries discussed in Note 5A , as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income . (c) In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. 2015 and 2016 also include incentives in Costa Rica and the Dominican Republic related to the Hospira infusion systems business, which was sold to ICU Medical in February 2017. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations. (d) The favorable rate impact in 2017 also reflects lower repatriation costs associated with estimated current year income of our foreign subsidiaries. The favorable rate impact in 2016 also includes the non-recurrence of the non-deductibility of a foreign currency loss related to Venezuela. The rate impact in 2015 also includes the non-deductibility of a foreign currency loss related to Venezuela. (e) For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and manufacturing deduction and the impact of certain legal settlements and charges, see Note 5A. (f) All other, net in 2017 and 2015 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. C. Deferred Taxes Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts. The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow: 2017 Deferred Tax* 2016 Deferred Tax (MILLIONS OF DOLLARS) Assets (Liabilities) Assets (Liabilities) Prepaid/deferred items $ 1,588 $ (132 ) $ 2,180 $ (68 ) Inventories 224 (3 ) 366 (47 ) Intangible assets (a) 685 (9,269 ) 1,139 (15,172 ) Property, plant and equipment 123 (755 ) 92 (982 ) Employee benefits 2,219 (109 ) 3,356 (74 ) Restructurings and other charges 226 (8 ) 458 (2 ) Legal and product liability reserves 459 — 650 — Net operating loss/tax credit carryforwards (b) 4,502 — 2,957 — Unremitted earnings (a), (c) — (1,067 ) — (23,108 ) State and local tax adjustments 218 — 301 — All other 488 (424 ) 306 (503 ) 10,732 (11,767 ) 11,806 (39,956 ) Valuation allowances (2,203 ) — (1,949 ) — Total deferred taxes $ 8,529 $ (11,767 ) $ 9,857 $ (39,956 ) Net deferred tax liability (d) $ (3,238 ) $ (30,099 ) * 2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A . (a) The decrease in 2017 is primarily the result of the enactment of the TCJA, which includes the remeasurement of deferred tax liabilities primarily associated with intangible assets and unremitted earnings of foreign subsidiaries as well as amortization on intangible assets. For additional information, see Note 5A. (b) The amounts in 2017 and 2016 are reduced for unrecognized tax benefits of $3.4 billion and $3.0 billion , respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. (c) The amount in 2017 primarily includes a provisional estimate on temporary differences associated with global intangible low-taxed income primarily related to basis differentials on intangibles. For additional information, see Note 5A. (d) In 2017 , Noncurrent deferred tax assets and other noncurrent tax assets ( $0.7 billion ), and Noncurrent deferred tax liabilities ( $3.9 billion ). In 2016 , Noncurrent deferred tax assets and other noncurrent tax assets ( $654 million ), and Noncurrent deferred tax liabilities ( $30.8 billion ). We have carryforwards, primarily related to foreign tax credits, net operating and capital losses and charitable contributions, which are available to reduce future U.S. federal and state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2018 to 2037. Certain of our U.S. net operating losses are subject to limitations under IRC Section 382. Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. We have not completed our analysis of the TCJA on our prior assertion of indefinitely reinvested earnings. Accordingly, we continue to evaluate our assertion with respect to our accumulated foreign earnings subject to the deemed repatriation tax and we also continue to evaluate the amount of earnings that are indefinitely reinvested. Additionally, we continue to evaluate our assertions on any remaining outside basis differences in our foreign subsidiaries as of December 31, 2017 as we have not finalized our analysis of the effects of all of the new provisions in the TCJA. As of December 31, 2017, it is not practicable to estimate the additional deferred tax liability that would be recorded if the earnings subject to the deemed repatriation tax and any remaining outside basis differences as of December 31, 2017 are not indefinitely reinvested. In accordance with the authoritative guidance issued by the SEC Staff Accounting Bulletin 118, we expect to complete our analysis within the measurement period. D. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. For a description of our accounting policies associated with accounting for income tax contingencies, see Note 1O. For a description of the risks associated with estimates and assumptions, see Note 1C. Uncertain Tax Positions As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2017 and 2016 , we had approximately $5.4 billion and $4.6 billion , respectively, in net unrecognized tax benefits, excluding associated interest. • Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2017 and 2016 , we had approximately $1.2 billion , in each year, in assets associated with uncertain tax positions. In 2017 , these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ( $1.0 billion ) and Noncurrent deferred tax liabilities ( $118 million ). In 2016 , these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ( $1.0 billion ) and Noncurrent deferred tax liabilities ( $201 million ). • Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows: (MILLIONS OF DOLLARS) 2017 2016 2015 Balance, beginning $ (5,826 ) $ (5,919 ) $ (6,182 ) Acquisitions (a) 10 (83 ) (110 ) Increases based on tax positions taken during a prior period (b) (49 ) (11 ) (31 ) Decreases based on tax positions taken during a prior period (b), (c) 28 409 496 Decreases based on settlements for a prior period (d) 35 126 64 Increases based on tax positions taken during the current period (b) (753 ) (489 ) (675 ) Impact of foreign exchange (121 ) (5 ) 319 Other, net (b), (e) 118 146 199 Balance, ending (f) $ (6,558 ) $ (5,826 ) $ (5,919 ) (a) For 2017 and 2016, primarily related to the acquisitions of Medivation and Anacor. For 2015, primarily related to the acquisition of Hospira. See also Note 2A . (b) Primarily included in Provision/(benefit) for taxes on income. (c) Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A. (d) Primarily related to cash payments and reductions of tax attributes. (e) Primarily related to decreases as a result of a lapse of applicable statutes of limitations. (f) In 2017 , included in Income taxes payable ( $1 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $123 million ), Noncurrent deferred tax liabilities ( $3.3 billion ) and Other taxes payable ( $3.2 billion ). In 2016 , included in Income taxes payable ( $14 million ), Current tax assets ( $17 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $184 million ), Noncurrent deferred tax liabilities ( $2.8 billion ) and Other taxes payable ( $2.8 billion ). • Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in Provision/(benefit) for taxes on income in our consolidated statements of income. In 2017 , we recorded a net increase in interest of $208 million . In 2016 , we recorded a net increase in interest of $72 million ; and in 2015 , we recorded a net increase in interest of $71 million . Gross accrued interest totaled $975 million as of December 31, 2017 (reflecting a decrease of approximately $4 million as a result of cash payments) and gross accrued interest totaled $771 million as of December 31, 2016 (reflecting a decrease of approximately $18 million as a result of cash payments). In 2017 , this amount was included in Other taxes payable ( $975 million ). In 2016 , these amounts were included in Income taxes payable ( $4 million ), Current tax asset s ( $13 million ) and Other taxes payable ( $754 million ). Accrued penalties are not significant. See also Note 5A. Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS: • With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014-2017 are open, but not under audit. All other tax years are closed. • With respect to Hospira, the federal income tax audit of tax years 2012-2013 was effectively settled in the third quarter of 2017. The IRS is currently auditing tax year 2014 through short-year 2015. All other tax years are closed. The tax years under audit for Hospira are not considered material to Pfizer. • With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2017), Japan (2015-2017), Europe (2011-2017, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2017, primarily reflecting Brazil) and Puerto Rico (2010-2017). Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $150 million , as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss) The following table provides the components of the Tax provision/(benefit) on other comprehensive income/(loss) : Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Foreign currency translation adjustments, net (a) $ (215 ) $ (15 ) $ 90 Unrealized holding gains/(losses) on derivative financial instruments, net 72 (75 ) (173 ) Reclassification adjustments for (gains)/losses included in net income (224 ) 158 104 (152 ) 83 (69 ) Unrealized holding gains/(losses) on available-for-sale securities, net 102 49 (104 ) Reclassification adjustments for (gains)/losses included in net income (60 ) (15 ) 59 42 34 (45 ) Benefit plans: actuarial losses, net (59 ) (535 ) (23 ) Reclassification adjustments related to amortization 192 186 183 Reclassification adjustments related to settlements, net 42 45 237 Other (39 ) 36 66 137 (269 ) 462 Benefit plans: prior service (costs)/credits and other, net — 67 160 Reclassification adjustments related to amortization (67 ) (64 ) (59 ) Reclassification adjustments related to curtailments, net (7 ) (10 ) (12 ) Other — (1 ) — (74 ) (7 ) 89 Tax provision/(benefit) on other comprehensive income/(loss) $ (262 ) $ (174 ) $ 528 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gain/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/ Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, January 1, 2015 $ (2,689 ) $ 517 $ (222 ) $ (5,654 ) $ 733 $ (7,316 ) Other comprehensive income/(loss) (a) (3,174 ) (96 ) (5 ) 921 148 (2,206 ) Balance, December 31, 2015 (5,863 ) 421 (227 ) (4,733 ) 880 (9,522 ) Other comprehensive income/(loss) (a) (797 ) (73 ) 96 (740 ) (1 ) (1,514 ) Balance, December 31, 2016 (6,659 ) 348 (131 ) (5,473 ) 879 (11,036 ) Other comprehensive income/(loss) (a) $ 1,479 (378 ) 532 $ 211 $ (129 ) $ 1,715 Balance, December 31, 2017 $ (5,180 ) $ (30 ) $ 401 $ (5,262 ) $ 750 $ (9,321 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $14 million income in 2017 , $3 million loss in 2016 and $26 million loss in 2015 . As of December 31, 2017 , we estimate that we will reclassify into 2018 income the following pre-tax amounts currently held in Accumulated other comprehensive loss : $81 million of unrealized pre-tax net losses on derivative financial instruments (which is expected to offset primarily net gains resulting from reclassification adjustments related to foreign currency exchange-denominated forecasted intercompany inventory sales and net gains related to available-for-sale securities); $247 million of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and $184 million of prior service credits, primarily related to benefit plan amendments.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2017
Financial Instruments [Abstract]
Financial Instruments	A. Fair Value Measurements Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We use a market approach, as described in Note 1E, in valuing financial instruments on a recurring basis. The following table presents the financial assets and liabilities measured at fair value on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Note 1E : Total Level 1 Level 2 Total Level 1 Level 2 (MILLIONS OF DOLLARS) December 31, 2017 December 31, 2016 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as trading securities: Equity (a) $ 19 $ — $ 19 $ — $ — $ — Classified as available-for-sale securities: Government and agency debt—non-U.S. 12,242 — 12,242 7,317 — 7,317 Corporate debt 2,766 — 2,766 2,783 — 2,783 Government debt—U.S. 252 — 252 2,630 — 2,630 Agency asset-backed debt—U.S. 23 — 23 39 — 39 Other asset-backed debt 79 — 79 367 — 367 Money market funds 2,115 — 2,115 1,431 — 1,431 Equity 16 16 — 1 1 — 17,493 16 17,477 14,567 1 14,566 Total short-term investments 17,512 16 17,496 14,567 1 14,566 Other current assets Derivative assets: Interest rate contracts 104 — 104 26 — 26 Foreign exchange contracts 234 — 234 540 — 540 Total other current assets 337 — 337 566 — 566 Long-term investments Classified as trading securities: Equity (a) 266 224 42 236 165 71 Debt 73 73 — 89 89 — 340 298 42 325 254 71 Classified as available-for-sale securities: Government and agency debt—non-U.S. 387 — 387 863 — 863 Corporate debt 4,172 36 4,136 4,306 — 4,306 Government debt—U.S. 495 — 495 88 — 88 Other asset-backed debt 35 — 35 239 — 239 Money market funds — — — 14 — 14 Equity 1,174 1,174 — 539 539 — 6,264 1,210 5,054 6,049 539 5,510 Total long-term investments 6,603 1,507 5,096 6,374 793 5,581 Other noncurrent assets Derivative assets: Interest rate contracts 477 — 477 599 — 599 Foreign exchange contracts 7 — 7 90 — 90 Total other noncurrent assets 484 — 484 689 — 689 Total assets $ 24,937 $ 1,523 $ 23,414 $ 22,197 $ 794 $ 21,403 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ 1 $ — $ 1 $ 1 $ — $ 1 Foreign exchange contracts 201 — 201 443 — 443 Total other current liabilities 201 — 201 444 — 444 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 177 — 177 147 — 147 Foreign exchange contracts 313 — 313 1,075 — 1,075 Total other noncurrent liabilities 490 — 490 1,222 — 1,222 Total liabilities $ 691 $ — $ 691 $ 1,666 $ — $ 1,666 (a) As of December 31, 2017 and December 31, 2016 , equity securities of $42 million and $71 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: December 31, 2017 December 31, 2016 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 33,538 $ 37,253 $ 37,253 $ 31,398 $ 34,896 $ 34,896 The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2017 or December 31, 2016 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach. In addition, as of December 31, 2017 and 2016 , we had long-term receivables where the determination of fair value employs discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. As of December 31, 2017 and 2016 , the differences between the estimated fair values and carrying values of these receivables were not significant. There were no significant impairments of financial assets recognized in any period presented. Total Short-Term and Long-Term Investments The following table represents our investments by classification type: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Short-term investments Trading securities $ 19 $ — Available-for-sale debt and equity securities 17,493 14,567 Held-to-maturity debt securities 1,138 688 Total Short-term investments $ 18,650 $ 15,255 Long-term investments Trading securities $ 340 $ 325 Available-for-sale debt and equity securities 6,264 6,049 Held-to-maturity debt securities 4 7 Private equity investments carried at equity-method or cost 408 735 Total Long-term investments $ 7,015 $ 7,116 Held-to-maturity cash equivalents $ 719 Fair Value Methodology The following inputs and valuation techniques were used to estimate the fair value of our financial assets and liabilities: • Trading equity securities—quoted market prices. • Trading debt securities—quoted market prices. • Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. Receivable-backed, loan-backed, and mortgage-backed debt securities are valued by third-party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates. • Available-for-sale equity securities—third-party pricing services that principally use a composite of observable prices. • Derivative assets and liabilities (financial instruments)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant. • Held-to-maturity debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. • Available-for-sale money market funds—observable net asset value prices. • Private equity securities, excluding equity-method investments—application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio. • Short-term borrowings and long-term debt—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and our own credit rating. We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments. B. Investments At December 31, 2017, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at December 31, 2017 and 2016 is as follows, including, as of December 31, 2017, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: December 31, 2017 December 31, 2016 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency debt –– non-U.S. $ 12,616 $ 61 $ (48 ) $ 12,629 $ 12,242 $ 387 $ — $ 12,629 $ 8,403 $ 11 $ (235 ) $ 8,179 Corporate debt (b) 6,955 15 (33 ) 6,938 2,766 2,630 1,542 6,938 7,162 16 (89 ) 7,089 Government debt––U.S. 765 — (19 ) 747 252 495 — 747 2,729 1 (12 ) 2,718 Agency asset-backed debt––U.S. 24 — (1 ) 24 23 — — 24 41 — (1 ) 39 Other asset-backed debt (c) 114 — — 114 79 32 3 114 607 1 (2 ) 605 Held-to-maturity debt securities Time deposits and other 1,091 — — 1,091 1,087 — 4 1,091 830 — — 830 Government and agency debt –– non-U.S. 770 — — 770 770 — — 770 412 — — 412 Total debt securities $ 22,337 $ 77 $ (100 ) $ 22,313 $ 17,219 $ 3,544 $ 1,550 $ 22,313 $ 20,184 $ 29 $ (339 ) $ 19,873 Available-for-sale equity securities Money market funds $ 2,115 $ — $ — $ 2,115 $ 1,446 $ — $ (1 ) $ 1,445 Equity 728 586 (124 ) 1,190 426 239 (125 ) 540 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 $ 1,872 $ 239 $ (126 ) $ 1,985 (a) Issued by a diverse group of corporations. (b) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. C. Short-Term Borrowings Short-term borrowings include: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Commercial paper $ 6,100 $ 5,800 Current portion of long-term debt, principal amount (a) 3,532 4,201 Other short-term borrowings, principal amount (b) 320 673 Total short-term borrowings, principal amount 9,951 10,674 Net fair value adjustments related to hedging and purchase accounting 14 24 Net unamortized discounts, premiums and debt issuance costs (12 ) (11 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 9,953 $ 10,688 (a) For additional information, see Note 7D . (b) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F . The weighted-average effective interest rate on commercial paper outstanding was approximately 1.36% as of December 31, 2017 and 0.83% as of December 31, 2016 . On June 24, 2016, we acquired Anacor and assumed its short-term debt with an acquisition date fair value of $698 million , which was redeemed in the second and third quarters of 2016. As of December 31, 2017 , we had approximately $7.0 billion of unused revolving credit facility, expiring in 2022, which may be used to support our commercial paper borrowings. D. Long-Term Debt New Issuances In 2017, we issued the following senior unsecured notes: Settlement Date Maturity Date Interest Rate Issue Currency Principal Amount March 6, 2017 March 2019 3-month EURIBOR+0.20% (0% floor) Euro € 1,250 March 2020 0.00 % Euro 1,000 March 2022 0.25 % Euro 1,000 March 2027 1.00 % Euro 750 € 4,000 (a) December 19, 2017 June 2043 2.735 % U.K. pound £ 1,376 (b) March 17, 2017 March 2047 4.20 % U.S. dollar $ 1,065 (c) (a) The weighted-average effective interest rate for the euro notes at issuance was 0.23% . (b) In December 2017, Pfizer exchanged approximately £ 833 million principal amount of the outstanding 6.50% debt due 2038 for £ 1.376 billion principal amount of 2.735% debt due 2043. This exchange constituted a debt extinguishment. See the following “Retirements” section for the income statement impact from the extinguishment. (c) The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020. On November 21, 2016, we completed a public offering of $6.0 billion aggregate principal amount of senior unsecured notes: $1.0 billion of notes due 2019; $1.0 billion of notes due 2021; $1.75 billion of notes due 2026; $1.0 billion of notes due 2036; and $1.25 billion of notes due 2046, with a weighted-average effective interest rate of 3.10% . On June 3, 2016, we completed a public offering of $5.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.09% . Acquisition of Hospira Debt On September 3, 2015, the Hospira acquisition date, our long-term debt increased due to the addition of an aggregate principal amount of $1,750 million of legacy Hospira debt, recorded at acquisition-date fair value of $1,928 million . In October 2015, Pfizer exchanged $1.7 billion debt of its then recently acquired subsidiary, Hospira, for virtually the same amount of Pfizer debt with the same interest rate and maturity terms as the Hospira debt, leaving a minor amount of outstanding debt in Hospira’s name that was redeemed during the fourth quarter of 2016. In connection with the exchange offers, the indenture governing the Hospira notes and the Hospira notes were amended to, among other things, eliminate substantially all of the restrictive covenants. The net income effect of this exchange was immaterial. Retirements In December 2017, we exchanged approximately £833 million and repurchased £197 million principal amount of the outstanding 6.50% debt before the maturity date at a redemption value of £1.7 billion , leaving £470 million principal amount of the 6.50% debt due 2038 outstanding. Also, in December 2017, we repurchased approximately €834 million principal amount of the outstanding 5.75% debt before the maturity date at a redemption value of €1.0 billion , leaving approximately €1.2 billion of the 5.75% euro-denominated debt due 2021 outstanding. As a result, we recorded a net loss of approximately $846 million and $153 million upon the exchange and early retirement of the U.K. pound-denominated debt and the early retirement of the euro-denominated debt, respectively, for a net loss on early retirement of debt of $999 million . which included the related termination of cross-currency swaps, and that were recorded in Other (income)/deductions––net in the consolidated statement of income (see Note 4 ). In November 2016, we repurchased $3.4 billion carrying value of outstanding debt before the maturity date at a redemption value of $3.7 billion . The debt repurchased included $3.27 billion carrying value of 6.20% senior notes due March 2019. As a result, we recorded a total net loss of approximately $312 million upon the early redemption of debt, which included the related termination of interest rate swaps, and which was recorded in Other (income)/deductions––net in the consolidated statement of income (see Note 4 ). The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2017 and 2016 by maturity. As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Notes due 2018 (2.3%) (a) $ — $ 3,532 Notes due 2019 (1.3% and 1.8%) 4,848 3,350 Notes due 2020 (1.1% and 5.2%) 1,528 330 Notes due 2021 (3.5% and 3.9%) 3,550 4,260 Notes due 2022 (0.3%) 1,199 — Notes due 2023 (4.3% and 4.3%) 1,592 1,592 Notes due 2024-2028 (3.5% and 3.9%) 6,259 5,360 Notes due 2034-2038 (5.7% and 5.9%) 4,886 6,102 Notes due 2039-2043 (5.2% and 6.4%) 5,606 3,745 Notes due 2044-2047 (4.2% and 4.2%) 3,315 2,250 Total long-term borrowings, principal amount 32,783 30,520 Net fair value adjustments related to hedging and purchase accounting 872 998 Net unamortized discounts, premiums and debt issuance costs (125 ) (130 ) Other long-term obligations 8 9 Total long-term borrowings, carried at historical proceeds, as adjusted $ 33,538 $ 31,398 Current portion of long-term debt, carried at historical proceeds (not included above (2.4% and 3.0%) $ 3,546 $ 4,225 (a) At December 31, 2017, the debt issuances have been reclassified to the current portion of long-term debt. Our long-term debt, provided in the above table, is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest. Other Noncurrent Liabilities In December 2017, the U.S. approved Bosulif (bosutinib) for the treatment of patients with newly-diagnosed chronic-phase Ph+ CML. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a ten-year period aggregating $416 million related to a research and development arrangement. As a result, during the fourth quarter of 2017 we recorded the estimated net present value of $364 million as an intangible asset in Developed technology rights , and we have recorded the present value of the remaining future payments of $281 million in Other noncurrent liabilities and $83 million in Other current liabilities as of December 31, 2017. In August 2017, the U.S. approved Besponsa (inotuzumab ozogamicin) and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating $296 million related to a research and development arrangement. As a result, during the third quarter of 2017 we recorded the estimated net present value of $248 million as an intangible asset in Developed technology rights , and we have recorded the present value of the remaining future payments of $236 million in Other noncurrent liabilities and $15 million in Other current liabilities as of December 31, 2017. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating $148 million related to a research and development arrangement. As a result, during the second quarter of 2017 we recorded the estimated net present value of $123 million as an intangible asset in Developed technology rights , and we have recorded the present value of the remaining future payments of $119 million in Other noncurrent liabilities and $6 million in Other current liabilities as of December 31, 2017. The differences between the estimated fair values, using a market approach in the Level 2 fair value hierarchy, and carrying values of the obligations were not significant as of December 31, 2017. F. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, and Canadian dollar. Changes in fair value are reported in earnings or in Other comprehensive income/(loss) , depending on the nature and purpose of the financial instrument (hedge or offset relationship) and the effectiveness of the hedge relationships, as follows: • We recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We recognize the offsetting foreign exchange impact attributable to the hedged item also in earnings. • We record in Other comprehensive income/(loss) the effective portion of the gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. • As part of our net investment hedging program, we recognize the gain and loss impact on foreign exchange contracts designated as hedges of our net investments in earnings in three ways: over time-for the periodic net swap payments; immediately-to the extent of any change in the difference between the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net investments-to the extent of change in the foreign exchange spot rates. We record in Other comprehensive income/(loss) the foreign exchange gains and losses related to foreign exchange-denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. • For certain foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on foreign currency exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted euro, Japanese yen, Chinese renminbi, U.K. pound, Canadian dollar, and Australian dollar-denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented. Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. We strive to invest and borrow primarily on a floating-rate basis; however, in light of current market conditions, we currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows: • We recognize the gains and losses on interest rate contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk also in earnings. Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented. The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) December 31, 2017 December 31, 2016 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,723 $ 179 $ 459 $ 14,424 $ 468 $ 1,135 Interest rate contracts 12,430 581 178 15,991 625 148 760 637 1,093 1,283 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,300 $ 62 $ 54 $ 13,100 $ 162 $ 382 Total $ 822 $ 691 $ 1,255 $ 1,665 (a) As of December 31, 2017, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion . The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of Gains/(Losses) Recognized in OID (a), (b) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (c) Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion) (a), (c) As of December 31, (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (d) $ (6 ) $ (4 ) $ (12 ) $ (444 ) $ 520 $ (451 ) Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (60 ) (181 ) — — — — Hedged item gain/(loss) 60 181 — — — — Foreign exchange contracts (19 ) (4 ) — — — — Hedged item gain/(loss) 19 4 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — 1 — (15 ) — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — — (26 ) — — Foreign currency long-term debt (e) — — (580 ) — — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (87 ) (105 ) — — — — All other net — — 2 1 1 (1 ) $ (93 ) $ (107 ) $ (591 ) $ (483 ) $ 520 $ (452 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income . COS = Cost of Sales, included in Cost of Sales in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income . (b) There was no significant ineffectiveness for any period presented. (c) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net. (d) Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $72 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.9 billion U.K. pound debt maturing in 2043. (e) Long-term debt includes foreign currency long-term borrowings with carrying values of $4.8 billion as of December 31, 2017, which are used as hedging instruments. Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. As of December 31, 2017 , the aggregate fair value of these derivative instruments that are in a net liability position was $336 million , for which we have posted collateral of $346 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties. As of December 31, 2017 , we received cash collateral of $226 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. For additional information, see Note 18C . For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request collateral payments, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see Note 7F above.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Finished goods $ 2,883 $ 2,293 Work in process 3,908 3,696 Raw materials and supplies 788 793 Inventories (a) $ 7,578 $ 6,783 Noncurrent inventories not included above (b) $ 683 $ 683 (a) The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, as well as an increase due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment The following table provides the components of Property, plant and equipment : Useful Lives As of December 31, (MILLIONS OF DOLLARS) (Years) 2017 2016 Land - $ 540 $ 530 Buildings 33-50 10,254 9,810 Machinery and equipment 8-20 11,902 11,248 Furniture, fixtures and other 3-12 1/2 4,661 4,410 Construction in progress - 2,680 2,127 30,037 28,125 Less: Accumulated depreciation 16,172 14,807 Property, plant and equipment (a) $ 13,865 $ 13,318 (a) The increase in total property, plant and equipment is primarily due to capital additions and the impact of foreign exchange, partially offset by depreciation, reductions due to restructuring efforts and disposals.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : December 31, 2017 December 31, 2016 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,550 $ (54,785 ) $ 34,765 $ 83,390 $ (49,650 ) $ 33,740 Brands 2,134 (1,152 ) 982 2,092 (1,032 ) 1,060 Licensing agreements and other 1,911 (1,096 ) 815 1,869 (1,005 ) 864 93,595 (57,033 ) 36,562 87,351 (51,687 ) 35,664 Indefinite-lived intangible assets Brands and other 6,929 6,929 6,883 6,883 IPR&D (a) 5,249 5,249 10,101 10,101 12,179 12,179 16,984 16,984 Identifiable intangible assets (b) $ 105,774 $ (57,033 ) $ 48,741 $ 104,335 $ (51,687 ) $ 52,648 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), (iv) the Developed technology rights of $364 million recorded in connection with the U.S. approval of Bosulif (see Note 7E ) and (v) the Developed technology rights of $140 million recorded in connection with the approvals of Bavencio (see Note 2C ) partially offset by (vi) measurement period adjustments related to Medivation (see Note 2A ) and (vii) impairments of Developed technology rights (see Note 4 ) . (b) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to (i) amortization, (ii) measurement period adjustments related to Medivation (see Note 2A ), as well as (iii) impairments of Developed technology rights (see Note 4 ), partially offset by (iv) assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (v) the assets recorded in connection with the EU and U.S. approvals of Besponsa and in connection with the U.S. approval of Bosulif (see Note 7E ) and (vi) the assets recorded in connection with the approvals of Bavencio (see Note 2C ). Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: December 31, 2017 IH EH WRD Developed technology rights 68 % 31 % — Brands, finite-lived 75 % 25 % — Brands, indefinite-lived 71 % 29 % — IPR&D 81 % 12 % 7 % Developed Technology Rights Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Xtandi, Prevnar 13/Prevenar 13 Infant, Eucrisa, Enbrel, Premarin, Prevnar 13/Prevenar 13 Adult, and, to a lesser extent Tygacil, Pristiq, Refacto AF and Zavicefta. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products. Brands Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. Most of these assets are associated with our Consumer Healthcare business unit. The more significant components of indefinite-lived brands are the following (in order of significance): Advil, Xanax/Xanax XR, Centrum, Caltrate, Medrol and Preparation H. The more significant components of finite-lived brands are the following (in order of significance): Nexium, Depo-Provera, Zavedos and, to a lesser extent, Idoform Bifiform, Polocard and Advil Cold and Sinus. IPR&D IPR&D assets represent R&D assets that have not yet received regulatory approval in a major market. The more significant components of IPR&D at December 31, 2017 are the programs for the treatment of non-metastatic and metastatic prostate cancer and the program for the oral PARP inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer, both acquired as part of the Medivation acquisition. IPR&D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&D effort. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&D and begin amortization. If the associated R&D effort is abandoned, the related IPR&D assets will likely be written-off, and we will record an impairment charge. For IPR&D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&D assets will become impaired and be written off at some time in the future. Amortization The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately 10 years. Total amortization expense for finite-lived intangible assets was $4.8 billion in 2017 , $4.1 billion in 2016 and $3.8 billion in 2015 . The following table provides the annual amortization expense expected for the years 2018 through 2022: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 2022 Amortization expense $ 4,798 $ 4,592 $ 3,569 $ 3,474 $ 3,223 B. Goodwill The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, January 1, 2016 $ 23,809 $ 24,433 $ 48,242 Additions (a) 6,357 12 6,369 Other (b) (32 ) (130 ) (162 ) Balance, December 31, 2016 30,134 24,315 54,449 Additions (c) 572 92 664 Other (d) 435 404 840 Balance, December 31, 2017 $ 31,141 $ 24,811 $ 55,952 (a) IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo (see Note 2A ). (b) Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $119 million to Assets held for sale during 2016 (see Note 2B ). (c) IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ). (d) Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans and Defined Contribution Plans	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans and Defined Contribution Plans	The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. Effective January 1, 2018, there were two significant defined benefit pension plans that were frozen to future benefit accruals in the U.S. and U.K. and will result in the elimination of future service costs for those plans. A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Loss The following table provides the annual (income)/cost and changes in Other comprehensive income/(loss) for our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) 2017 2016 2015 2017 2016 2015 2017 2016 2015 2017 2016 2015 Service cost $ 269 $ 257 $ 287 $ 24 $ 18 $ 22 $ 171 $ 165 $ 186 $ 42 $ 41 $ 55 Interest cost 634 646 676 54 53 54 204 233 307 90 101 117 Expected return on plan assets (1,005 ) (958 ) (1,089 ) — — — (345 ) (381 ) (418 ) (36 ) (34 ) (53 ) Amortization of: Actuarial losses 393 395 346 50 37 44 116 93 122 31 32 38 Prior service cost/(credits) 3 5 (5 ) (1 ) (1 ) (2 ) (4 ) (3 ) (7 ) (182 ) (174 ) (146 ) Curtailments 13 10 3 1 1 — — (2 ) 5 (19 ) (26 ) (31 ) Settlements 75 90 556 39 28 34 4 9 81 — — — Special termination benefits — — — — — — 1 1 1 — — — Net periodic benefit costs/(income) reported in Income 382 444 773 166 137 153 147 115 277 (75 ) (59 ) (21 ) (Income)/cost reported in Other comprehensive income/(loss) (b) 141 253 (396 ) 23 121 (143 ) (301 ) 640 (542 ) (8 ) 3 (540 ) (Income)/cost recognized in Comprehensive income $ 523 $ 697 $ 378 $ 189 $ 258 $ 10 $ (154 ) $ 755 $ (265 ) $ (83 ) $ (56 ) $ (560 ) (a) In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3 ). In 2015, the net periodic benefit costs included settlement losses primarily related to participants accepting the lump-sum option made in an offer to certain plan participants to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or to elect an early annuity. (b) In 2017 and 2016, the changes to Other comprehensive (income)/loss for the international plans was impacted by foreign currency movements. For details of the changes in Other comprehensive (income)/loss, see the benefit plan activity in the consolidated statements of comprehensive income. The following table provides the amounts in Accumulated other comprehensive loss expected to be amortized into 2018 net periodic benefit costs: Pension Plans (MILLIONS OF DOLLARS) U.S. U.S. Supplemental International Postretirement Plans Actuarial losses (a) $ (121 ) $ (16 ) $ (101 ) $ (9 ) Prior service credits and other (2 ) 1 4 181 Total $ (123 ) $ (15 ) $ (97 ) $ 172 (a) Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans will reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for 2018 are 24.8 years for our U.S. qualified plans, 26.2 years for our U.S. supplemental (non-qualified) plans, 20.0 years for our international plans, and 9.7 for our postretirement plans. B. Actuarial Assumptions The following table provides the weighted-average actuarial assumptions of our benefit plans: (PERCENTAGES) 2017 2016 2015 Weighted-average assumptions used to determine benefit obligations Discount rate: U.S. qualified pension plans 3.8% 4.3% 4.5% U.S. non-qualified pension plans 3.7% 4.2% 4.5% International pension plans 2.3% 2.4% 3.1% Postretirement plans 3.7% 4.2% 4.5% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.5% 2.6% 2.6% Weighted-average assumptions used to determine net periodic benefit cost Discount rate: U.S. qualified pension plans 4.3% 4.5% 4.2% U.S. non-qualified pension plans 4.2% 4.5% 4.0% International pension plans interest cost (a) 2.1% 2.7% 3.0% International pension plans service cost (a) 2.3% 3.0% 3.0% Postretirement plans 4.2% 4.5% 4.2% Expected return on plan assets: U.S. qualified pension plans 8.0% 8.0% 8.3% International pension plans 4.7% 5.2% 5.5% Postretirement plans 8.0% 8.0% 8.3% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.6% 2.6% 2.7% (a) Effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with this change, the effective rate for interest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans. The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit obligations are established at each fiscal year-end. The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits. The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2017 resulted in lower discount rates as compared to the prior year. The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans: 2017 2016 Healthcare cost trend rate assumed for next year (up to age 65) 6.1 % 6.3 % Healthcare cost trend rate assumed for next year (age 65 and older) 7.0 % 7.4 % Rate to which the cost trend rate is assumed to decline 4.5 % 4.5 % Year that the rate reaches the ultimate trend rate 2037 2037 The following table provides the effects as of December 31, 2017 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits: (MILLIONS OF DOLLARS) Increase Decrease Effect on total service and interest cost components $ 3 $ (4 ) Effect on postretirement benefit obligation 47 (26 ) Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see Note 1C . C. Obligations and Funded Status The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International (b) Postretirement Plans (c) (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 2017 2016 Change in benefit obligation (d) Benefit obligation, beginning $ 15,547 $ 14,926 $ 1,450 $ 1,343 $ 9,691 $ 9,214 $ 2,254 $ 2,463 Service cost 269 257 24 18 171 165 42 41 Interest cost 634 646 54 53 204 233 90 101 Employee contributions — — — — 6 7 94 85 Plan amendments — — — — 2 (6 ) — (177 ) Changes in actuarial assumptions and other 1,614 725 110 185 135 1,273 (177 ) 22 Foreign exchange impact — — — — 760 (781 ) 5 — Acquisitions/divestitures/other, net — — — — 26 1 1 — Curtailments 11 9 — 1 — (14 ) 1 — Settlements (842 ) (449 ) (98 ) (78 ) (31 ) (45 ) — — Special termination benefits — — — — 1 1 — — Benefits paid (530 ) (568 ) (45 ) (72 ) (357 ) (358 ) (280 ) (282 ) Benefit obligation, ending (d) 16,702 15,547 1,495 1,450 10,607 9,691 2,028 2,254 Change in plan assets Fair value of plan assets, beginning 12,556 11,633 — — 7,683 7,959 458 622 Actual gain/(loss) on plan assets 2,005 939 — — 811 693 39 44 Company contributions 1,095 1,000 143 151 160 209 183 (12 ) Employee contributions — — — — 6 7 94 85 Foreign exchange impact — — — — 561 (782 ) — — Acquisitions/divestitures, net — — — — 30 (1 ) — — Settlements (842 ) (449 ) (98 ) (78 ) (31 ) (45 ) — — Benefits paid (530 ) (568 ) (45 ) (72 ) (357 ) (358 ) (280 ) (282 ) Fair value of plan assets, ending 14,284 12,556 — — 8,863 7,683 494 458 Funded status—Plan assets less than benefit obligation $ (2,418 ) $ (2,990 ) $ (1,495 ) $ (1,450 ) $ (1,745 ) $ (2,008 ) $ (1,534 ) $ (1,796 ) (a) The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017. (b) The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements. (c) The favorable change in the funded status of our postretirement plans was primarily due to a change to reimbursements of certain benefits provided under the plan, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017. (d) For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $16.7 billion in 2017 and $15.4 billion in 2016 . The ABO for our U.S. supplemental (non-qualified) pension plans was $1.5 billion in 2017 and $1.4 billion in 2016 . The ABO for our international pension plans was $10.1 billion in 2017 and $9.3 billion in 2016 . The following table provides information as to how the funded status is recognized in our consolidated balance sheets: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 2017 2016 Noncurrent assets (a) $ — $ — $ — $ — $ 454 $ 300 $ — $ — Current liabilities (b) — (160 ) (160 ) (152 ) (26 ) (28 ) (31 ) (30 ) Noncurrent liabilities (c) (2,418 ) (2,830 ) (1,336 ) (1,297 ) (2,172 ) (2,279 ) (1,504 ) (1,766 ) Funded status $ (2,418 ) $ (2,990 ) $ (1,495 ) $ (1,450 ) $ (1,745 ) $ (2,008 ) $ (1,534 ) $ (1,796 ) (a) Included primarily in Other noncurrent assets . (b) Included in Accrued compensation and related items . (c) Included in Pension benefit obligations, net and Postretirement benefit obligations , net, as appropriate. The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss : As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 2017 2016 Actuarial losses (a) $ (4,677 ) $ (4,530 ) $ (561 ) $ (538 ) $ (2,322 ) $ (2,629 ) $ (293 ) $ (502 ) Prior service (costs)/credits (23 ) (27 ) 1 2 34 40 1,190 1,392 Total $ (4,699 ) $ (4,558 ) $ (559 ) $ (536 ) $ (2,288 ) $ (2,589 ) $ (897 ) $ (889 ) (a) The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the expected life expectancy of plan participants for frozen plans, using the corridor approach. The following table provides information related to the funded status of selected benefit plans: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 Pension plans with an ABO in excess of plan assets: Fair value of plan assets $ 14,284 $ 12,556 $ — $ — $ 882 $ 4,625 ABO 16,702 15,422 1,495 1,410 2,724 6,558 Pension plans with a PBO in excess of plan assets: Fair value of plan assets 14,284 12,556 — — 1,626 4,936 PBO 16,702 15,547 1,495 1,450 3,825 7,244 All of our U.S. plans and many of our international plans were underfunded as of December 31, 2017 . D. Plan Assets The following table provides the components of plan assets: Fair Value (a) Fair Value (a) (MILLIONS OF DOLLARS) As of Level 1 Level 2 Level 3 Assets Measured at NAV (b) As of Level 1 Level 2 Level 3 Assets Measured at NAV (b) U.S. qualified pension plans Cash and cash equivalents $ 655 $ 115 $ 540 $ — $ — $ 672 $ 92 $ 580 $ — $ — Equity securities: Global equity securities 4,157 4,118 38 1 — 3,970 3,943 27 — — Equity commingled funds 1,194 — 802 — 392 1,062 — 772 — 290 Fixed income securities: Corporate debt securities 4,250 5 4,242 3 — 3,232 14 3,217 1 — Government and agency obligations 1,316 — 1,316 — — 1,060 — 1,060 — — Fixed income commingled funds 94 — — — 94 92 — — — 92 Other investments: Partnership investments (c) 1,197 — — — 1,197 1,093 — — — 1,093 Insurance contracts 215 — 215 — — 235 — 235 — — Other commingled funds (d) 1,206 — — — 1,206 1,140 — — — 1,140 Total 14,284 4,238 7,153 4 2,889 12,556 4,049 5,891 1 2,615 International pension plans Cash and cash equivalents $ 385 $ 48 $ 337 $ — $ — 439 38 401 — — Equity securities: Global equity securities 154 146 8 — — 174 163 11 — — Equity commingled funds 2,897 — 1,594 — 1,303 2,490 — 1,265 — 1,224 Fixed income securities: Corporate debt securities 588 — 588 — — 489 — 474 — 15 Government and agency obligations (e) 716 — 716 — — 853 — 786 — 67 Fixed income commingled funds 2,181 — 1,340 — 841 1,750 — 1,174 — 576 Other investments: Partnership investments (c) 42 — 7 — 35 32 — — — 32 Insurance contracts (f) 496 — 75 420 1 272 — 17 254 1 Other (d), (f) 1,404 — 408 468 528 1,185 — 430 324 431 Total 8,863 194 5,073 887 2,709 7,683 201 4,558 578 2,346 U.S. postretirement plans (g) Cash and cash equivalents — — — — — — — — — — Equity securities: Global equity securities — — — — — — — — — — Equity commingled funds — — — — — — — — — — Fixed income securities: Corporate debt securities — — — — — — — — — — Government and agency obligations — — — — — — — — — — Fixed income commingled funds — — — — — — — — — — Other investments: Partnership investments (c) — — — — — — — — — — Insurance contracts 494 — 494 — — 458 — 458 — — Other commingled funds (d) — — — — — — — — — — Total $ 494 $ — $ 494 $ — $ — $ 458 $ — $ 458 $ — $ — (a) Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E ). (b) Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets. (c) Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital. (d) Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds. (e) Government and agency obligations are inclusive of repurchase agreements. (f) See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs. (g) Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans. The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs: Year Ended December 31, International Pension Plans Insurance contracts Other (MILLIONS OF DOLLARS) 2017 2016 2017 2016 Fair value, beginning $ 254 $ 219 $ 324 $ 398 Actual return on plan assets: Assets held, ending 1 11 18 (1 ) Assets sold during the period — — 1 6 Purchases, sales and settlements, net 138 20 94 (18 ) Exchange rate changes 27 4 30 (61 ) Fair value, ending $ 420 $ 254 $ 468 $ 324 A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C. Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months. The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets: • Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds. • Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price. • Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs. • Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures. The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans: As of December 31, Target Allocation Percentage Percentage of Plan Assets (PERCENTAGES) 2017 2017 2016 U.S. qualified pension plans Cash and cash equivalents 0-10% 4.6 % 5.3 % Equity securities 35-55% 37.5 % 40.1 % Fixed income securities 30-55% 39.6 % 34.9 % Other investments (a) 5-17.5% 18.3 % 19.7 % Total 100 % 100 % 100 % International pension plans Cash and cash equivalents 0-10% 4.3 % 5.7 % Equity securities 25-50% 34.4 % 34.7 % Fixed income securities 30-55% 39.3 % 40.2 % Other investments 10-30% 21.9 % 19.4 % Total 100 % 100 % 100 % U.S. postretirement plans Cash and cash equivalents 0-5% — — Equity securities — — — Fixed income securities — — — Other investments 95-100% 100 % 100 % Total 100 % 100 % 100 % (a) Actual percentage of plan assets in Other investments for 2017 includes $215 million , as compared to $235 million in 2016, related to a group fixed annuity insurance contract that was executed by legacy Wyeth for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $253 million in 2017, as compared to $144 million in 2016, related to an investment in a partnership whose primary holdings are public equity securities. Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations. Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans’ long-term benefit obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset classes and our liability profile. Each pension plan is overseen by a local committee or board that is responsible for the overall investment of the pension plan assets. In determining investment policies and associated target allocations, each committee or board considers a wide variety of factors. As such, the target asset allocation for each of our international pension plans is set on a standalone basis by the relevant board or committee. The target asset allocation ranges shown for the international pension plans seek to reflect the combined target allocations across all such plans, while also showing the range within which the target allocations for each plan typically falls. The investment managers of certain separately managed accounts, commingled funds and private equity funds may be permitted to use repurchase agreements and derivative securities, including U.S. Treasury and equity futures contracts as described in each respective investment management, subscription, partnership or other governing agreement. E. Cash Flows It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws. The following table provides the expected future cash flow information related to our benefit plans: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Expected employer contributions: 2018 (a) $ 500 $ 160 $ 226 $ 167 Expected benefit payments: 2018 $ 1,225 $ 160 $ 368 $ 173 2019 1,071 129 373 179 2020 1,087 128 385 181 2021 1,059 122 394 179 2022 1,032 123 401 173 2023–2027 4,865 513 2,101 802 (a) For the U.S. qualified plans, a $500 million voluntary contribution was paid in February 2018. The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation and, therefore, actual benefit payments may differ from projected benefit payments. F. Defined Contribution Plans We have defined contribution plans in the U.S. and several other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. Beginning on January 1, 2011, for newly hired non-union employees, rehires and transfers to the U.S. or Puerto Rico, we no longer offer a defined benefit pension plan and, instead, offer a Retirement Savings Contribution (RSC) in the defined contribution plan. The RSC is an annual non-contributory employer contribution (that is not dependent upon the participant making a contribution) determined based on each employee’s eligible compensation, age and years of service. Beginning on January 1, 2018, all non-union employees in the U.S. and Puerto Rico defined benefit plans transitioned to the RSC in the defined contribution plans. We recorded charges related to the employer contributions to global defined contribution plans of $380 million in 2017 , $317 million in 2016 and $287 million in 2015 .

Equity

Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Equity	Equity A. Common Stock We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. On June 27, 2013, we announced that the Board of Directors had authorized a $10 billion share-purchase plan, which was exhausted in the first quarter of 2015. On October 23, 2014, we announced that the Board of Directors had authorized an additional $11 billion share repurchase program, which was exhausted in the first quarter of 2017. In December 2015, the Board of Directors authorized a new $11 billion share repurchase program (the December 2015 Stock Purchase Plan) to be utilized over time, and share repurchases commenced thereunder in the first quarter of 2017. In December 2017, the Board of Directors authorized a new $10 billion share repurchase program to be utilized over time. This new program is in addition to the $6.4 billion remaining under the December 2015 Stock Purchase Plan as of December 31, 2017. On February 9, 2015, we entered into an accelerated share repurchase agreement with GS&Co. to repurchase shares of our common stock. This agreement was entered into under our previously announced share repurchase authorization. Pursuant to the terms of the agreement, on February 11, 2015, we paid $5 billion to GS&Co. and received approximately 151 million shares of our common stock from GS&Co. On July 2, 2015, the accelerated share repurchase agreement with GS&Co. was completed, which, per the terms of the agreement, resulted in us owing GS&Co. a certain number of shares of Pfizer common stock or its equivalent dollar value. Pursuant to the agreement’s settlement terms, we elected to settle this amount in cash and paid an additional $160 million to GS&Co. on July 13, 2015, resulting in a total of approximately $5.2 billion paid to GS&Co. The final average price paid for the shares delivered under the accelerated share repurchase agreement was $34.13 per share. On March 8, 2016, we entered into an accelerated share repurchase agreement with GS&Co. to repurchase $5 billion of our common stock. Pursuant to the terms of the agreement, on March 10, 2016, we paid $5 billion to GS&Co. and received an initial delivery of approximately 136 million shares of our common stock from GS&Co. based on a price of $29.36 per share, which represented, based on the closing share price of our common stock on the NYSE on March 8, 2016, approximately 80% of the notional amount of the accelerated share repurchase agreement. On June 20, 2016, the accelerated share repurchase agreement with GS&Co. was completed, which, per the terms of the agreement, resulted in GS&Co. owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 18 million shares of our common stock from GS&Co. on June 20, 2016. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was $32.38 per share. The common stock received is included in Treasury stock . This agreement was entered into pursuant to our previously announced share repurchase authorization. On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase $5 billion of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid $5 billion to Citibank and received an initial delivery of approximately 126 million shares of our common stock from Citibank at a price of $31.73 per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately 80% of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 24 million shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was $33.31 per share. The common stock received is included in Treasury Stock . This agreement was entered into pursuant to our previously announced share repurchase authorization. The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including our accelerated share repurchase agreements: (SHARES IN MILLIONS, DOLLARS IN BILLIONS) 2017 (a) 2016 (b) 2015 (c) Shares of common stock purchased 150 154 182 Cost of purchase $ 5.0 $ 5.0 $ 6.2 (a) Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on February 2, 2017. See above for additional information. (b) Represents shares purchased pursuant to the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information. (c) Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015. At December 31, 2017 , our remaining share-purchase authorization was approximately $16.4 billion . B. Preferred Stock The Series A convertible perpetual preferred stock is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of 6.25% , which are accumulated and paid quarterly. The per-share stated value is $40,300 and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder’s option, into 2,574.87 shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of $40,300 per share. C. Employee Stock Ownership Plans We have two employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP). Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of December 31, 2017 , the Preferred ESOP held preferred shares convertible into approximately 1 million shares of our common stock, and the Common ESOP held approximately 51 million shares of our common stock. As of December 31, 2017 , all shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $11 million in 2017 , $9 million in 2016 and $8 million in 2015 . Prior to 2015, Pfizer matching contributions were primarily invested in the Common ESOP. Beginning in January 2015, Pfizer matching contributions are being invested based on the investment direction of the employees’ own contributions. As a result, the compensation cost related to the Common ESOP was significantly lower after 2014.

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments Our compensation programs can include share-based payments. The award value is determined by reference to the fair value of share-based awards to similar employees in competitive survey data or industry peer groups used for compensation purposes; and is allocated between different long-term incentive vehicles, in the form of RSUs, PPSs, TSRUs, stock options, PSAs, PTSRUs and PTUs, as determined by the Compensation Committee. The 2014 Stock Plan (2014 Plan) replaced and superseded the 2004 Plan, as amended and restated. The 2014 Plan provides for 520 million shares to be authorized for grants, plus any shares remaining available for grant under the 2004 Plan as of April 24, 2014 (the carryforward shares). In addition, the 2014 Plan provides that the number of stock options, Stock Appreciation Rights (known as TSRUs and PTSRUs), RSUs, or other performance-based awards that may be granted to any one individual during any 36-month period is limited to 20 million shares, and that RSUs, PPSs and PSAs count as three shares, while TSRUs, PTSRUs and stock options count as one share, toward the maximum shares available under the 2014 plan. The 2004 Plan provided that the number of stock options, TSRUs or other performance-based awards granted to any one individual during any 36-month period was limited to 8 million shares, and that RSUs, PPSs and PSAs counted against the maximum available shares as two shares, while stock options and TSRUs counted as one share. As of December 31, 2017 , 290 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs. A. Impact on Net Income The following table provides the components of share-based compensation expense and the associated tax benefit: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Restricted Stock Units $ 301 $ 299 $ 306 Total Shareholder Return Units 221 134 36 Portfolio Performance Shares 209 135 147 Stock Options 55 106 165 Performance Share Awards 47 13 11 Directors’ compensation 7 4 4 Share-based payment expense 840 691 669 Tax benefit for share-based compensation expense (a) (163 ) (205 ) (198 ) Share-based payment expense, net of tax $ 677 $ 486 $ 471 (a) 2017 includes the impact of the TCJA on income taxes. Amounts capitalized as part of inventory cost were not significant for any period presented. B. Restricted Stock Units RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of our common stock, including shares resulting from dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after three years of continuous service from the grant date. We measure the value of RSU grants as of the grant date using the closing price of our common stock. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate. The following table summarizes all RSU activity during 2017: Shares (Thousands) Weighted-Average Grant-Date Fair Value Per Share Nonvested, December 31, 2016 29,605 $ 32.59 Granted 9,669 34.05 Vested (a) (16,677 ) 33.41 Reinvested dividend equivalents 1,106 33.41 Forfeited (1,463 ) 32.77 Nonvested, December 31, 2017 22,241 $ 32.64 (a) Includes the modification for a commitment to pay 6.4 million RSUs to approximately 9,900 employees, including senior and key management employees, for the 6.6 million RSUs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification. The following table provides data related to all RSU activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2017 2016 2015 Total fair value of shares vested (a) $ 584 $ 293 $ 371 Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax $ 254 $ 262 $ 279 Weighted-average period over which RSU cost is expected to be recognized (years) 1.7 1.7 1.8 (a) Includes the modification for a commitment to pay 6.4 million RSUs to approximately 9,900 employees, including senior and key management employees, for the 6.6 million RSUs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification. C. Stock Options Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant. Beginning in 2016, only a limited set of overseas employees received stock option grants. No stock options were awarded to senior and other key management in any period presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted since 2005 vest after three years of continuous service from the grant date and have a contractual term of 10 years. In most cases, stock options must be held for at least one year from the grant date before any vesting may occur. In the event of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period from three months to their remaining term, depending on various conditions. We measure the value of stock option grants as of the grant date using the Black-Scholes-Merton option-pricing model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate. The following table provides the weighted-average assumptions used in the valuation of stock options: Year Ended December 31, 2017 2016 2015 Expected dividend yield (a) 3.69 % 3.85 % 3.19 % Risk-free interest rate (b) 2.23 % 1.55 % 1.89 % Expected stock price volatility (c) 18.39 % 21.64 % 18.34 % Expected term (years) (d) 6.75 6.75 6.75 (a) Determined using a constant dividend yield during the expected term of the option. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility. (d) Determined using historical exercise and post-vesting termination patterns. The following table summarizes all stock option activity during 2017: Shares (Thousands) Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (a) (Millions) Outstanding, December 31, 2016 186,676 $ 26.86 Granted 1,375 34.06 Exercised (34,686 ) 24.94 Forfeited (1,208 ) 34.26 Expired (1,400 ) 30.78 Outstanding, December 31, 2017 150,757 27.27 5.1 $ 1,350 Vested and expected to vest, December 31, 2017 (b) 150,368 27.25 5.1 1,349 Exercisable, December 31, 2017 108,747 $ 24.49 4.3 $ 1,276 (a) Market price of our underlying common stock less exercise price. (b) The number of options expected to vest takes into account an estimate of expected forfeitures. The following table summarizes data related to all stock option activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS) 2017 2016 2015 Weighted-average grant-date fair value per stock option $ 4.01 $ 3.89 $ 4.30 Aggregate intrinsic value on exercise $ 331 $ 389 $ 666 Cash received upon exercise $ 862 $ 1,019 $ 1,263 Tax benefits realized related to exercise $ 95 $ 112 $ 187 Total compensation cost related to nonvested stock options not yet recognized, pre-tax $ 10 $ 58 $ 159 Weighted-average period over which stock option compensation cost is expected to be recognized (years) 0.8 1.1 1.8 D. Portfolio Performance Shares PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible range of shares of our common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards vest after three years of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a 5-year performance period from the year of the grant date. The number of shares that may be earned over the performance period ranges from 0% to 200% of the initial award. We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved and/or changes in management’s assessment of the probable vesting term. The following table summarizes all PPS activity during 2017, with the shares representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2016 22,266 $ 32.48 Granted 7,013 34.06 Vested (7,196 ) 34.28 Forfeited (1,110 ) 33.62 Nonvested, December 31, 2017 (a) 20,973 $ 36.22 (a) Vested and non-vested shares outstanding, but not paid as of December 31, 2017 were 35.0 million . Included in this amount is the modification for a commitment to pay 5.7 million PPSs to approximately 2,800 employees, including senior and key management employees, for the 5.9 million PPSs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. The following table provides data related to all PPS activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2017 2016 2015 Total fair value of shares vested $ 131 $ 118 $ 60 Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax $ 94 $ 93 $ 102 Weighted-average period over which PPS cost is expected to be recognized (years) 1.7 1.8 1.7 E. Total Shareholder Return Units TSRUs are awarded to senior and other key management, and, beginning in 2016, to certain other employees. TSRUs entitle the holders to receive a number of shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the five-year or seven-year term, if and to the extent the total value is positive. The settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant. The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture. On October 26, 2016, the Compensation Committee approved the modification of current outstanding grants of TSRU awards, effective November 1, 2016, to permit a holder who is "retiree eligible" (at least age 55 with at least 10 years of service), to elect to exercise and convert his/her TSRUs when vested, into PTUs. The value received upon the election and conversion is calculated by taking the change in stock price ( 20 trading day average ending on the exercise date (Election Price) less the grant price) plus accumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to determine the number of PTUs. The PTUs will be entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs original settlement date (i.e., the fifth or seventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. This modification applied to approximately 2,900 employees, including members of senior management. There was no incremental compensation cost resulting from the modification. In 2017, TSRUs were granted with the right for retirement-eligible employees to elect to exercise and convert their TSRUs, when vested, into PTUs. We measure the value of TSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate. The following table provides the weighted-average assumptions used in the valuation of TSRUs: Year Ended December 31, 2017 2016 2015 Expected dividend yield (a) 3.69 % 3.85 % 3.19 % Risk-free interest rate (b) 1.98 % 1.31 % 1.76 % Expected stock price volatility (c) 18.39 % 21.64 % 18.41 % Contractual term (years) 5.11 5.12 5.91 (a) Determined using a constant dividend yield during the expected term of the TSRU. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility. The following table summarizes all TSRU activity during 2017: TSRUs (Thousands) Weighted-Average Grant-Date Fair Value Per TSRU Weighted-Average Grant Price Per TSRU Nonvested, December 31, 2016 62,007 $ 5.97 $ 31.10 Granted 52,574 6.23 34.06 Vested (5,805 ) 6.50 32.25 Forfeited (4,870 ) 6.02 32.36 Nonvested, December 31, 2017 103,906 $ 6.07 $ 32.47 The following table summarizes TSRU and PTU information as of December 31, 2017 (a), (b) : TSRUs (Thousands) PTUs (Thousands) Weighted-Average Grant Price Per TSRU Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions) TSRUs Outstanding 124,745 — $ 31.37 3.3 $ 896 TSRUs Vested (c) 20,839 — 25.89 1.2 335 TSRUs Expected to vest (d) 95,485 — 32.45 3.7 516 TSRUs exercised and converted to PTUs (e) — 36 $ — 0.2 $ 1 (a) In 2017 , we settled 11,327,156 TSRUs with a weighted-average grant price of $22.26 per unit. This includes the modification for a commitment to pay 7.0 million TSRUs to approximately 150 employees, including senior and key management employees, for the 7.2 million TSRUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. (b) In 2017 , 46,278 TSRUs with a weighted-average grant price of $22.65 per unit were converted into 24,602 PTUs. (c) This includes the modification for a commitment to pay 7.0 million TSRUs to approximately 150 employees, including senior and key management employees, for the 7.2 million TSRUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. (d) The number of TSRUs expected to vest takes into account an estimate of expected forfeitures. (e) Includes the modification for a commitment to pay 17,000 PTUs to a few employees, including senior and key management employees, for the 17,000 PTUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. The following table provides data related to all TSRU activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS) 2017 2016 2015 Weighted-average grant-date fair value per TSRU $ 6.23 $ 5.83 $ 6.66 Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax $ 232 $ 164 $ 29 Weighted-average period over which TSRU cost is expected to be recognized (years) 1.7 1.9 1.8 F. Performance Share Awards PSAs are awarded to senior and other key management. PSAs vest after three years of continuous service from the grant date. The number of shares paid, if any, including shares resulting from dividend equivalents, for awards granted in 2015 and later, depends upon the achievement of predetermined goals related to two measures: (i) operating income over three one-year periods; and (ii) TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the three-year performance period. The number of shares paid from awards granted in 2014 depends upon the achievement of predetermined goals related to Pfizer's TSR as compared to an industry peer group, for the three-year performance period from the year of the grant date. The number of shares that are earned over the performance period ranges from 0% to 200% of the initial award. We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved. The following table summarizes all PSA activity during 2017, with the shares granted representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2016 4,546 $ 32.48 Granted 1,753 34.06 Vested (a) (1,639 ) 35.65 Forfeited (635 ) 34.16 Nonvested, December 31, 2017 4,024 $ 36.22 (a) Includes the modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and key management employees, for the 1.1 million PSAs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification. The following table provides data related to all PSA activity: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Total fair value of shares vested (a) $ 58 $ 9 $ 14 Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax $ 34 $ 30 $ 24 Weighted-average period over which PSA cost is expected to be recognized (years) 1.8 1.8 1.9 (a) Includes the modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and key management employees, for the 1.1 million PSAs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification. G. Performance Total Shareholder Return Units PTSRUs were awarded to the Chairman and Chief Executive Officer and the Group President, Pfizer Essential Health. These awards were granted in connection with our announcement on November 13, 2017, that our Group President, Pfizer Innovative Health, had been appointed Chief Operating Officer of Pfizer effective January 1, 2018. We also announced that effective January 1, 2018, the Group President, Pfizer Essential Health, had been appointed Group President, Pfizer Innovative Health. In addition to having the same characteristics of TSRUs, PTSRUs require special service and performance conditions. On December 29, 2017, 1,372,213 PTSRUs were granted to the Chairman and Chief Executive Officer and 343,053 PTSRUs were granted to the new head of Innovative Health at a grant price of $36.22 and a grant-date fair value of $5.83 . We measure the value of PTSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Selling, informational and administrative expenses as appropriate. The following table provides the weighted-average assumptions used in the valuation of PTSRUs: Year Ended December 31, 2017 Expected dividend yield (a) 3.69 % Risk-free interest rate (b) 2.25 % Expected stock price volatility (c) 16.12 % Contractual term (years) 5 (a) Determined using a constant dividend yield during the expected term of the PTSRU. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility.

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders The following table provides the detailed calculation of Earnings per common share (EPS): Year Ended December 31, (IN MILLIONS) 2017 2016 2015 EPS Numerator––Basic Income from continuing operations $ 21,353 $ 7,229 $ 6,975 Less: Net income attributable to noncontrolling interests 47 31 26 Income from continuing operations attributable to Pfizer Inc. 21,306 7,198 6,949 Less: Preferred stock dividends––net of tax 1 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 21,305 7,197 6,948 Discontinued operations––net of tax 2 17 11 Less: Discontinued operations––net of tax, attributable to noncontrolling interests — — — Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders 2 17 11 Net income attributable to Pfizer Inc. common shareholders $ 21,307 $ 7,214 $ 6,959 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 21,306 $ 7,197 $ 6,948 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 2 17 11 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 21,308 $ 7,214 $ 6,960 EPS Denominator Weighted-average number of common shares outstanding––Basic (a) 5,970 6,089 6,176 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (a) 89 70 81 Weighted-average number of common shares outstanding––Diluted 6,058 6,159 6,257 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (b) 36 63 50 (a) 2017 shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement. (b) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Lease Commitments	Lease Commitments We lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay directly for taxes, insurance, maintenance and other operating expenses or to pay higher rent when operating expenses increase. Rental expense, net of sublease income, was $314 million in 2017 , $292 million in 2016 and $243 million in 2015 . The future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 2022 After 2022 Lease commitments $ 209 $ 172 $ 150 $ 136 $ 123 $ 891

Insurance

Insurance	12 Months Ended
	Dec. 31, 2017
Insurance Coverage [Abstract]
Insurance	Insurance Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued (see Note 17 ).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 5D. Pending approval in the EU of Mylotarg––Mylotarg was developed, in part, through a research arrangement with a third party. If Mylotarg is approved in the EU in 2018 for the treatment of acute myeloid leukemia, we will incur an obligation for additional fixed payments over a 10-year period aggregating $310 million . A. Legal Proceedings Our non-tax contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the United States. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff Bosulif (bosutinib) In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of two other patents challenged by Sun, which expire in 2025 and 2026 respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia. EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Precedex Premix In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer. In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In January 2018, the District Court ruled that one of the four patents was valid and infringed, and that the other three patents were invalid. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit. In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals). Toviaz (fesoterodine) We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH (UCB), which owns the patents relating to Toviaz. Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book”. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with four of the generic defendants. The trial relating to the four remaining defendants occurred in July 2015. In April 2016, the District Court held that the patents that were the subject of the lawsuit were valid and infringed. The defendants’ deadline to appeal this decision expired in June 2016. In December 2014, Mylan Pharmaceuticals, Inc. (Mylan Pharmaceuticals) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In January 2015, we filed an action against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In January 2017, the District Court issued a verdict finding that the five patents that are the subject of the lawsuit are valid and infringed. In August 2017, the District Court issued a written decision consistent with the verdict, finding the five patents valid and infringed. In September 2017, Mylan Pharmaceuticals appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. In January 2018, Mylan Pharmaceuticals withdrew its appeal. Xeljanz (tofacitinib) In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Of the three patents that are the subject of the lawsuit, one covers the active ingredient and expires in December 2025, the second covers an enantiomer of tofacitinib and expires in 2022, and the third covers a polymorphic form of tofacitinib and expires in 2023. Three other patents for Xeljanz expiring in December 2020 have not been challenged by MicroLabs. Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Pharmaceuticals Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Pharmaceuticals Industries Ltd, which covers the active ingredient and expires in December 2025. In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of the same three patents that are the subject of the action against MicroLabs, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Also in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively Breckenridge) on the two patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of four additional patents challenged by Breckenridge, three of which expire in December 2020 and one of which expires in December 2025. Xtandi (enzalutamide) In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’ respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane’s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. Matters Involving Our Collaboration/Licensing Partners Toviaz (fesoterodine)––Inter-Partes Reviews In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews of five of the patents covering fesoterodine, the active ingredient in Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute inter partes reviews of all five patents. Amerigen Pharmaceuticals Limited (Amerigen), Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions upholding all five patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the Federal Circuit . In January 2018, Mylan withdrew its appeal. Eliquis In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer and we and BMS may settle with other generic companies in the future. Bavencio (avelumab) In July 2017, BMS, E.R. Squibb & Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District of Delaware against Pfizer, Merck KGaA, and EMD Serono, alleging that Bavencio (avelumab) infringes one patent relating to methods for treating tumors with anti-PD-L1 antibodies, which expires in 2023. Actions In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Claims with respect to four of the patents have since been dismissed by the plaintiffs, leaving two patents at issue in the ongoing action: the infliximab antibody patent and a patent relating to cell culture media. In August 2016, the District Court ruled that the antibody patent was invalid, and Janssen appealed that ruling to the Court of Appeals for the Federal Circuit. In January 2018, the Court of Appeals for the Federal Circuit ruled that the infliximab antibody patent was invalid in Janssen’s appeal of a separate decision from the U.S. Patent and Trademark Office that also declared the antibody patent invalid. Subsequently, the Court of Appeals for the Federal Circuit dismissed Janssen’s appeal of the District Court decision. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of December 31, 2017 , approximately 56,500 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Zoloft A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Zoloft Products Liability Litigation MDL-2342 ) in the U.S. District Court for the Eastern District of Pennsylvania. A number of plaintiffs have voluntarily dismissed their actions. In April 2016, the District Court granted our motion for summary judgment, dismissing the claims of almost all of the remaining plaintiffs. In May 2016, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Third Circuit. In June 2017, the U.S. Court of Appeals for the Third Circuit affirmed the District Court’s decision. Lipitor • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded substantially all of the claims to the District Court. Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. • Personal Injury Actions A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Fourth Circuit. Viagra A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the exacerbation of melanoma as a result of the purported ingestion of Viagra. Plaintiffs seek co

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH operating segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. We regularly review our segments and the approach used by management to evaluate performance and allocate resources. As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 , 2016 and 2015 . Operating Segments Some additional information about our business segments as of the date of the filing of this 2017 Financial Report follows: IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients’ lives, as well as products for consumer healthcare. Key therapeutic areas include internal medicine, vaccines, oncology, inflammation & immunology, rare disease and consumer healthcare. EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars, select branded products including anti-infectives and, through February 2, 2017, HIS. EH also includes an R&D organization, as well as our contract manufacturing business. Leading brands include: - Prevnar 13/Prevenar 13 - Xeljanz - Eliquis - Lyrica (U.S., Japan and certain other markets) - Enbrel (outside the U.S. and Canada) - Ibrance - Xtandi - Several OTC consumer healthcare products (e.g., Advil and Centrum ) Leading brands include: - Lipitor - Premarin family - Norvasc - Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries) - Celebrex - Viagra * - Inflectra/Remsima - Several sterile injectable products * Viagra lost exclusivity in the U.S. in December 2017. Beginning in the first quarter of 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through December 2017, will be reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, total Viagra worldwide revenues will be reported in EH from 2018 forward. Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects, including EH R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities. • GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&D projects. • Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of 2017 , Corporate also includes the costs associated with our Pfizer Medical organization (Medical), previously reported as part of Other Business Activities. Medical is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. In 2015, Medical was also responsible for regulatory inspection readiness reviews, internal audits of Pfizer-sponsored clinical trials and internal regulatory compliance processes, which are now part of the compliance function within Corporate. • Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production). • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $172 billion as of December 31, 2017 and approximately $172 billion as of December 31, 2016 . Selected Income Statement Information As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 , 2016 and 2015 . The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 2017 2016 2015 2017 2016 2015 Reportable Segments: IH $ 31,422 $ 29,197 $ 26,758 $ 18,341 $ 15,854 $ 14,581 $ 534 $ 583 $ 552 EH 21,124 23,627 22,094 11,283 12,898 12,714 579 600 446 Total reportable segments 52,546 52,824 48,851 29,625 28,752 27,295 1,113 1,183 998 Other business activities (c) — — — (3,137 ) (3,020 ) (2,914 ) 90 85 76 Reconciling Items: Corporate (d) — — — (5,522 ) (5,491 ) (5,607 ) 337 356 355 Purchase accounting adjustments (d) — — — (4,758 ) (4,185 ) (3,953 ) 4,565 3,890 3,573 Acquisition-related costs (d) — — — (456 ) (785 ) (894 ) 39 7 75 Certain significant items (e) — — — (2,647 ) (5,888 ) (4,321 ) 52 200 48 Other unallocated (d) — — — (799 ) (1,032 ) (642 ) 72 35 33 $ 52,546 $ 52,824 $ 48,851 $ 12,305 $ 8,351 $ 8,965 $ 6,269 $ 5,757 $ 5,157 (a) Income from continuing operations before provision/(benefit) for taxes on income . IH’s earnings in 2017 include d ividend income of $266 million from our investment in ViiV. For additional information, see Note 4. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $165 million and $177 million of costs from Other Business Activities to Corporate in 2016 and 2015 , respectively, to conform to the current period presentation. (d) For a description, see the “Other Costs and Business Activities” section above. (e) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $348 million , (ii) charges for certain legal matters of $237 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $55 million , (iv) certain asset impairment charges of $379 million , (v) charges for business and legal entity alignment of $71 million , (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $556 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million , (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $197 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in 2015 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4 . Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and Income from continuing operations before provision/(benefit) for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 , 2016 and 2015 . The following table provides revenues by geographic area: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 United States $ 26,026 $ 26,369 $ 21,704 Developed Europe (a) 8,508 9,306 9,714 Developed Rest of World (b) 6,612 6,729 6,298 Emerging Markets (c) 11,399 10,420 11,136 Revenues $ 52,546 $ 52,824 $ 48,851 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $6.8 billion in 2017 , $7.2 billion in 2016 and $7.4 billion in 2015 . (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey. Revenues exceeded $500 million in each of 11 countries outside the U.S. in 2017 and 2016 , respectively, and 12 countries outside the U.S. in 2015 . The U.S. is the only country to contribute more than 10% of total revenue in 2017 , 2016 and 2015 . As a percentage of revenues, our two largest national markets outside the U.S. were Japan, which contributed 8% of total revenue in each of 2017, 2016 and 2015, and China, which contributed 7% of total revenue in 2017 and 6% of total revenue in 2016 and 2015, respectively. The following table provides long-lived assets by geographic area: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Property, plant and equipment, net United States $ 6,971 $ 6,649 $ 7,072 Developed Europe (a) 4,345 4,228 4,376 Developed Rest of World (b) 632 643 660 Emerging Markets (c) 1,917 1,797 1,658 Property, plant and equipment, net $ 13,865 $ 13,318 $ 13,766 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey. C. Other Revenue Information Significant Customers We sell our biopharmaceutical products primarily to customers in the wholesale sector. In 2017 , sales to our three largest U.S. wholesaler customers represented approximately 16% , 12% and 10% of total revenues, respectively, and, collectively, represented approximately 36% of total trade accounts receivable as of December 31, 2017 . In 2016 , sales to our three largest U.S. wholesaler customers represented approximately 16% , 12% and 10% of total revenues, respectively, and, collectively, represented approximately 29% of total trade accounts receivable as of December 31, 2016 . In 2015 , sales to our three largest U.S. wholesaler customers represented approximately 14% , 11% and 10% of total revenues, respectively, and, collectively, represented approximately 23% of total trade accounts receivable as of December 31, 2015 . For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses. Significant Product Revenues As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 , 2016 and 2015 . The following table provides detailed revenue information: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 PFIZER INNOVATIVE HEALTH (IH) (a) $ 31,422 $ 29,197 $ 26,758 Internal Medicine $ 9,684 $ 8,858 $ 7,611 Lyrica IH (b) 4,511 4,165 3,655 Eliquis alliance revenues and direct sales 2,523 1,713 913 Chantix/Champix 997 842 671 Viagra IH (c) 823 1,181 1,297 BMP2 261 251 232 Toviaz 257 258 267 All other Internal Medicine 312 447 577 Vaccines $ 6,001 $ 6,071 $ 6,454 Prevnar 13/Prevenar 13 5,601 5,718 6,245 FSME/IMMUN-TicoVac 134 114 104 All other Vaccines 266 239 104 Oncology $ 6,056 $ 4,563 $ 2,955 Ibrance 3,126 2,135 723 Sutent 1,081 1,095 1,120 Xalkori 594 561 488 Xtandi alliance revenues 590 140 — Inlyta 339 401 430 Bosulif 233 167 111 All other Oncology 93 63 83 Inflammation & Immunology (I&I) $ 3,968 $ 3,928 $ 3,918 Enbrel (Outside the U.S. and Canada) 2,452 2,909 3,333 Xeljanz 1,345 927 523 Eucrisa 67 — — All other I&I 103 93 61 Rare Disease $ 2,240 $ 2,369 2,425 BeneFIX 604 712 752 Refacto AF/Xyntha 551 554 533 Genotropin 532 579 617 Somavert 254 232 218 All other Rare Disease 300 292 306 Consumer Healthcare $ 3,472 $ 3,407 $ 3,395 PFIZER ESSENTIAL HEALTH (EH) (d) $ 21,124 $ 23,627 $ 22,094 Legacy Established Products (LEP) (e) $ 10,894 $ 11,197 $ 11,745 Lipitor 1,915 1,758 1,860 Premarin family 977 1,017 1,018 Norvasc 926 962 991 Xalatan/Xalacom 335 363 399 Effexor 297 278 288 Zoloft 291 304 374 EpiPen 290 386 339 Zithromax 270 272 275 Relpax 236 323 352 Xanax 225 222 224 Sildenafil Citrate 56 — — All other LEP 5,077 5,313 5,625 Sterile Injectable Pharmaceuticals (SIP) (f) $ 5,673 $ 6,014 $ 3,944 Medrol 483 450 402 Sulperazon 471 396 339 Fragmin 306 318 335 Tygacil 260 274 304 Precedex 243 264 76 Tazosyn/Zosyn 194 146 144 All other SIP 3,715 4,166 2,343 Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Peri-LOE Products (g) $ 3,223 $ 4,220 $ 5,326 Celebrex 775 733 830 Lyrica EH (b) 553 801 1,183 Vfend 421 590 682 Viagra EH (c) 382 383 411 Pristiq 303 732 715 Zyvox 281 421 883 Revatio 252 285 260 All other Peri-LOE Products 257 276 362 Biosimilars (h) $ 531 $ 319 $ 63 Inflectra/Remsima 419 192 30 All other Biosimilars 112 127 33 Pfizer CentreOne (i) $ 706 $ 718 $ 612 Hospira Infusion Systems (HIS) (j) $ 97 $ 1,158 $ 403 Revenues $ 52,546 $ 52,824 $ 48,851 Total Lyrica (b) $ 5,065 $ 4,966 $ 4,839 Total Viagra (c) $ 1,204 $ 1,564 $ 1,708 Total Alliance revenues $ 2,927 $ 1,746 $ 1,312 (a) The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. Viagra lost exclusivity in the U.S. in December 2017. Beginning in the first quarter of 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through December 2017, will be reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore total Viagra worldwide revenues will be reported in EH from 2018 forward. (d) The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017), and includes all legacy Hospira commercial operations. (e) Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above. (f) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (g) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. Beginning in the first quarter of 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through December 2017, will be reported in EH. Therefore total Viagra worldwide revenues will be reported in EH from 2018 forward. See note (c) above. (h) Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. (i) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. (j) HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. We performed certain reclassifications, primarily between Legacy Established Products and Sterile Injectable Pharmaceuticals, to conform to current period presentation.

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).
Consolidation	The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Taxes paid on intercompany sales transactions are deferred until recognized upon sale of the asset to a third party.
Adoption of New Accounting Standards in 2017	Adoption of New Accounting Standards in 2017 We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our consolidated financial statements from adopting this standard. We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. There was no material impact to our consolidated financial statements from adopting this standard.
Estimates and Assumptions	Estimates and Assumptions In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income. Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. For information on estimates and assumptions in connection with the TCJA, see Notes to Consolidated Financial Statements–– Note 5A . Tax Matters: Taxes on Income from Continuing Operations.
Acquisitions	Acquisitions Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed. Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net . Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Fair Value	Fair Value We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques: • Income approach, which is based on the present value of a future stream of net cash flows. • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. • Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence. Our fair value methodologies depend on the following types of inputs: • Quoted prices for identical assets or liabilities in active markets (Level 1 inputs). • Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs). • Unobservable inputs that reflect estimates and assumptions (Level 3 inputs). A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Foreign Currency Translation	Foreign Currency Translation For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss) . The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net . For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net , and we translate non-monetary items at historical rates.
Revenues	Revenue Recognition —We record revenues from product sales when the goods are shipped and title passes to the customer. At the time of sale, we also record estimates for a variety of revenue deductions, such as chargebacks, rebates, sales allowances and sales returns. When we cannot reasonably estimate the amount of future sales returns and/or other revenue deductions, we record revenues when the risk of product return and/or additional revenue deductions has been substantially eliminated. Deductions from Revenues–– Our gross product revenues are subject to a variety of deductions, that generally are estimated and recorded in the same period that the revenues are recognized, and primarily represent chargebacks, rebates and sales allowances to wholesalers, and, to a lesser extent, distributors like MCOs, retailers and government agencies with respect to our pharmaceutical products. Those deductions represent estimates of rebates and discounts related to gross sales for the reporting period and, as such, knowledge and judgment of market conditions and practice are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Specifically: • In the U.S., we record provisions for pharmaceutical Medicare, Medicaid, and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates. • Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds, and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals. • Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability. • Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit. • We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior. Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues . Collaborative Arrangements— Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded when our collaboration partners ship the product and title passes to their customer. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when our collaboration partners sell the product and title passes to their customers. All royalty payments to collaboration partners are included in Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net.
Trade Accounts Receivable	Trade Accounts Receivable —Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
Cost of Sales and Inventories	Cost of Sales and Inventories We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.
Selling, Informational and Administrative Expenses	Selling, Informational and Administrative Expenses Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.
Research and Development Expenses	Research and Development Expenses R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
Property, Plant and Equipment	Property, plant and equipment, less accumulated depreciation —These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
Goodwill and Intangible Assets	• Identifiable intangible assets, less accumulated amortization —These acquired assets are recorded at fair value. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated. • Goodwill —Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized. Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate. Specifically: • For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate. • For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate. • For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.
Property, Plant and Equipment, Impairment	We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.
Restructuring Charges and Certain Acquisition-Related Costs	Restructuring Charges and Certain Acquisition-Related Costs We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other costs incurred in connection with a business acquisition are expensed as incurred . Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Cash Equivalents	Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments .
Statement of Cash Flows	Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.
Investments	Our investments are comprised of the following: trading funds and securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and ability to hold the investment to maturity) and private equity securities. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. • Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net. • Available-for-sale debt and equity securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized. • Held-to-maturity debt securities are carried at amortized cost. • Private equity securities are carried at equity method or at cost method. For equity investments where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and expenses in Other (income)/deductions—net . The excess of the cost of the investment over our share of the equity of the investee as of the acquisition date is allocated to the identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not include amounts of contingent consideration. Realized gains or losses on sales of investments are determined by using the specific identification cost method. We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Derivative Financial Instruments	Derivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A ), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7F ).
Tax Assets and Liabilities and Income Tax Contingencies	Tax Assets and Liabilities and Income Tax Contingencies Current tax assets primarily includes (i) tax effects associated with intercompany transfers of assets within our consolidated group, which are recognized in the consolidated statement of income when the asset transferred is sold to a third-party or recovered through amortization of the asset's remaining economic life; and (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations. Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws, including the recently enacted TCJA. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet. Other taxes payable includes liabilities for uncertain tax positions and an estimate of the repatriation tax liability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we plan to elect payment over eight years through 2026. See Note 5A for additional information. We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information. Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related tax liability. Given the significant changes resulting from and complexities associated with the TCJA, the estimated financial impacts for 2017 are provisional and subject to further analysis, interpretation and clarification of the TCJA, which could result in changes to these estimates during 2018. For additional information, see Note 5A . Amounts recorded for valuation allowances and income tax contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both qualified and supplemental (non-qualified) defined benefit and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic benefit costs are recognized, as required, into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Legal and Environmental Contingencies	Legal and Environmental Contingencies We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured. Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Share-Based Payments	Share-Based Payments Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Basis of Presentation and Sig30

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Information About Balance Sheet Classification of Accruals	The following table provides information about the balance sheet classification of these accruals: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,352 $ 1,154 Other current liabilities : Accrued rebates 2,674 2,261 Other accruals 512 509 Other noncurrent liabilities 385 357 Total accrued rebates and other accruals $ 4,923 $ 4,282

Acquisitions, Sale of Hospira31

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Schedule of Amounts Recognized for Assets Acquired and Liabilities Assumed	The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: (MILLIONS OF DOLLARS) Amounts Recognized as of Acquisition Date Final Working capital, excluding inventories (a) $ 342 Inventories 1,901 PP&E 2,352 Identifiable intangible assets, excluding IPR&D (b) 8,290 IPR&D 1,030 Other noncurrent assets 362 Long-term debt (1,928 ) Benefit obligations (117 ) Net income tax accounts (c) (3,380 ) Other noncurrent liabilities (61 ) Total identifiable net assets 8,791 Goodwill 7,295 Net assets acquired/total consideration transferred $ 16,087 (a) Includes cash and cash equivalents, short-term investments, accounts receivable, other current assets, assets held for sale, accounts payable and other current liabilities. (b) Comprised of finite-lived developed technology rights with a weighted-average life of approximately 17 years ( $7.7 billion ) and other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ( $570 million ). (c) Final amounts recognized as of the acquisition date, included in Current tax assets ( $57 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $58 million ), Income taxes payable ( $5 million ), Noncurrent deferred tax liabilities ( $3.4 billion ) and Other taxes payable ( $101 million , including accrued interest of $5 million ).
Summary of Pro Forma Information	The following table presents information for Hospira’s operations that are included in Pfizer’s consolidated statements of income beginning from the acquisition date, September 3, 2015 through Pfizer’s domestic and international year-ends in 2015 (see Note 1A ): (MILLIONS OF DOLLARS) December 31, 2015 Revenues $ 1,513 Net loss attributable to Pfizer Inc. common shareholders (a) (575 ) (a) Includes purchase accounting charges related to the provisional estimated fair values recognized as of the acquisition date for (i) the fair value adjustment for acquisition-date inventory that has been sold ( $378 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Hospira ( $161 million pre-tax); (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Hospira ( $34 million pre-tax ); and (iv) amortization expense related to the fair value adjustment of long-term debt acquired from Hospira ( $13 million income pre-tax), as well as restructuring and integration costs ( $556 million pre-tax). The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014: Unaudited Supplemental Pro Forma Consolidated Results (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) Year Ended December 31, 2015 Revenues $ 52,082 Net income attributable to Pfizer Inc. common shareholders 7,669 Diluted EPS attributable to Pfizer Inc. common shareholders 1.23
Summary of Assets and Liabilities Held For Sale	The amounts associated with HIS, as well as other assets classified as held for sale consisted of the following: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Assets Held for Sale Inventories $ — $ 377 PP&E — 457 Identifiable intangible assets — 1,319 Goodwill — 119 Other assets — 152 Less: adjustment to HIS assets for net realizable value (a) — (1,681 ) Total HIS assets held for sale — 743 Other assets held for sale (b) 12 58 Assets held for sale $ 12 $ 801 Liabilities Held for Sale Accrued compensation and related items $ — $ 54 Other liabilities — 103 Total HIS liabilities held for sale $ — $ 157 (a) For 2016 , we recorded an adjustment to HIS assets for net realizable value of $1,681 million plus estimated costs to sell of $31 million for a total impairment on HIS net assets of $1,712 million . (b) Other assets held for sale consist primarily of PP&E and other assets.
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions	The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Revenues —Revenues (a) $ 606 $ 659 $ 644 Revenue s—Alliance revenues (b) 2,927 1,746 1,312 Total revenues from collaborative arrangements 3,533 2,405 1,956 Cost of sales (c) (329 ) (315 ) (282 ) Selling, informational and administrative expenses (d) (54 ) (5 ) (287 ) Research and development expenses (e) 222 64 (330 ) Other income/(deductions)—net (f) 249 542 482 (a) Represents sales to our partners of products manufactured by us. (b) Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2017 reflects an increase in alliance revenues from Eliquis and Xtandi. The increase in 2016 reflects an increase in alliance revenues from Eliquis and the inclusion of Xtandi revenues resulting from the acquisition of Medivation in September 2016, partially offset by the expiration of the Rebif co-promotion collaboration at the end of 2015. (c) Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners. (d) Represents net reimbursements to our partners for selling, informational and administrative expenses incurred. (e) Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $15 million in 2017 , $15 million in 2016 and $310 million in 2015 (primarily related to our collaboration with OPKO, see below). 2017 and 2016 also include reimbursements related to our collaboration with Lilly (see below) of $147 million and $120 million , respectively. (f) Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our 36 month royalty arrangement on sales of Enbrel in the U.S. and Canada, partially offset by a full year of royalties earned in 2017, versus a partial year in 2016, on Xtandi ex-U.S. sales.

Restructuring Charges and Oth32

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	12 Months Ended
	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Restructuring charges (a) : Employee terminations $ (34 ) $ 940 $ 489 Asset impairments (b) 190 142 254 Exit costs 21 74 68 Total restructuring charges 178 1,156 811 Transaction costs (c) 4 127 123 Integration costs (d) 305 441 219 Restructuring charges and certain acquisition-related costs 487 1,724 1,152 Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows (e) : Cost of sales 91 201 117 Selling, informational and administrative expenses — — — Research and development expenses — 7 5 Total additional depreciation––asset restructuring 91 207 122 Implementation costs recorded in our consolidated statements of income as follows (f) : Cost of sales 118 230 102 Selling, informational and administrative expenses 71 81 82 Research and development expenses 38 25 14 Other (income)/deductions––net — 3 5 Total implementation costs 227 340 203 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 805 $ 2,271 $ 1,478 (a) In 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In 2015, restructuring charges are largely associated with.cost-reduction and productivity initiatives not associated with acquisitions. In 2017 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities in 2017 are associated with the following: • IH ( $64 million income); EH ( $4 million income); WRD/GPD ( $80 million ); manufacturing operations ( $115 million ); and Corporate ( $51 million ). The restructuring activities in 2016 are associated with the following: • IH ( $272 million ); EH ( $158 million ); WRD/GPD ( $169 million ); manufacturing operations ( $368 million ); and Corporate ( $189 million ), The restructuring activities in 2015 , which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following: • IH ( $85 million ); EH ( $402 million ); WRD/GPD ( $80 million ); manufacturing operations ( $80 million ); and Corporate ( $164 million ). In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million , which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million , which is included in Asset impairments ; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million , which is included in Asset impairments ; and (iii) a payment to Celltrion of $20 million , which is included in Exit costs . (b) The asset impairment charges for 2017 are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for 2017 and 2016 are primarily associated with abandoned assets. The asset impairment charges for 2015 are primarily associated with our acquisition of Hospira. See (a) above for additional information. (c) Transaction costs represent external costs for banking, legal, accounting and other similar services, which in 2017 are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in 2016 are mostly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and the terminated transaction with Allergan and primarily include expenditures for banking, legal, accounting and other similar services. (d) I ntegration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2017 , integration costs primarily relate to our acquisitions of Hospira and Medivation, as well as a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 11 ). In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira. (e) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (f) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Restructuring Reserve by Type of Cost	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, January 1, 2016 $ 1,109 $ — $ 48 $ 1,157 Provision 940 142 74 1,156 Utilization and other (a) (502 ) (142 ) (86 ) (730 ) Balance, December 31, 2016 (b) 1,547 — 36 1,583 Provision (34 ) 190 21 178 Utilization and other (a) (474 ) (190 ) 9 (656 ) Balance, December 31, 2017 (c) $ 1,039 $ — $ 66 $ 1,105 (a) Includes adjustments for foreign currency translation. (b) Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million ). (c) Included in Other current liabilities ( $643 million ) and Other noncurrent liabilities ( $462 million ).

Other (Income)_Deductions - N33

Other (Income)/Deductions - Net (Tables)	12 Months Ended
	Dec. 31, 2017
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	The following table provides components of Other (income)/deductions––net : Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Interest income (a) $ (391 ) $ (470 ) $ (471 ) Interest expense (a) 1,270 1,186 1,199 Net interest expense 879 716 728 Foreign currency loss related to Venezuela (b) — — 806 Royalty-related income (c) (499 ) (905 ) (922 ) Certain legal matters, net (d) 240 510 975 Net gains on asset disposals (e) (343 ) (171 ) (232 ) Loss on sale and impairment on remeasurement of HIS net assets (f) 55 1,712 — Certain asset impairments (g) 395 1,447 818 Business and legal entity alignment costs (h) 71 261 282 Net losses on early retirement of debt (i) 999 312 — Other, net (j) (482 ) (227 ) 403 Other (income)/deductions––net $ 1,315 $ 3,655 $ 2,860 (a) 2017 v. 2016 ––Interest income decreased primarily driven by a lower investment balance. Interest expense increased, primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt. Capitalized interest expense totaled $72 million 2017 , $ 61 million in 2016 and $ 32 million in 2015 . (b) In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.3 , but rather at the then SIMADI rate of 200 , the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy. (c) Royalty-related income decreased in 2017 and 2016 , primarily due to lower royalty income for Enbrel of $470 million in 2017 , compared to 2016, and $54 million in 2016 , compared to 2015, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by increases in Xtandi royalty-related income of $176 million in 2017 , compared to 2016, and $63 million in 2016 , compared to 2015. (d) In 2017 , primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to court approval (for additional information, see Note 17A2 ), and a $79 million charge to reflect damages awarded by a jury in a patent matter. In 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, 2016 includes a settlement related to a patent matter. In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. (e) In 2017 , primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $451 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $281 million ; (iii) gross realized gains on sales of available-for-sale equity securities of $75 million ; (iv) a net loss of $120 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of $187 million ; (vi) gains on sales of investments in private equity securities of $80 million ; (vii) a gain on sale of property of $52 million ; (viii) a net loss of $30 million related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest; and (ix) a loss of $81 million related to the sale of our 49% equity share in Hisun Pfizer. Proceeds from the sale of available-for-sale securities were $5.1 billion in 2017. In 2016, primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $666 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $548 million ; (iii) a net loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of $84 million ; and (v) gains on sales of investments in private equity securities of $2 million . Proceeds from the sale of available-for-sale securities were $10.2 billion in 2016. In 2015, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $164 million ; (ii) gross realized losses on sales of available-for-sale debt securities of $960 million ; (iii) net gain of $937 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of $90 million ; and (v) gains on sales of investments in private equity securities of $3 million . Proceeds from the sale of available-for-sale securities were $4.3 billion in 2015. (f) In 2017, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information . (g) In 2017 , primarily includes intangible asset impairment charges of $337 million , reflecting (i) $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) $124 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) $39 million related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) $26 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) $20 million related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with EH and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of $43 million for an impairment of our AM-Pharma B.V. long-term investment (see Note 2E ). In 2016, primarily includes intangible asset impairment charges of $869 million , reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ( $840 million ) and IH ( $29 million ). In addition, 2016 includes an impairment loss of $452 million related to Pfizer’s then 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a then recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. In 2015, primarily includes an impairment loss of $463 million related to Pfizer’s then 49% -owned equity-method investment in Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2D ) and intangible asset impairment charges of $323 million , reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: EH ( $294 million ), WRD ( $13 million ); and Consumer Healthcare ( $17 million ). The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. (h) Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (i) In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in 2016. (j) In 2017, includes, among other things, dividend income of $266 million from our investment in ViiV, and income of $62 million from resolution of a contract disagreement. In 2016, includes among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A ); and income of $116 million from resolution of a contract disagreement. In 2015, includes, among other things, (i) charges of $194 million related to the write-down of assets to net realizable value; (ii) charges of $159 million , reflecting the change in the fair value of contingent consideration liabilities; and (iii) income of $45 million associated with equity-method investees.
Schedule of Additional Information About Intangible Assets Impaired	The asset impairment charges included in Other (income)/deductions––net are based on estimates of fair value. The following table provides additional information about the intangible assets that were impaired during 2017 in Other (income)/deductions––net : Year Ended December 31, Fair Value (a) 2017 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– Developed technology rights (b) 50 — — 50 337 Total $ 50 $ — $ — $ 50 $ 337 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E. (b) Reflects intangible assets written down to fair value in 2017 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters (Tables)

Tax Matters (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The following table provides the components of Income from continuing operations before provision/(benefit) for taxes on income : Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 United States $ (6,879 ) $ (8,534 ) $ (6,809 ) International 19,184 16,886 15,773 Income from continuing operations before provision/(benefit) for taxes on income ( a), (b) $ 12,305 $ 8,351 $ 8,965 (a) 2017 v. 2016 –– The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower certain asset impairments and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in international income was primarily due to the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower restructuring charges and certain acquisition-related costs, and lower certain asset impairments. (b) 2016 v. 2015 –– The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs.
Schedule of Provision for Taxes on Income	The following table provides the components of Provision/(benefit) for taxes on income based on the location of the taxing authorities: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 United States Current income taxes: Federal $ 14,127 $ 342 $ 67 State and local 320 (52 ) (8 ) Deferred income taxes: Federal (25,964 ) (419 ) 300 State and local (268 ) (106 ) (36 ) Total U.S. tax provision (11,785 ) (235 ) 323 International Current income taxes 2,709 1,532 1,951 Deferred income taxes 28 (175 ) (284 ) Total international tax provision 2,737 1,358 1,667 Provision/(benefit) for taxes on income $ (9,049 ) $ 1,123 $ 1,990
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations follows: Year Ended December 31, 2017 2016 2015 U.S. statutory income tax rate 35.0 % 35.0 % 35.0 % TCJA impact (a) (86.6 ) — — Taxation of non-U.S. operations (b), (c), (d) (17.0 ) (13.8 ) (9.6 ) Tax settlements and resolution of certain tax positions (e) (1.2 ) (5.5 ) (4.0 ) U.S. Healthcare Legislation (e) 0.9 1.3 0.9 U.S. R&D tax credit and manufacturing deduction (e) (0.7 ) (1.0 ) (1.0 ) Certain legal settlements and charges (e) 0.1 (2.9 ) 3.1 All other, net (f) (3.9 ) 0.3 (2.1 ) Effective tax rate for income from continuing operations (73.5 )% 13.4 % 22.2 % (a) For a discussion about the enactment of the TCJA, see Note 5A. (b) For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which includes the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries discussed in Note 5A , as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income . (c) In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. 2015 and 2016 also include incentives in Costa Rica and the Dominican Republic related to the Hospira infusion systems business, which was sold to ICU Medical in February 2017. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations. (d) The favorable rate impact in 2017 also reflects lower repatriation costs associated with estimated current year income of our foreign subsidiaries. The favorable rate impact in 2016 also includes the non-recurrence of the non-deductibility of a foreign currency loss related to Venezuela. The rate impact in 2015 also includes the non-deductibility of a foreign currency loss related to Venezuela. (e) For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and manufacturing deduction and the impact of certain legal settlements and charges, see Note 5A. (f) All other, net in 2017 and 2015 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business.
Schedule of Deferred Tax Assets and Liabilities	The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow: 2017 Deferred Tax* 2016 Deferred Tax (MILLIONS OF DOLLARS) Assets (Liabilities) Assets (Liabilities) Prepaid/deferred items $ 1,588 $ (132 ) $ 2,180 $ (68 ) Inventories 224 (3 ) 366 (47 ) Intangible assets (a) 685 (9,269 ) 1,139 (15,172 ) Property, plant and equipment 123 (755 ) 92 (982 ) Employee benefits 2,219 (109 ) 3,356 (74 ) Restructurings and other charges 226 (8 ) 458 (2 ) Legal and product liability reserves 459 — 650 — Net operating loss/tax credit carryforwards (b) 4,502 — 2,957 — Unremitted earnings (a), (c) — (1,067 ) — (23,108 ) State and local tax adjustments 218 — 301 — All other 488 (424 ) 306 (503 ) 10,732 (11,767 ) 11,806 (39,956 ) Valuation allowances (2,203 ) — (1,949 ) — Total deferred taxes $ 8,529 $ (11,767 ) $ 9,857 $ (39,956 ) Net deferred tax liability (d) $ (3,238 ) $ (30,099 ) * 2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A . (a) The decrease in 2017 is primarily the result of the enactment of the TCJA, which includes the remeasurement of deferred tax liabilities primarily associated with intangible assets and unremitted earnings of foreign subsidiaries as well as amortization on intangible assets. For additional information, see Note 5A. (b) The amounts in 2017 and 2016 are reduced for unrecognized tax benefits of $3.4 billion and $3.0 billion , respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. (c) The amount in 2017 primarily includes a provisional estimate on temporary differences associated with global intangible low-taxed income primarily related to basis differentials on intangibles. For additional information, see Note 5A. (d) In 2017 , Noncurrent deferred tax assets and other noncurrent tax assets ( $0.7 billion ), and Noncurrent deferred tax liabilities ( $3.9 billion ). In 2016 , Noncurrent deferred tax assets and other noncurrent tax assets ( $654 million ), and Noncurrent deferred tax liabilities ( $30.8 billion ).
Schedule of Unrecognized Tax Benefits Roll Forward	The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows: (MILLIONS OF DOLLARS) 2017 2016 2015 Balance, beginning $ (5,826 ) $ (5,919 ) $ (6,182 ) Acquisitions (a) 10 (83 ) (110 ) Increases based on tax positions taken during a prior period (b) (49 ) (11 ) (31 ) Decreases based on tax positions taken during a prior period (b), (c) 28 409 496 Decreases based on settlements for a prior period (d) 35 126 64 Increases based on tax positions taken during the current period (b) (753 ) (489 ) (675 ) Impact of foreign exchange (121 ) (5 ) 319 Other, net (b), (e) 118 146 199 Balance, ending (f) $ (6,558 ) $ (5,826 ) $ (5,919 ) (a) For 2017 and 2016, primarily related to the acquisitions of Medivation and Anacor. For 2015, primarily related to the acquisition of Hospira. See also Note 2A . (b) Primarily included in Provision/(benefit) for taxes on income. (c) Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A. (d) Primarily related to cash payments and reductions of tax attributes. (e) Primarily related to decreases as a result of a lapse of applicable statutes of limitations. (f) In 2017 , included in Income taxes payable ( $1 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $123 million ), Noncurrent deferred tax liabilities ( $3.3 billion ) and Other taxes payable ( $3.2 billion ). In 2016 , included in Income taxes payable ( $14 million ), Current tax assets ( $17 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $184 million ), Noncurrent deferred tax liabilities ( $2.8 billion ) and Other taxes payable ( $2.8 billion ).
Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)	The following table provides the components of the Tax provision/(benefit) on other comprehensive income/(loss) : Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Foreign currency translation adjustments, net (a) $ (215 ) $ (15 ) $ 90 Unrealized holding gains/(losses) on derivative financial instruments, net 72 (75 ) (173 ) Reclassification adjustments for (gains)/losses included in net income (224 ) 158 104 (152 ) 83 (69 ) Unrealized holding gains/(losses) on available-for-sale securities, net 102 49 (104 ) Reclassification adjustments for (gains)/losses included in net income (60 ) (15 ) 59 42 34 (45 ) Benefit plans: actuarial losses, net (59 ) (535 ) (23 ) Reclassification adjustments related to amortization 192 186 183 Reclassification adjustments related to settlements, net 42 45 237 Other (39 ) 36 66 137 (269 ) 462 Benefit plans: prior service (costs)/credits and other, net — 67 160 Reclassification adjustments related to amortization (67 ) (64 ) (59 ) Reclassification adjustments related to curtailments, net (7 ) (10 ) (12 ) Other — (1 ) — (74 ) (7 ) 89 Tax provision/(benefit) on other comprehensive income/(loss) $ (262 ) $ (174 ) $ 528 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensi35

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gain/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/ Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, January 1, 2015 $ (2,689 ) $ 517 $ (222 ) $ (5,654 ) $ 733 $ (7,316 ) Other comprehensive income/(loss) (a) (3,174 ) (96 ) (5 ) 921 148 (2,206 ) Balance, December 31, 2015 (5,863 ) 421 (227 ) (4,733 ) 880 (9,522 ) Other comprehensive income/(loss) (a) (797 ) (73 ) 96 (740 ) (1 ) (1,514 ) Balance, December 31, 2016 (6,659 ) 348 (131 ) (5,473 ) 879 (11,036 ) Other comprehensive income/(loss) (a) $ 1,479 (378 ) 532 $ 211 $ (129 ) $ 1,715 Balance, December 31, 2017 $ (5,180 ) $ (30 ) $ 401 $ (5,262 ) $ 750 $ (9,321 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $14 million income in 2017 , $3 million loss in 2016 and $26 million loss in 2015 .

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Financial Instruments [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the financial assets and liabilities measured at fair value on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Note 1E : Total Level 1 Level 2 Total Level 1 Level 2 (MILLIONS OF DOLLARS) December 31, 2017 December 31, 2016 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as trading securities: Equity (a) $ 19 $ — $ 19 $ — $ — $ — Classified as available-for-sale securities: Government and agency debt—non-U.S. 12,242 — 12,242 7,317 — 7,317 Corporate debt 2,766 — 2,766 2,783 — 2,783 Government debt—U.S. 252 — 252 2,630 — 2,630 Agency asset-backed debt—U.S. 23 — 23 39 — 39 Other asset-backed debt 79 — 79 367 — 367 Money market funds 2,115 — 2,115 1,431 — 1,431 Equity 16 16 — 1 1 — 17,493 16 17,477 14,567 1 14,566 Total short-term investments 17,512 16 17,496 14,567 1 14,566 Other current assets Derivative assets: Interest rate contracts 104 — 104 26 — 26 Foreign exchange contracts 234 — 234 540 — 540 Total other current assets 337 — 337 566 — 566 Long-term investments Classified as trading securities: Equity (a) 266 224 42 236 165 71 Debt 73 73 — 89 89 — 340 298 42 325 254 71 Classified as available-for-sale securities: Government and agency debt—non-U.S. 387 — 387 863 — 863 Corporate debt 4,172 36 4,136 4,306 — 4,306 Government debt—U.S. 495 — 495 88 — 88 Other asset-backed debt 35 — 35 239 — 239 Money market funds — — — 14 — 14 Equity 1,174 1,174 — 539 539 — 6,264 1,210 5,054 6,049 539 5,510 Total long-term investments 6,603 1,507 5,096 6,374 793 5,581 Other noncurrent assets Derivative assets: Interest rate contracts 477 — 477 599 — 599 Foreign exchange contracts 7 — 7 90 — 90 Total other noncurrent assets 484 — 484 689 — 689 Total assets $ 24,937 $ 1,523 $ 23,414 $ 22,197 $ 794 $ 21,403 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ 1 $ — $ 1 $ 1 $ — $ 1 Foreign exchange contracts 201 — 201 443 — 443 Total other current liabilities 201 — 201 444 — 444 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 177 — 177 147 — 147 Foreign exchange contracts 313 — 313 1,075 — 1,075 Total other noncurrent liabilities 490 — 490 1,222 — 1,222 Total liabilities $ 691 $ — $ 691 $ 1,666 $ — $ 1,666 (a) As of December 31, 2017 and December 31, 2016 , equity securities of $42 million and $71 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
Financial Liabilities Not Measured at Fair Value on a Recurring Basis	The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: December 31, 2017 December 31, 2016 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 33,538 $ 37,253 $ 37,253 $ 31,398 $ 34,896 $ 34,896
Summary of Investments	The following table represents our investments by classification type: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Short-term investments Trading securities $ 19 $ — Available-for-sale debt and equity securities 17,493 14,567 Held-to-maturity debt securities 1,138 688 Total Short-term investments $ 18,650 $ 15,255 Long-term investments Trading securities $ 340 $ 325 Available-for-sale debt and equity securities 6,264 6,049 Held-to-maturity debt securities 4 7 Private equity investments carried at equity-method or cost 408 735 Total Long-term investments $ 7,015 $ 7,116 Held-to-maturity cash equivalents $ 719
Contractual Maturities of Available-for-sale and Held-to-maturity Securities	At December 31, 2017, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at December 31, 2017 and 2016 is as follows, including, as of December 31, 2017, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: December 31, 2017 December 31, 2016 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency debt –– non-U.S. $ 12,616 $ 61 $ (48 ) $ 12,629 $ 12,242 $ 387 $ — $ 12,629 $ 8,403 $ 11 $ (235 ) $ 8,179 Corporate debt (b) 6,955 15 (33 ) 6,938 2,766 2,630 1,542 6,938 7,162 16 (89 ) 7,089 Government debt––U.S. 765 — (19 ) 747 252 495 — 747 2,729 1 (12 ) 2,718 Agency asset-backed debt––U.S. 24 — (1 ) 24 23 — — 24 41 — (1 ) 39 Other asset-backed debt (c) 114 — — 114 79 32 3 114 607 1 (2 ) 605 Held-to-maturity debt securities Time deposits and other 1,091 — — 1,091 1,087 — 4 1,091 830 — — 830 Government and agency debt –– non-U.S. 770 — — 770 770 — — 770 412 — — 412 Total debt securities $ 22,337 $ 77 $ (100 ) $ 22,313 $ 17,219 $ 3,544 $ 1,550 $ 22,313 $ 20,184 $ 29 $ (339 ) $ 19,873 Available-for-sale equity securities Money market funds $ 2,115 $ — $ — $ 2,115 $ 1,446 $ — $ (1 ) $ 1,445 Equity 728 586 (124 ) 1,190 426 239 (125 ) 540 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 $ 1,872 $ 239 $ (126 ) $ 1,985 (a) Issued by a diverse group of corporations. (b) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
Schedule of Available-for-sale Securities Reconciliation	At December 31, 2017, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at December 31, 2017 and 2016 is as follows, including, as of December 31, 2017, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: December 31, 2017 December 31, 2016 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency debt –– non-U.S. $ 12,616 $ 61 $ (48 ) $ 12,629 $ 12,242 $ 387 $ — $ 12,629 $ 8,403 $ 11 $ (235 ) $ 8,179 Corporate debt (b) 6,955 15 (33 ) 6,938 2,766 2,630 1,542 6,938 7,162 16 (89 ) 7,089 Government debt––U.S. 765 — (19 ) 747 252 495 — 747 2,729 1 (12 ) 2,718 Agency asset-backed debt––U.S. 24 — (1 ) 24 23 — — 24 41 — (1 ) 39 Other asset-backed debt (c) 114 — — 114 79 32 3 114 607 1 (2 ) 605 Held-to-maturity debt securities Time deposits and other 1,091 — — 1,091 1,087 — 4 1,091 830 — — 830 Government and agency debt –– non-U.S. 770 — — 770 770 — — 770 412 — — 412 Total debt securities $ 22,337 $ 77 $ (100 ) $ 22,313 $ 17,219 $ 3,544 $ 1,550 $ 22,313 $ 20,184 $ 29 $ (339 ) $ 19,873 Available-for-sale equity securities Money market funds $ 2,115 $ — $ — $ 2,115 $ 1,446 $ — $ (1 ) $ 1,445 Equity 728 586 (124 ) 1,190 426 239 (125 ) 540 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 $ 1,872 $ 239 $ (126 ) $ 1,985 (a) Issued by a diverse group of corporations. (b) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
Held-to-maturity Securities	At December 31, 2017, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at December 31, 2017 and 2016 is as follows, including, as of December 31, 2017, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: December 31, 2017 December 31, 2016 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency debt –– non-U.S. $ 12,616 $ 61 $ (48 ) $ 12,629 $ 12,242 $ 387 $ — $ 12,629 $ 8,403 $ 11 $ (235 ) $ 8,179 Corporate debt (b) 6,955 15 (33 ) 6,938 2,766 2,630 1,542 6,938 7,162 16 (89 ) 7,089 Government debt––U.S. 765 — (19 ) 747 252 495 — 747 2,729 1 (12 ) 2,718 Agency asset-backed debt––U.S. 24 — (1 ) 24 23 — — 24 41 — (1 ) 39 Other asset-backed debt (c) 114 — — 114 79 32 3 114 607 1 (2 ) 605 Held-to-maturity debt securities Time deposits and other 1,091 — — 1,091 1,087 — 4 1,091 830 — — 830 Government and agency debt –– non-U.S. 770 — — 770 770 — — 770 412 — — 412 Total debt securities $ 22,337 $ 77 $ (100 ) $ 22,313 $ 17,219 $ 3,544 $ 1,550 $ 22,313 $ 20,184 $ 29 $ (339 ) $ 19,873 Available-for-sale equity securities Money market funds $ 2,115 $ — $ — $ 2,115 $ 1,446 $ — $ (1 ) $ 1,445 Equity 728 586 (124 ) 1,190 426 239 (125 ) 540 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 $ 1,872 $ 239 $ (126 ) $ 1,985 (a) Issued by a diverse group of corporations. (b) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
Schedule of Short-term Borrowings	Short-term borrowings include: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Commercial paper $ 6,100 $ 5,800 Current portion of long-term debt, principal amount (a) 3,532 4,201 Other short-term borrowings, principal amount (b) 320 673 Total short-term borrowings, principal amount 9,951 10,674 Net fair value adjustments related to hedging and purchase accounting 14 24 Net unamortized discounts, premiums and debt issuance costs (12 ) (11 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 9,953 $ 10,688 (a) For additional information, see Note 7D . (b) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F .
Schedule of Long-term Debt Instruments	The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2017 and 2016 by maturity. As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Notes due 2018 (2.3%) (a) $ — $ 3,532 Notes due 2019 (1.3% and 1.8%) 4,848 3,350 Notes due 2020 (1.1% and 5.2%) 1,528 330 Notes due 2021 (3.5% and 3.9%) 3,550 4,260 Notes due 2022 (0.3%) 1,199 — Notes due 2023 (4.3% and 4.3%) 1,592 1,592 Notes due 2024-2028 (3.5% and 3.9%) 6,259 5,360 Notes due 2034-2038 (5.7% and 5.9%) 4,886 6,102 Notes due 2039-2043 (5.2% and 6.4%) 5,606 3,745 Notes due 2044-2047 (4.2% and 4.2%) 3,315 2,250 Total long-term borrowings, principal amount 32,783 30,520 Net fair value adjustments related to hedging and purchase accounting 872 998 Net unamortized discounts, premiums and debt issuance costs (125 ) (130 ) Other long-term obligations 8 9 Total long-term borrowings, carried at historical proceeds, as adjusted $ 33,538 $ 31,398 Current portion of long-term debt, carried at historical proceeds (not included above (2.4% and 3.0%) $ 3,546 $ 4,225 (a) At December 31, 2017, the debt issuances have been reclassified to the current portion of long-term debt. In 2017, we issued the following senior unsecured notes: Settlement Date Maturity Date Interest Rate Issue Currency Principal Amount March 6, 2017 March 2019 3-month EURIBOR+0.20% (0% floor) Euro € 1,250 March 2020 0.00 % Euro 1,000 March 2022 0.25 % Euro 1,000 March 2027 1.00 % Euro 750 € 4,000 (a) December 19, 2017 June 2043 2.735 % U.K. pound £ 1,376 (b) March 17, 2017 March 2047 4.20 % U.S. dollar $ 1,065 (c) (a) The weighted-average effective interest rate for the euro notes at issuance was 0.23% . (b) In December 2017, Pfizer exchanged approximately £ 833 million principal amount of the outstanding 6.50% debt due 2038 for £ 1.376 billion principal amount of 2.735% debt due 2043. This exchange constituted a debt extinguishment. See the following “Retirements” section for the income statement impact from the extinguishment. (c) The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.
Schedule of Derivative Financial Instruments	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) December 31, 2017 December 31, 2016 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,723 $ 179 $ 459 $ 14,424 $ 468 $ 1,135 Interest rate contracts 12,430 581 178 15,991 625 148 760 637 1,093 1,283 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,300 $ 62 $ 54 $ 13,100 $ 162 $ 382 Total $ 822 $ 691 $ 1,255 $ 1,665 (a) As of December 31, 2017, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion .
Schedule of Derivative Assets at Fair Value	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) December 31, 2017 December 31, 2016 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,723 $ 179 $ 459 $ 14,424 $ 468 $ 1,135 Interest rate contracts 12,430 581 178 15,991 625 148 760 637 1,093 1,283 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,300 $ 62 $ 54 $ 13,100 $ 162 $ 382 Total $ 822 $ 691 $ 1,255 $ 1,665 (a) As of December 31, 2017, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion .
Schedule of Derivative Liabilities at Fair Value	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) December 31, 2017 December 31, 2016 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 18,723 $ 179 $ 459 $ 14,424 $ 468 $ 1,135 Interest rate contracts 12,430 581 178 15,991 625 148 760 637 1,093 1,283 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 14,300 $ 62 $ 54 $ 13,100 $ 162 $ 382 Total $ 822 $ 691 $ 1,255 $ 1,665 (a) As of December 31, 2017, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion .
Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of Gains/(Losses) Recognized in OID (a), (b) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (c) Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion) (a), (c) As of December 31, (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (d) $ (6 ) $ (4 ) $ (12 ) $ (444 ) $ 520 $ (451 ) Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (60 ) (181 ) — — — — Hedged item gain/(loss) 60 181 — — — — Foreign exchange contracts (19 ) (4 ) — — — — Hedged item gain/(loss) 19 4 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — 1 — (15 ) — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — — (26 ) — — Foreign currency long-term debt (e) — — (580 ) — — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (87 ) (105 ) — — — — All other net — — 2 1 1 (1 ) $ (93 ) $ (107 ) $ (591 ) $ (483 ) $ 520 $ (452 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income . COS = Cost of Sales, included in Cost of Sales in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income . (b) There was no significant ineffectiveness for any period presented. (c) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net. (d) Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $72 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.9 billion U.K. pound debt maturing in 2043. (e) Long-term debt includes foreign currency long-term borrowings with carrying values of $4.8 billion as of December 31, 2017, which are used as hedging instruments.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Finished goods $ 2,883 $ 2,293 Work in process 3,908 3,696 Raw materials and supplies 788 793 Inventories (a) $ 7,578 $ 6,783 Noncurrent inventories not included above (b) $ 683 $ 683 (a) The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, as well as an increase due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Component of Inventories, Noncurrent	The following table provides the components of Inventories : As of December 31, (MILLIONS OF DOLLARS) 2017 2016 Finished goods $ 2,883 $ 2,293 Work in process 3,908 3,696 Raw materials and supplies 788 793 Inventories (a) $ 7,578 $ 6,783 Noncurrent inventories not included above (b) $ 683 $ 683 (a) The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, as well as an increase due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Components of Property, Plant and Equipment	The following table provides the components of Property, plant and equipment : Useful Lives As of December 31, (MILLIONS OF DOLLARS) (Years) 2017 2016 Land - $ 540 $ 530 Buildings 33-50 10,254 9,810 Machinery and equipment 8-20 11,902 11,248 Furniture, fixtures and other 3-12 1/2 4,661 4,410 Construction in progress - 2,680 2,127 30,037 28,125 Less: Accumulated depreciation 16,172 14,807 Property, plant and equipment (a) $ 13,865 $ 13,318 (a) The increase in total property, plant and equipment is primarily due to capital additions and the impact of foreign exchange, partially offset by depreciation, reductions due to restructuring efforts and disposals.

Identifiable Intangible Asset39

Identifiable Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : December 31, 2017 December 31, 2016 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,550 $ (54,785 ) $ 34,765 $ 83,390 $ (49,650 ) $ 33,740 Brands 2,134 (1,152 ) 982 2,092 (1,032 ) 1,060 Licensing agreements and other 1,911 (1,096 ) 815 1,869 (1,005 ) 864 93,595 (57,033 ) 36,562 87,351 (51,687 ) 35,664 Indefinite-lived intangible assets Brands and other 6,929 6,929 6,883 6,883 IPR&D (a) 5,249 5,249 10,101 10,101 12,179 12,179 16,984 16,984 Identifiable intangible assets (b) $ 105,774 $ (57,033 ) $ 48,741 $ 104,335 $ (51,687 ) $ 52,648 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), (iv) the Developed technology rights of $364 million recorded in connection with the U.S. approval of Bosulif (see Note 7E ) and (v) the Developed technology rights of $140 million recorded in connection with the approvals of Bavencio (see Note 2C ) partially offset by (vi) measurement period adjustments related to Medivation (see Note 2A ) and (vii) impairments of Developed technology rights (see Note 4 ) . (b) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to (i) amortization, (ii) measurement period adjustments related to Medivation (see Note 2A ), as well as (iii) impairments of Developed technology rights (see Note 4 ), partially offset by (iv) assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (v) the assets recorded in connection with the EU and U.S. approvals of Besponsa and in connection with the U.S. approval of Bosulif (see Note 7E ) and (vi) the assets recorded in connection with the approvals of Bavencio (see Note 2C ). Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: December 31, 2017 IH EH WRD Developed technology rights 68 % 31 % — Brands, finite-lived 75 % 25 % — Brands, indefinite-lived 71 % 29 % — IPR&D 81 % 12 % 7 %
Schedule of Indefinite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : December 31, 2017 December 31, 2016 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,550 $ (54,785 ) $ 34,765 $ 83,390 $ (49,650 ) $ 33,740 Brands 2,134 (1,152 ) 982 2,092 (1,032 ) 1,060 Licensing agreements and other 1,911 (1,096 ) 815 1,869 (1,005 ) 864 93,595 (57,033 ) 36,562 87,351 (51,687 ) 35,664 Indefinite-lived intangible assets Brands and other 6,929 6,929 6,883 6,883 IPR&D (a) 5,249 5,249 10,101 10,101 12,179 12,179 16,984 16,984 Identifiable intangible assets (b) $ 105,774 $ (57,033 ) $ 48,741 $ 104,335 $ (51,687 ) $ 52,648 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), (iv) the Developed technology rights of $364 million recorded in connection with the U.S. approval of Bosulif (see Note 7E ) and (v) the Developed technology rights of $140 million recorded in connection with the approvals of Bavencio (see Note 2C ) partially offset by (vi) measurement period adjustments related to Medivation (see Note 2A ) and (vii) impairments of Developed technology rights (see Note 4 ) . (b) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to (i) amortization, (ii) measurement period adjustments related to Medivation (see Note 2A ), as well as (iii) impairments of Developed technology rights (see Note 4 ), partially offset by (iv) assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (v) the assets recorded in connection with the EU and U.S. approvals of Besponsa and in connection with the U.S. approval of Bosulif (see Note 7E ) and (vi) the assets recorded in connection with the approvals of Bavencio (see Note 2C ). Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: December 31, 2017 IH EH WRD Developed technology rights 68 % 31 % — Brands, finite-lived 75 % 25 % — Brands, indefinite-lived 71 % 29 % — IPR&D 81 % 12 % 7 %
Schedule of Expected Amortization Expense	The following table provides the annual amortization expense expected for the years 2018 through 2022: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 2022 Amortization expense $ 4,798 $ 4,592 $ 3,569 $ 3,474 $ 3,223
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, January 1, 2016 $ 23,809 $ 24,433 $ 48,242 Additions (a) 6,357 12 6,369 Other (b) (32 ) (130 ) (162 ) Balance, December 31, 2016 30,134 24,315 54,449 Additions (c) 572 92 664 Other (d) 435 404 840 Balance, December 31, 2017 $ 31,141 $ 24,811 $ 55,952 (a) IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo (see Note 2A ). (b) Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $119 million to Assets held for sale during 2016 (see Note 2B ). (c) IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ). (d) Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.

Pension and Postretirement Be40

Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the annual (income)/cost and changes in Other comprehensive income/(loss) for our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) 2017 2016 2015 2017 2016 2015 2017 2016 2015 2017 2016 2015 Service cost $ 269 $ 257 $ 287 $ 24 $ 18 $ 22 $ 171 $ 165 $ 186 $ 42 $ 41 $ 55 Interest cost 634 646 676 54 53 54 204 233 307 90 101 117 Expected return on plan assets (1,005 ) (958 ) (1,089 ) — — — (345 ) (381 ) (418 ) (36 ) (34 ) (53 ) Amortization of: Actuarial losses 393 395 346 50 37 44 116 93 122 31 32 38 Prior service cost/(credits) 3 5 (5 ) (1 ) (1 ) (2 ) (4 ) (3 ) (7 ) (182 ) (174 ) (146 ) Curtailments 13 10 3 1 1 — — (2 ) 5 (19 ) (26 ) (31 ) Settlements 75 90 556 39 28 34 4 9 81 — — — Special termination benefits — — — — — — 1 1 1 — — — Net periodic benefit costs/(income) reported in Income 382 444 773 166 137 153 147 115 277 (75 ) (59 ) (21 ) (Income)/cost reported in Other comprehensive income/(loss) (b) 141 253 (396 ) 23 121 (143 ) (301 ) 640 (542 ) (8 ) 3 (540 ) (Income)/cost recognized in Comprehensive income $ 523 $ 697 $ 378 $ 189 $ 258 $ 10 $ (154 ) $ 755 $ (265 ) $ (83 ) $ (56 ) $ (560 ) (a) In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3 ). In 2015, the net periodic benefit costs included settlement losses primarily related to participants accepting the lump-sum option made in an offer to certain plan participants to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or to elect an early annuity. (b) In 2017 and 2016, the changes to Other comprehensive (income)/loss for the international plans was impacted by foreign currency movements. For details of the changes in Other comprehensive (income)/loss, see the benefit plan activity in the consolidated statements of comprehensive income.
Schedule of Amounts in Accumulated Other Comprehensive Income/(Loss) Expected to be Amortized into 2014 Net Periodic Benefit Costs	The following table provides the amounts in Accumulated other comprehensive loss expected to be amortized into 2018 net periodic benefit costs: Pension Plans (MILLIONS OF DOLLARS) U.S. U.S. Supplemental International Postretirement Plans Actuarial losses (a) $ (121 ) $ (16 ) $ (101 ) $ (9 ) Prior service credits and other (2 ) 1 4 181 Total $ (123 ) $ (15 ) $ (97 ) $ 172 (a) Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans will reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for 2018 are 24.8 years for our U.S. qualified plans, 26.2 years for our U.S. supplemental (non-qualified) plans, 20.0 years for our international plans, and 9.7 for our postretirement plans.
Schedule of Assumptions Used	The following table provides the weighted-average actuarial assumptions of our benefit plans: (PERCENTAGES) 2017 2016 2015 Weighted-average assumptions used to determine benefit obligations Discount rate: U.S. qualified pension plans 3.8% 4.3% 4.5% U.S. non-qualified pension plans 3.7% 4.2% 4.5% International pension plans 2.3% 2.4% 3.1% Postretirement plans 3.7% 4.2% 4.5% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.5% 2.6% 2.6% Weighted-average assumptions used to determine net periodic benefit cost Discount rate: U.S. qualified pension plans 4.3% 4.5% 4.2% U.S. non-qualified pension plans 4.2% 4.5% 4.0% International pension plans interest cost (a) 2.1% 2.7% 3.0% International pension plans service cost (a) 2.3% 3.0% 3.0% Postretirement plans 4.2% 4.5% 4.2% Expected return on plan assets: U.S. qualified pension plans 8.0% 8.0% 8.3% International pension plans 4.7% 5.2% 5.5% Postretirement plans 8.0% 8.0% 8.3% Rate of compensation increase: U.S. qualified pension plans 2.8% 2.8% 2.8% U.S. non-qualified pension plans 2.8% 2.8% 2.8% International pension plans 2.6% 2.6% 2.7% (a) Effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with this change, the effective rate for interest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans.
Schedule of Health Care Cost Trend Rates	The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans: 2017 2016 Healthcare cost trend rate assumed for next year (up to age 65) 6.1 % 6.3 % Healthcare cost trend rate assumed for next year (age 65 and older) 7.0 % 7.4 % Rate to which the cost trend rate is assumed to decline 4.5 % 4.5 % Year that the rate reaches the ultimate trend rate 2037 2037 The following table provides the effects as of December 31, 2017 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits: (MILLIONS OF DOLLARS) Increase Decrease Effect on total service and interest cost components $ 3 $ (4 ) Effect on postretirement benefit obligation 47 (26 )
Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates	The following table provides the effects as of December 31, 2017 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits: (MILLIONS OF DOLLARS) Increase Decrease Effect on total service and interest cost components $ 3 $ (4 ) Effect on postretirement benefit obligation 47 (26 )
Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans	The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans: Year Ended December 31, Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International (b) Postretirement Plans (c) (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 2017 2016 Change in benefit obligation (d) Benefit obligation, beginning $ 15,547 $ 14,926 $ 1,450 $ 1,343 $ 9,691 $ 9,214 $ 2,254 $ 2,463 Service cost 269 257 24 18 171 165 42 41 Interest cost 634 646 54 53 204 233 90 101 Employee contributions — — — — 6 7 94 85 Plan amendments — — — — 2 (6 ) — (177 ) Changes in actuarial assumptions and other 1,614 725 110 185 135 1,273 (177 ) 22 Foreign exchange impact — — — — 760 (781 ) 5 — Acquisitions/divestitures/other, net — — — — 26 1 1 — Curtailments 11 9 — 1 — (14 ) 1 — Settlements (842 ) (449 ) (98 ) (78 ) (31 ) (45 ) — — Special termination benefits — — — — 1 1 — — Benefits paid (530 ) (568 ) (45 ) (72 ) (357 ) (358 ) (280 ) (282 ) Benefit obligation, ending (d) 16,702 15,547 1,495 1,450 10,607 9,691 2,028 2,254 Change in plan assets Fair value of plan assets, beginning 12,556 11,633 — — 7,683 7,959 458 622 Actual gain/(loss) on plan assets 2,005 939 — — 811 693 39 44 Company contributions 1,095 1,000 143 151 160 209 183 (12 ) Employee contributions — — — — 6 7 94 85 Foreign exchange impact — — — — 561 (782 ) — — Acquisitions/divestitures, net — — — — 30 (1 ) — — Settlements (842 ) (449 ) (98 ) (78 ) (31 ) (45 ) — — Benefits paid (530 ) (568 ) (45 ) (72 ) (357 ) (358 ) (280 ) (282 ) Fair value of plan assets, ending 14,284 12,556 — — 8,863 7,683 494 458 Funded status—Plan assets less than benefit obligation $ (2,418 ) $ (2,990 ) $ (1,495 ) $ (1,450 ) $ (1,745 ) $ (2,008 ) $ (1,534 ) $ (1,796 ) (a) The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017. (b) The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements. (c) The favorable change in the funded status of our postretirement plans was primarily due to a change to reimbursements of certain benefits provided under the plan, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017. (d) For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $16.7 billion in 2017 and $15.4 billion in 2016 . The ABO for our U.S. supplemental (non-qualified) pension plans was $1.5 billion in 2017 and $1.4 billion in 2016 . The ABO for our international pension plans was $10.1 billion in 2017 and $9.3 billion in 2016 .
Schedule of Amounts Recognized in Balance Sheet	The following table provides information as to how the funded status is recognized in our consolidated balance sheets: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 2017 2016 Noncurrent assets (a) $ — $ — $ — $ — $ 454 $ 300 $ — $ — Current liabilities (b) — (160 ) (160 ) (152 ) (26 ) (28 ) (31 ) (30 ) Noncurrent liabilities (c) (2,418 ) (2,830 ) (1,336 ) (1,297 ) (2,172 ) (2,279 ) (1,504 ) (1,766 ) Funded status $ (2,418 ) $ (2,990 ) $ (1,495 ) $ (1,450 ) $ (1,745 ) $ (2,008 ) $ (1,534 ) $ (1,796 ) (a) Included primarily in Other noncurrent assets . (b) Included in Accrued compensation and related items . (c) Included in Pension benefit obligations, net and Postretirement benefit obligations , net, as appropriate.
Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)	The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss : As of December 31, Pension Plans U.S. Qualified U.S. Supplemental International Postretirement (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 2017 2016 Actuarial losses (a) $ (4,677 ) $ (4,530 ) $ (561 ) $ (538 ) $ (2,322 ) $ (2,629 ) $ (293 ) $ (502 ) Prior service (costs)/credits (23 ) (27 ) 1 2 34 40 1,190 1,392 Total $ (4,699 ) $ (4,558 ) $ (559 ) $ (536 ) $ (2,288 ) $ (2,589 ) $ (897 ) $ (889 ) (a) The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the expected life expectancy of plan participants for frozen plans, using the corridor approach.
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets	The following table provides information related to the funded status of selected benefit plans: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 Pension plans with an ABO in excess of plan assets: Fair value of plan assets $ 14,284 $ 12,556 $ — $ — $ 882 $ 4,625 ABO 16,702 15,422 1,495 1,410 2,724 6,558 Pension plans with a PBO in excess of plan assets: Fair value of plan assets 14,284 12,556 — — 1,626 4,936 PBO 16,702 15,547 1,495 1,450 3,825 7,244
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets	The following table provides information related to the funded status of selected benefit plans: As of December 31, Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International (MILLIONS OF DOLLARS) 2017 2016 2017 2016 2017 2016 Pension plans with an ABO in excess of plan assets: Fair value of plan assets $ 14,284 $ 12,556 $ — $ — $ 882 $ 4,625 ABO 16,702 15,422 1,495 1,410 2,724 6,558 Pension plans with a PBO in excess of plan assets: Fair value of plan assets 14,284 12,556 — — 1,626 4,936 PBO 16,702 15,547 1,495 1,450 3,825 7,244
Schedule of Allocation of Plan Assets	The following table provides the components of plan assets: Fair Value (a) Fair Value (a) (MILLIONS OF DOLLARS) As of Level 1 Level 2 Level 3 Assets Measured at NAV (b) As of Level 1 Level 2 Level 3 Assets Measured at NAV (b) U.S. qualified pension plans Cash and cash equivalents $ 655 $ 115 $ 540 $ — $ — $ 672 $ 92 $ 580 $ — $ — Equity securities: Global equity securities 4,157 4,118 38 1 — 3,970 3,943 27 — — Equity commingled funds 1,194 — 802 — 392 1,062 — 772 — 290 Fixed income securities: Corporate debt securities 4,250 5 4,242 3 — 3,232 14 3,217 1 — Government and agency obligations 1,316 — 1,316 — — 1,060 — 1,060 — — Fixed income commingled funds 94 — — — 94 92 — — — 92 Other investments: Partnership investments (c) 1,197 — — — 1,197 1,093 — — — 1,093 Insurance contracts 215 — 215 — — 235 — 235 — — Other commingled funds (d) 1,206 — — — 1,206 1,140 — — — 1,140 Total 14,284 4,238 7,153 4 2,889 12,556 4,049 5,891 1 2,615 International pension plans Cash and cash equivalents $ 385 $ 48 $ 337 $ — $ — 439 38 401 — — Equity securities: Global equity securities 154 146 8 — — 174 163 11 — — Equity commingled funds 2,897 — 1,594 — 1,303 2,490 — 1,265 — 1,224 Fixed income securities: Corporate debt securities 588 — 588 — — 489 — 474 — 15 Government and agency obligations (e) 716 — 716 — — 853 — 786 — 67 Fixed income commingled funds 2,181 — 1,340 — 841 1,750 — 1,174 — 576 Other investments: Partnership investments (c) 42 — 7 — 35 32 — — — 32 Insurance contracts (f) 496 — 75 420 1 272 — 17 254 1 Other (d), (f) 1,404 — 408 468 528 1,185 — 430 324 431 Total 8,863 194 5,073 887 2,709 7,683 201 4,558 578 2,346 U.S. postretirement plans (g) Cash and cash equivalents — — — — — — — — — — Equity securities: Global equity securities — — — — — — — — — — Equity commingled funds — — — — — — — — — — Fixed income securities: Corporate debt securities — — — — — — — — — — Government and agency obligations — — — — — — — — — — Fixed income commingled funds — — — — — — — — — — Other investments: Partnership investments (c) — — — — — — — — — — Insurance contracts 494 — 494 — — 458 — 458 — — Other commingled funds (d) — — — — — — — — — — Total $ 494 $ — $ 494 $ — $ — $ 458 $ — $ 458 $ — $ — (a) Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E ). (b) Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets. (c) Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital. (d) Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds. (e) Government and agency obligations are inclusive of repurchase agreements. (f) See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs. (g) Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans. The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans: As of December 31, Target Allocation Percentage Percentage of Plan Assets (PERCENTAGES) 2017 2017 2016 U.S. qualified pension plans Cash and cash equivalents 0-10% 4.6 % 5.3 % Equity securities 35-55% 37.5 % 40.1 % Fixed income securities 30-55% 39.6 % 34.9 % Other investments (a) 5-17.5% 18.3 % 19.7 % Total 100 % 100 % 100 % International pension plans Cash and cash equivalents 0-10% 4.3 % 5.7 % Equity securities 25-50% 34.4 % 34.7 % Fixed income securities 30-55% 39.3 % 40.2 % Other investments 10-30% 21.9 % 19.4 % Total 100 % 100 % 100 % U.S. postretirement plans Cash and cash equivalents 0-5% — — Equity securities — — — Fixed income securities — — — Other investments 95-100% 100 % 100 % Total 100 % 100 % 100 % (a) Actual percentage of plan assets in Other investments for 2017 includes $215 million , as compared to $235 million in 2016, related to a group fixed annuity insurance contract that was executed by legacy Wyeth for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $253 million in 2017, as compared to $144 million in 2016, related to an investment in a partnership whose primary holdings are public equity securities.
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs: Year Ended December 31, International Pension Plans Insurance contracts Other (MILLIONS OF DOLLARS) 2017 2016 2017 2016 Fair value, beginning $ 254 $ 219 $ 324 $ 398 Actual return on plan assets: Assets held, ending 1 11 18 (1 ) Assets sold during the period — — 1 6 Purchases, sales and settlements, net 138 20 94 (18 ) Exchange rate changes 27 4 30 (61 ) Fair value, ending $ 420 $ 254 $ 468 $ 324
Schedule of Expected Future Cash Flow Information	The following table provides the expected future cash flow information related to our benefit plans: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Expected employer contributions: 2018 (a) $ 500 $ 160 $ 226 $ 167 Expected benefit payments: 2018 $ 1,225 $ 160 $ 368 $ 173 2019 1,071 129 373 179 2020 1,087 128 385 181 2021 1,059 122 394 179 2022 1,032 123 401 173 2023–2027 4,865 513 2,101 802 (a) For the U.S. qualified plans, a $500 million voluntary contribution was paid in February 2018.

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Common Stock Purchases	The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including our accelerated share repurchase agreements: (SHARES IN MILLIONS, DOLLARS IN BILLIONS) 2017 (a) 2016 (b) 2015 (c) Shares of common stock purchased 150 154 182 Cost of purchase $ 5.0 $ 5.0 $ 6.2 (a) Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on February 2, 2017. See above for additional information. (b) Represents shares purchased pursuant to the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information. (c) Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table provides the components of share-based compensation expense and the associated tax benefit: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Restricted Stock Units $ 301 $ 299 $ 306 Total Shareholder Return Units 221 134 36 Portfolio Performance Shares 209 135 147 Stock Options 55 106 165 Performance Share Awards 47 13 11 Directors’ compensation 7 4 4 Share-based payment expense 840 691 669 Tax benefit for share-based compensation expense (a) (163 ) (205 ) (198 ) Share-based payment expense, net of tax $ 677 $ 486 $ 471 (a) 2017 includes the impact of the TCJA on income taxes.
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes all RSU activity during 2017: Shares (Thousands) Weighted-Average Grant-Date Fair Value Per Share Nonvested, December 31, 2016 29,605 $ 32.59 Granted 9,669 34.05 Vested (a) (16,677 ) 33.41 Reinvested dividend equivalents 1,106 33.41 Forfeited (1,463 ) 32.77 Nonvested, December 31, 2017 22,241 $ 32.64 (a) Includes the modification for a commitment to pay 6.4 million RSUs to approximately 9,900 employees, including senior and key management employees, for the 6.6 million RSUs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification. The following table provides data related to all RSU activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2017 2016 2015 Total fair value of shares vested (a) $ 584 $ 293 $ 371 Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax $ 254 $ 262 $ 279 Weighted-average period over which RSU cost is expected to be recognized (years) 1.7 1.7 1.8 (a) Includes the modification for a commitment to pay 6.4 million RSUs to approximately 9,900 employees, including senior and key management employees, for the 6.6 million RSUs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification.
Schedule of Valuation Assumptions	The following table provides the weighted-average assumptions used in the valuation of stock options: Year Ended December 31, 2017 2016 2015 Expected dividend yield (a) 3.69 % 3.85 % 3.19 % Risk-free interest rate (b) 2.23 % 1.55 % 1.89 % Expected stock price volatility (c) 18.39 % 21.64 % 18.34 % Expected term (years) (d) 6.75 6.75 6.75 (a) Determined using a constant dividend yield during the expected term of the option. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility. (d) Determined using historical exercise and post-vesting termination patterns.
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes all stock option activity during 2017: Shares (Thousands) Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (a) (Millions) Outstanding, December 31, 2016 186,676 $ 26.86 Granted 1,375 34.06 Exercised (34,686 ) 24.94 Forfeited (1,208 ) 34.26 Expired (1,400 ) 30.78 Outstanding, December 31, 2017 150,757 27.27 5.1 $ 1,350 Vested and expected to vest, December 31, 2017 (b) 150,368 27.25 5.1 1,349 Exercisable, December 31, 2017 108,747 $ 24.49 4.3 $ 1,276 (a) Market price of our underlying common stock less exercise price. (b) The number of options expected to vest takes into account an estimate of expected forfeitures. The following table summarizes data related to all stock option activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS) 2017 2016 2015 Weighted-average grant-date fair value per stock option $ 4.01 $ 3.89 $ 4.30 Aggregate intrinsic value on exercise $ 331 $ 389 $ 666 Cash received upon exercise $ 862 $ 1,019 $ 1,263 Tax benefits realized related to exercise $ 95 $ 112 $ 187 Total compensation cost related to nonvested stock options not yet recognized, pre-tax $ 10 $ 58 $ 159 Weighted-average period over which stock option compensation cost is expected to be recognized (years) 0.8 1.1 1.8
Schedule of Nonvested Performance-based Units Activity	The following table summarizes all PPS activity during 2017, with the shares representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2016 22,266 $ 32.48 Granted 7,013 34.06 Vested (7,196 ) 34.28 Forfeited (1,110 ) 33.62 Nonvested, December 31, 2017 (a) 20,973 $ 36.22 (a) Vested and non-vested shares outstanding, but not paid as of December 31, 2017 were 35.0 million . Included in this amount is the modification for a commitment to pay 5.7 million PPSs to approximately 2,800 employees, including senior and key management employees, for the 5.9 million PPSs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. The following table provides data related to all PPS activity: (MILLIONS OF DOLLARS) Year Ended December 31, 2017 2016 2015 Total fair value of shares vested $ 131 $ 118 $ 60 Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax $ 94 $ 93 $ 102 Weighted-average period over which PPS cost is expected to be recognized (years) 1.7 1.8 1.7 The following table summarizes all PSA activity during 2017, with the shares granted representing the maximum award that could be achieved: Shares (Thousands) Weighted-Average Intrinsic Value Per Share Nonvested, December 31, 2016 4,546 $ 32.48 Granted 1,753 34.06 Vested (a) (1,639 ) 35.65 Forfeited (635 ) 34.16 Nonvested, December 31, 2017 4,024 $ 36.22 (a) Includes the modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and key management employees, for the 1.1 million PSAs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification. The following table provides data related to all PSA activity: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Total fair value of shares vested (a) $ 58 $ 9 $ 14 Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax $ 34 $ 30 $ 24 Weighted-average period over which PSA cost is expected to be recognized (years) 1.8 1.8 1.9 (a) Includes the modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and key management employees, for the 1.1 million PSAs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification.
Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions	The following table provides the weighted-average assumptions used in the valuation of TSRUs: Year Ended December 31, 2017 2016 2015 Expected dividend yield (a) 3.69 % 3.85 % 3.19 % Risk-free interest rate (b) 1.98 % 1.31 % 1.76 % Expected stock price volatility (c) 18.39 % 21.64 % 18.41 % Contractual term (years) 5.11 5.12 5.91 (a) Determined using a constant dividend yield during the expected term of the TSRU. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility. The following table provides the weighted-average assumptions used in the valuation of PTSRUs: Year Ended December 31, 2017 Expected dividend yield (a) 3.69 % Risk-free interest rate (b) 2.25 % Expected stock price volatility (c) 16.12 % Contractual term (years) 5 (a) Determined using a constant dividend yield during the expected term of the PTSRU. (b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues. (c) Determined using implied volatility, after consideration of historical volatility.
Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity	The following table summarizes all TSRU activity during 2017: TSRUs (Thousands) Weighted-Average Grant-Date Fair Value Per TSRU Weighted-Average Grant Price Per TSRU Nonvested, December 31, 2016 62,007 $ 5.97 $ 31.10 Granted 52,574 6.23 34.06 Vested (5,805 ) 6.50 32.25 Forfeited (4,870 ) 6.02 32.36 Nonvested, December 31, 2017 103,906 $ 6.07 $ 32.47 The following table summarizes TSRU and PTU information as of December 31, 2017 (a), (b) : TSRUs (Thousands) PTUs (Thousands) Weighted-Average Grant Price Per TSRU Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (Millions) TSRUs Outstanding 124,745 — $ 31.37 3.3 $ 896 TSRUs Vested (c) 20,839 — 25.89 1.2 335 TSRUs Expected to vest (d) 95,485 — 32.45 3.7 516 TSRUs exercised and converted to PTUs (e) — 36 $ — 0.2 $ 1 (a) In 2017 , we settled 11,327,156 TSRUs with a weighted-average grant price of $22.26 per unit. This includes the modification for a commitment to pay 7.0 million TSRUs to approximately 150 employees, including senior and key management employees, for the 7.2 million TSRUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. (b) In 2017 , 46,278 TSRUs with a weighted-average grant price of $22.65 per unit were converted into 24,602 PTUs. (c) This includes the modification for a commitment to pay 7.0 million TSRUs to approximately 150 employees, including senior and key management employees, for the 7.2 million TSRUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. (d) The number of TSRUs expected to vest takes into account an estimate of expected forfeitures. (e) Includes the modification for a commitment to pay 17,000 PTUs to a few employees, including senior and key management employees, for the 17,000 PTUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification. The following table provides data related to all TSRU activity: Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS) 2017 2016 2015 Weighted-average grant-date fair value per TSRU $ 6.23 $ 5.83 $ 6.66 Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax $ 232 $ 164 $ 29 Weighted-average period over which TSRU cost is expected to be recognized (years) 1.7 1.9 1.8

Earnings Per Common Share Att43

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of Earnings per common share (EPS): Year Ended December 31, (IN MILLIONS) 2017 2016 2015 EPS Numerator––Basic Income from continuing operations $ 21,353 $ 7,229 $ 6,975 Less: Net income attributable to noncontrolling interests 47 31 26 Income from continuing operations attributable to Pfizer Inc. 21,306 7,198 6,949 Less: Preferred stock dividends––net of tax 1 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 21,305 7,197 6,948 Discontinued operations––net of tax 2 17 11 Less: Discontinued operations––net of tax, attributable to noncontrolling interests — — — Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders 2 17 11 Net income attributable to Pfizer Inc. common shareholders $ 21,307 $ 7,214 $ 6,959 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 21,306 $ 7,197 $ 6,948 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 2 17 11 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 21,308 $ 7,214 $ 6,960 EPS Denominator Weighted-average number of common shares outstanding––Basic (a) 5,970 6,089 6,176 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (a) 89 70 81 Weighted-average number of common shares outstanding––Diluted 6,058 6,159 6,257 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (b) 36 63 50 (a) 2017 shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement. (b) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Schedule of Future Minimum Rental Commitments Under Non-Cancelable Operating Leases	The future minimum rental commitments under non-cancelable operating leases follow: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 2022 After 2022 Lease commitments $ 209 $ 172 $ 150 $ 136 $ 123 $ 891

Segment, Geographic and Other45

Segment, Geographic and Other Revenue Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 2017 2016 2015 2017 2016 2015 Reportable Segments: IH $ 31,422 $ 29,197 $ 26,758 $ 18,341 $ 15,854 $ 14,581 $ 534 $ 583 $ 552 EH 21,124 23,627 22,094 11,283 12,898 12,714 579 600 446 Total reportable segments 52,546 52,824 48,851 29,625 28,752 27,295 1,113 1,183 998 Other business activities (c) — — — (3,137 ) (3,020 ) (2,914 ) 90 85 76 Reconciling Items: Corporate (d) — — — (5,522 ) (5,491 ) (5,607 ) 337 356 355 Purchase accounting adjustments (d) — — — (4,758 ) (4,185 ) (3,953 ) 4,565 3,890 3,573 Acquisition-related costs (d) — — — (456 ) (785 ) (894 ) 39 7 75 Certain significant items (e) — — — (2,647 ) (5,888 ) (4,321 ) 52 200 48 Other unallocated (d) — — — (799 ) (1,032 ) (642 ) 72 35 33 $ 52,546 $ 52,824 $ 48,851 $ 12,305 $ 8,351 $ 8,965 $ 6,269 $ 5,757 $ 5,157 (a) Income from continuing operations before provision/(benefit) for taxes on income . IH’s earnings in 2017 include d ividend income of $266 million from our investment in ViiV. For additional information, see Note 4. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $165 million and $177 million of costs from Other Business Activities to Corporate in 2016 and 2015 , respectively, to conform to the current period presentation. (d) For a description, see the “Other Costs and Business Activities” section above. (e) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $348 million , (ii) charges for certain legal matters of $237 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $55 million , (iv) certain asset impairment charges of $379 million , (v) charges for business and legal entity alignment of $71 million , (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $556 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million , (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $197 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in 2015 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4 .
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 2017 2016 2015 2017 2016 2015 Reportable Segments: IH $ 31,422 $ 29,197 $ 26,758 $ 18,341 $ 15,854 $ 14,581 $ 534 $ 583 $ 552 EH 21,124 23,627 22,094 11,283 12,898 12,714 579 600 446 Total reportable segments 52,546 52,824 48,851 29,625 28,752 27,295 1,113 1,183 998 Other business activities (c) — — — (3,137 ) (3,020 ) (2,914 ) 90 85 76 Reconciling Items: Corporate (d) — — — (5,522 ) (5,491 ) (5,607 ) 337 356 355 Purchase accounting adjustments (d) — — — (4,758 ) (4,185 ) (3,953 ) 4,565 3,890 3,573 Acquisition-related costs (d) — — — (456 ) (785 ) (894 ) 39 7 75 Certain significant items (e) — — — (2,647 ) (5,888 ) (4,321 ) 52 200 48 Other unallocated (d) — — — (799 ) (1,032 ) (642 ) 72 35 33 $ 52,546 $ 52,824 $ 48,851 $ 12,305 $ 8,351 $ 8,965 $ 6,269 $ 5,757 $ 5,157 (a) Income from continuing operations before provision/(benefit) for taxes on income . IH’s earnings in 2017 include d ividend income of $266 million from our investment in ViiV. For additional information, see Note 4. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $165 million and $177 million of costs from Other Business Activities to Corporate in 2016 and 2015 , respectively, to conform to the current period presentation. (d) For a description, see the “Other Costs and Business Activities” section above. (e) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $348 million , (ii) charges for certain legal matters of $237 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $55 million , (iv) certain asset impairment charges of $379 million , (v) charges for business and legal entity alignment of $71 million , (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $556 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million , (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $197 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in 2015 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4 .
Reconciliation Of Depreciation And Amortization From Segments To Consolidated	The following table provides selected income statement information by reportable segment: Revenues Earnings (a) Depreciation and Amortization (b) Year Ended December 31, Year Ended December 31, Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 2017 2016 2015 2017 2016 2015 Reportable Segments: IH $ 31,422 $ 29,197 $ 26,758 $ 18,341 $ 15,854 $ 14,581 $ 534 $ 583 $ 552 EH 21,124 23,627 22,094 11,283 12,898 12,714 579 600 446 Total reportable segments 52,546 52,824 48,851 29,625 28,752 27,295 1,113 1,183 998 Other business activities (c) — — — (3,137 ) (3,020 ) (2,914 ) 90 85 76 Reconciling Items: Corporate (d) — — — (5,522 ) (5,491 ) (5,607 ) 337 356 355 Purchase accounting adjustments (d) — — — (4,758 ) (4,185 ) (3,953 ) 4,565 3,890 3,573 Acquisition-related costs (d) — — — (456 ) (785 ) (894 ) 39 7 75 Certain significant items (e) — — — (2,647 ) (5,888 ) (4,321 ) 52 200 48 Other unallocated (d) — — — (799 ) (1,032 ) (642 ) 72 35 33 $ 52,546 $ 52,824 $ 48,851 $ 12,305 $ 8,351 $ 8,965 $ 6,269 $ 5,757 $ 5,157 (a) Income from continuing operations before provision/(benefit) for taxes on income . IH’s earnings in 2017 include d ividend income of $266 million from our investment in ViiV. For additional information, see Note 4. (b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. (c) Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $165 million and $177 million of costs from Other Business Activities to Corporate in 2016 and 2015 , respectively, to conform to the current period presentation. (d) For a description, see the “Other Costs and Business Activities” section above. (e) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $348 million , (ii) charges for certain legal matters of $237 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $55 million , (iv) certain asset impairment charges of $379 million , (v) charges for business and legal entity alignment of $71 million , (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $556 million . For additional information, see Note 2B, Note 3 and Note 4 . For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion , (ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million , (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $197 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in 2015 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million , (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million , (iii) certain asset impairment charges of $787 million , (iv) a charge related to pension settlements of $491 million , (v) charges for business and legal entity alignment of $282 million , (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million . For additional information, see Note 3 and Note 4 .
Revenue from External Customers by Geographic Areas	As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 , 2016 and 2015 . The following table provides revenues by geographic area: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 United States $ 26,026 $ 26,369 $ 21,704 Developed Europe (a) 8,508 9,306 9,714 Developed Rest of World (b) 6,612 6,729 6,298 Emerging Markets (c) 11,399 10,420 11,136 Revenues $ 52,546 $ 52,824 $ 48,851 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $6.8 billion in 2017 , $7.2 billion in 2016 and $7.4 billion in 2015 . (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Long-lived Assets by Geographic Areas	The following table provides long-lived assets by geographic area: As of December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Property, plant and equipment, net United States $ 6,971 $ 6,649 $ 7,072 Developed Europe (a) 4,345 4,228 4,376 Developed Rest of World (b) 632 643 660 Emerging Markets (c) 1,917 1,797 1,658 Property, plant and equipment, net $ 13,865 $ 13,318 $ 13,766 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Schedule of Significant Product Revenues	As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 , 2016 and 2015 . The following table provides detailed revenue information: Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 PFIZER INNOVATIVE HEALTH (IH) (a) $ 31,422 $ 29,197 $ 26,758 Internal Medicine $ 9,684 $ 8,858 $ 7,611 Lyrica IH (b) 4,511 4,165 3,655 Eliquis alliance revenues and direct sales 2,523 1,713 913 Chantix/Champix 997 842 671 Viagra IH (c) 823 1,181 1,297 BMP2 261 251 232 Toviaz 257 258 267 All other Internal Medicine 312 447 577 Vaccines $ 6,001 $ 6,071 $ 6,454 Prevnar 13/Prevenar 13 5,601 5,718 6,245 FSME/IMMUN-TicoVac 134 114 104 All other Vaccines 266 239 104 Oncology $ 6,056 $ 4,563 $ 2,955 Ibrance 3,126 2,135 723 Sutent 1,081 1,095 1,120 Xalkori 594 561 488 Xtandi alliance revenues 590 140 — Inlyta 339 401 430 Bosulif 233 167 111 All other Oncology 93 63 83 Inflammation & Immunology (I&I) $ 3,968 $ 3,928 $ 3,918 Enbrel (Outside the U.S. and Canada) 2,452 2,909 3,333 Xeljanz 1,345 927 523 Eucrisa 67 — — All other I&I 103 93 61 Rare Disease $ 2,240 $ 2,369 2,425 BeneFIX 604 712 752 Refacto AF/Xyntha 551 554 533 Genotropin 532 579 617 Somavert 254 232 218 All other Rare Disease 300 292 306 Consumer Healthcare $ 3,472 $ 3,407 $ 3,395 PFIZER ESSENTIAL HEALTH (EH) (d) $ 21,124 $ 23,627 $ 22,094 Legacy Established Products (LEP) (e) $ 10,894 $ 11,197 $ 11,745 Lipitor 1,915 1,758 1,860 Premarin family 977 1,017 1,018 Norvasc 926 962 991 Xalatan/Xalacom 335 363 399 Effexor 297 278 288 Zoloft 291 304 374 EpiPen 290 386 339 Zithromax 270 272 275 Relpax 236 323 352 Xanax 225 222 224 Sildenafil Citrate 56 — — All other LEP 5,077 5,313 5,625 Sterile Injectable Pharmaceuticals (SIP) (f) $ 5,673 $ 6,014 $ 3,944 Medrol 483 450 402 Sulperazon 471 396 339 Fragmin 306 318 335 Tygacil 260 274 304 Precedex 243 264 76 Tazosyn/Zosyn 194 146 144 All other SIP 3,715 4,166 2,343 Year Ended December 31, (MILLIONS OF DOLLARS) 2017 2016 2015 Peri-LOE Products (g) $ 3,223 $ 4,220 $ 5,326 Celebrex 775 733 830 Lyrica EH (b) 553 801 1,183 Vfend 421 590 682 Viagra EH (c) 382 383 411 Pristiq 303 732 715 Zyvox 281 421 883 Revatio 252 285 260 All other Peri-LOE Products 257 276 362 Biosimilars (h) $ 531 $ 319 $ 63 Inflectra/Remsima 419 192 30 All other Biosimilars 112 127 33 Pfizer CentreOne (i) $ 706 $ 718 $ 612 Hospira Infusion Systems (HIS) (j) $ 97 $ 1,158 $ 403 Revenues $ 52,546 $ 52,824 $ 48,851 Total Lyrica (b) $ 5,065 $ 4,966 $ 4,839 Total Viagra (c) $ 1,204 $ 1,564 $ 1,708 Total Alliance revenues $ 2,927 $ 1,746 $ 1,312 (a) The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. Viagra lost exclusivity in the U.S. in December 2017. Beginning in the first quarter of 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through December 2017, will be reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore total Viagra worldwide revenues will be reported in EH from 2018 forward. (d) The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017), and includes all legacy Hospira commercial operations. (e) Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above. (f) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (g) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. Beginning in the first quarter of 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through December 2017, will be reported in EH. Therefore total Viagra worldwide revenues will be reported in EH from 2018 forward. See note (c) above. (h) Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. (i) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. (j) HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. We performed certain reclassifications, primarily between Legacy Established Products and Sterile Injectable Pharmaceuticals, to conform to current period presentation.

Basis of Presentation and Sig46

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Millions		Dec. 22, 2016USD ($)	Sep. 28, 2016USD ($)$ / shares	Jun. 24, 2016USD ($)$ / shares	Apr. 08, 2016USD ($)	Sep. 03, 2015USD ($)$ / shares	Dec. 31, 2017USD ($)Operating_Segment	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Feb. 03, 2017USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of operating segments | Operating_Segment							2
Cash payments for acquisition, net of cash acquired	[1]						$ 1,000	$ 18,368	$ 16,466
Payments for merger termination costs					$ 150			150
Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns							4,923	4,282
Advertising expense							3,100	3,200	3,100
Research and development expenses	[2],[3]						7,657	7,872	7,690
Nonsoftware License Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Research and development expenses							$ 169	$ 82	$ 429
AstraZeneca [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred		$ 1,045
Payments to acquire businesses, cash portion		$ 555
Medivation [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares			$ 81.5
Payments to acquire businesses, cash portion			$ 14,300
Cash payments for acquisition, net of cash acquired			$ 13,900
Anacor [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares				$ 99.25
Payments to acquire businesses, cash portion				$ 4,900
Cash payments for acquisition, net of cash acquired				4,500
Debt assumed				$ 698
Hospira [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares						$ 90
Payments to acquire businesses, cash portion						$ 16,100
Cash payments for acquisition, net of cash acquired						$ 15,700
ICU Medical [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received for disposition										$ 900
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

Basis of Presentation and Sig47

Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 4,923	$ 4,282
Trade Accounts Receivable [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	1,352	1,154
Other Current Liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates	2,674	2,261
Other accruals	512	509
Other Noncurrent Liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 385	$ 357

Acquisitions, Sale of Hospira48

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - AstraZeneca's Small Molecule Anti-Infectives Business (Details) - USD ($) $ in Millions	Dec. 22, 2016	Feb. 22, 2018	Jul. 02, 2017	Dec. 31, 2017	[1]	Dec. 31, 2016	[1]	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill				$ 55,952		$ 54,449		$ 48,242
AstraZeneca [Member]
Business Acquisition [Line Items]
Upfront payment to acquire business	$ 552
Additional payment for contractual purchase price adjustment			$ 3
Milestone payment			$ 50
Deferred payment	175
Potential milestone payments	75
Maximum amount of sales-related payments	600
Consideration transferred	1,045
Payments to acquire businesses, cash portion	555
Assumed contingent consideration	490
Intangible assets	879
Other current assets	92
Goodwill	92
Net deferred tax liabilities	17
Minimum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Royalty payments	250
Maximum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Royalty payments	425
Developed Technology Rights [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Intangible assets	660
In Process Research and Development [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Intangible assets	$ 219
Subsequent Event [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Milestone payment		$ 125
[1]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira49

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Medivation, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 28, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2017
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 1,000		$ 18,368		$ 16,466
Goodwill			55,952	[2]	54,449	[2]	$ 48,242	$ 55,952	[2]
Medivation [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 81.5
Payments to acquire businesses, cash portion		$ 14,300
Cash payments for acquisition, net of cash acquired		13,900
Acquisition consideration, amount payable					$ 365
Intangible assets		12,200
Goodwill		6,100
Net deferred tax liabilities		4,000
Assumed contingent consideration		259
Identifiable intangible assets, excluding IPR&D								$ 1,000
Decrease in amortization of intangible assets			$ 38
Developed Technology Rights [Member] | Medivation [Member]
Business Acquisition [Line Items]
Intangible assets		$ 8,100
Acquired intangible assets, useful life		12 years
In Process Research and Development [Member] | Medivation [Member]
Business Acquisition [Line Items]
Intangible assets		$ 4,100
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira50

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Bamboo Therapeutics, Inc. (Details) - USD ($) $ in Millions		Aug. 01, 2016	Oct. 02, 2016	Apr. 03, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]				$ 1,000		$ 18,368		$ 16,466
Goodwill					$ 55,952	[2]	$ 54,449	[2]	$ 48,242
Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Total consideration transferred		$ 150
Potential milestone payments		495
Consideration transferred, including equity interest held prior to business combination		343
Payments to acquire businesses, cash portion		130		$ 43
Cash payments for acquisition, net of cash acquired		101
Assumed contingent consideration		167
Fair value of previously held equity interest in acquiree		45
Goodwill		142
Net deferred tax liabilities		94
Bamboo Therapeutics [Member] | Other Nonoperating Income (Expense) [Member]
Business Acquisition [Line Items]
Gain recognized			$ 2
In Process Research and Development [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Intangible assets		$ 330
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira51

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Anacor Pharmaceuticals, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		Jun. 24, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 1,000		$ 18,368		$ 16,466
Goodwill			$ 55,952	[2]	$ 54,449	[2]	$ 48,242
Anacor [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 99.25
Payments to acquire businesses, cash portion		$ 4,900
Cash payments for acquisition, net of cash acquired		4,500
Debt assumed		698
Indefinite-lived intangible assets		4,900
Goodwill		646
Net deferred tax liabilities		346
In Process Research and Development [Member] | Anacor [Member]
Business Acquisition [Line Items]
Intangible assets		$ 4,800
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira52

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Hospira Acquisition (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 03, 2015	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 1,000		$ 18,368		$ 16,466
Amounts Recognized as of Acquisition Date
Goodwill			55,952	[2]	54,449	[2]	48,242
Uncertain tax positions			6,558	[3]	5,826	[3]	5,919	[3]	$ 6,182
Tax impact from tax matters to be resolved in a different manner following acquisition			424	[4]	503
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)	[5]		$ 21,308		$ 7,215		6,960
Hospira [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 90
Payments to acquire businesses, cash portion		$ 16,100
Cash payments for acquisition, net of cash acquired		15,700
Amounts Recognized as of Acquisition Date
Working capital, excluding inventories	[6]	342
Inventories		1,901
PP&E		2,352
Other noncurrent assets		362
Long-term debt		(1,928)
Benefit obligations		(117)
Net income tax accounts	[7]	(3,380)
Other noncurrent liabilities		(61)
Total identifiable net assets		8,791
Goodwill		7,295
Net assets acquired/total consideration transferred		16,087
Current tax assets		57
Noncurrent tax assets		58
Income taxes payable		5
Noncurrent deferred tax liabilities		3,400
Other taxes payable		101
Accrued interest		5
Acquired receivables, gross contractual amount		565
Acquired receivables, not expected to be collected		12
Uncertain tax positions		109
Additional tax liability adjustments		3,200
Tax impact from tax matters to be resolved in a different manner following acquisition		719
Business Acquisition, Pro Forma Information [Abstract]
Revenues							1,513
Net loss attributable to Pfizer Inc. common shareholders	[8]						(575)
Revenues							52,082
Net income attributable to Pfizer Inc. common shareholders							$ 7,669
Diluted EPS attributable to Pfizer Inc. common shareholders (in dollars per share)							$ 1.23
Additional amortization expense							$ 342
Additional depreciation expense							52
Adjustment to interest expense							(18)
Hospira [Member] | Developed Technology Rights and Other Intangible Assets [Member]
Amounts Recognized as of Acquisition Date
Identifiable intangible assets	[9]	$ 8,290
Hospira [Member] | Developed Technology Rights [Member]
Amounts Recognized as of Acquisition Date
Acquired intangible assets, useful life		17 years
Acquired intangible assets		$ 7,700
Hospira [Member] | Other Intangible Assets [Member]
Amounts Recognized as of Acquisition Date
Acquired intangible assets, useful life		12 years
Acquired intangible assets		$ 570
Fair Value Adjustment to Inventory [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							378
Amortization Expense Adjustment to Intangible Assets [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							161
Depreciation Expense Adjustment to Fixed Assets [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							34
Amortization Expense Adjustment to Long-term Debt [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							(13)
Restructuring and Integration Costs [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							(556)
Eliminations [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Elimination of intangible asset amortization expense							33
Eliminations [Member] | Fair Value Adjustment to Inventory [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							364
Eliminations [Member] | Acquisition-related Costs [Member] | Hospira [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)							$ 877
In Process Research and Development [Member] | Hospira [Member]
Amounts Recognized as of Acquisition Date
Indefinite-lived intangible assets		$ 1,030
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	In 2017, included in Income taxes payable ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($123 million), Noncurrent deferred tax liabilities ($3.3 billion) and Other taxes payable ($3.2 billion). In 2016, included in Income taxes payable ($14 million), Current tax assets ($17 million), Noncurrent deferred tax assets and other noncurrent tax assets ($184 million), Noncurrent deferred tax liabilities ($2.8 billion) and Other taxes payable ($2.8 billion).
[4]	2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A.
[5]	Amounts may not add due to rounding.
[6]	ncludes cash and cash equivalents, short-term investments, accounts receivable, other current assets, assets held for sale, accounts payable and other current liabilities.
[7]	Final amounts recognized as of the acquisition date, included in Current tax assets ($57 million), Noncurrent deferred tax assets and other noncurrent tax assets ($58 million), Income taxes payable ($5 million), Noncurrent deferred tax liabilities ($3.4 billion) and Other taxes payable ($101 million, including accrued interest of $5 million).
[8]	Includes purchase accounting charges related to the provisional estimated fair values recognized as of the acquisition date for (i) the fair value adjustment for acquisition-date inventory that has been sold ($378 million pre-tax); (ii) amortization expense related to the fair value of identifiable intangible assets acquired from Hospira ($161 million pre-tax); (iii) depreciation expense related to the fair value adjustment of fixed assets acquired from Hospira ($34 million pre-tax ); and (iv) amortization expense related to the fair value adjustment of long-term debt acquired from Hospira ($13 million income pre-tax), as well as restructuring and integration costs ($556 million pre-tax).
[9]	Comprised of finite-lived developed technology rights with a weighted-average life of approximately 17 years ($7.7 billion) and other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ($570 million).

Acquisitions, Sale of Hospira53

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Baxter International (Details) - USD ($) $ in Millions	Dec. 01, 2014	Dec. 31, 2017	[1]	Dec. 31, 2016	[1]	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill		$ 55,952		$ 54,449		$ 48,242
Baxter International Inc. [Member]
Business Acquisition [Line Items]
Total consideration transferred	$ 648
Identifiable intangible assets	376
Inventories	194
Goodwill	12
Developed Technology Rights [Member] | Baxter International Inc. [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 371
[1]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira54

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (Details) - USD ($) shares in Millions, $ in Millions		Feb. 03, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 06, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on sale of HIS net assets	[1],[2]		$ 55	$ 1,712	$ 0
Assets held for sale	[3]		12	801
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other assets	[4]		12	58
Assets held for sale			12	801
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on sale of HIS net assets				1,712
Inventories			0	377
PP&E			0	457
Identifiable intangible assets			0	1,319
Goodwill			0	119
Other assets			0	152
Less: adjustment to HIS assets for net realizable value	[5]		0	(1,681)
Assets held for sale			0	743
Accrued compensation and related items			0	54
Other liabilities			0	103
Total HIS liabilities held for sale			$ 0	157
Selling costs				$ 31
ICU Medical [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and common stock to be received for disposition						$ 1,000
ICU Medical [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and common stock to be received for disposition		$ 900
Shares of common stock received for disposal		3.2
Value of common stock received for disposal		$ 428
Consideration receivable		75
Cash proceeds from disposal		200
Maximum contingent consideration		$ 225
Noncontrolling interest, ownership percentage by parent			16.00%
Share transfer restriction term for disposition		18 months
Loss on sale of HIS net assets			$ 55
Administrative service period		24 months
Manufacturing service period		5 years
[1]	Amounts may not add due to rounding.
[2]	In 2017, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[3]	Amounts may not add due to rounding.
[4]	Other assets held for sale consist primarily of PP&E and other assets.
[5]	For 2016, we recorded an adjustment to HIS assets for net realizable value of $1,681 million plus estimated costs to sell of $31 million for a total impairment on HIS net assets of $1,712 million.

Acquisitions, Sale of Hospira55

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Research and Development and Collaborative Arrangements (Detail) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2016

Oct. 31, 2016

May 31, 2016

Apr. 30, 2016

Jan. 31, 2016

Mar. 31, 2015

Feb. 28, 2015

Apr. 02, 2017

Dec. 31, 2014

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues from collaborative arrangements

[1]

$ 52,546,000,000

$ 52,824,000,000

$ 48,851,000,000

Cost of sales

[1],[2]

(11,240,000,000)

(12,329,000,000)

(9,648,000,000)

Selling, informational and administrative expenses

[1],[2]

(14,784,000,000)

(14,837,000,000)

(14,809,000,000)

Research and development expenses

[1],[2]

(7,657,000,000)

(7,872,000,000)

(7,690,000,000)

Other income/(deductions)—net

[1]

(1,315,000,000)

(3,655,000,000)

(2,860,000,000)

NovaQuest Co-Investment Fund II, L.P. [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Amount refunded to NovaQuest

$ 31,300,000

Maximum funding amount

$ 250,000,000

Percentage of costs to be reimbursed

40.00%

Reduction to research and development expense

180,300,000

NovaQuest Co-Investment Fund V, L.P. [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Maximum funding amount

$ 200,000,000

Percentage of costs to be reimbursed

100.00%

Reduction to research and development expense

72,100,000

46,600,000

Term over which funding will be received

3 years

Research and development, contingent payments, maximum exposure

$ 267,000,000

RPI Finance Trust [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Maximum funding amount

$ 300,000,000

Percentage of costs to be reimbursed

100.00%

Reduction to research and development expense

75,600,000

44,900,000

Research and development, contingent payments, maximum exposure

$ 250,000,000

Collaborative Arrangement [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues from collaborative arrangements

3,533,000,000

2,405,000,000

1,956,000,000

Cost of sales

[3]

(329,000,000)

(315,000,000)

(282,000,000)

Selling, informational and administrative expenses

[4]

(54,000,000)

(5,000,000)

(287,000,000)

Research and development expenses

[5]

222,000,000

64,000,000

(330,000,000)

Other income/(deductions)—net

[6]

249,000,000

542,000,000

482,000,000

Upfront payments and milestone payments

15,000,000

15,000,000

310,000,000

Collaborative arrangement sales based milestones payments

20,000,000

Collaborative Arrangement [Member] | Eli Lilly & Company [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds received from upfront payments and milestone payments

147,000,000

120,000,000

Collaborative Arrangement [Member] | Merck KGaA [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Collaborative arrangement sales based milestones payments

$ 140,000,000

Potential milestone payments

$ 2,000,000,000

Collaborative Arrangement [Member] | Merck KGaA [Member] | Other Nonoperating Income (Expense) [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Collaborator's revenue and expense ownership percentage

60.00%

Company's revenue and expense ownership percentage

40.00%

Collaborative Arrangement [Member] | Merck [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds received from upfront payments and milestone payments

$ 150,000,000

Collaborative Arrangement [Member] | Merck [Member] | Other Nonoperating Income (Expense) [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds received from upfront payments and milestone payments

$ 90,000,000

Milestone payment due to be received

60,000,000

Deferred milestone payment

60,000,000

Collaborative Arrangement [Member] | OPKO Health, Inc. [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront payments and milestone payments

$ 295,000,000

Potential milestone payments

$ 275,000,000

Collaborative Arrangement [Member] | Deferred Revenue [Member] | Eli Lilly & Company [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds received from upfront payments and milestone payments

$ 200,000,000

Collaborative Arrangement, Product [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues—Revenues

[7]

606,000,000

659,000,000

644,000,000

Collaborative Arrangement, Co-promotion [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Revenues—Alliance revenues

[8]

$ 2,927,000,000

$ 1,746,000,000

$ 1,312,000,000

Royalty revenue, term

36 months

Collaborative Arrangement, Upfront Cash Payment [Member] | Merck KGaA [Member] | Research and Development Expense [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront payments and milestone payments

$ 850,000,000

[1]

Amounts may not add due to rounding.

[2]

Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

[3]

Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners.

[4]

Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.

[5]

Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $15 million in 2017, $15 million in 2016 and $310 million in 2015 (primarily related to our collaboration with OPKO, see below). 2017 and 2016 also include reimbursements related to our collaboration with Lilly (see below) of $147 million and $120 million, respectively.

[6]

Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our 36 month royalty arrangement on sales of Enbrel in the U.S. and Canada, partially offset by a full year of royalties earned in 2017, versus a partial year in 2016, on Xtandi ex-U.S. sales.

[7]

Represents sales to our partners of products manufactured by us.

[8]

Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2017 reflects an increase in alliance revenues from Eliquis and Xtandi. The increase in 2016 reflects an increase in alliance revenues from Eliquis and the inclusion of Xtandi revenues resulting from the acquisition of Medivation in September 2016, partially offset by the expiration of the Rebif co-promotion collaboration at the end of 2015.

Acquisitions, Sale of Hospira56

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Equity and Cost-Method Investments (Details) - USD ($) $ in Millions

Nov. 10, 2017

Apr. 30, 2015

Dec. 31, 2017

Jul. 02, 2017

Dec. 31, 2016

Jul. 03, 2016

Apr. 03, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Jun. 30, 2017

Sep. 30, 2012

Hisun Pfizer Pharmaceuticals Co. Ltd [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, registered capital

$ 250

Equity method investments

$ 270

$ 270

$ 775

$ 122.5

Equity method investment, ownership percentage

49.00%

49.00%

49.00%

Proceeds from sale of equity method investments

$ 286

Equity method investment, carrying value of share sold

270

Proceeds from sale of equity method investment used to cover taxes incurred on transaction

$ 16

Loss on disposal of equity method investment

$ 81

Equity method investment, other than temporary impairment

$ 241

$ 130

$ 81

$ 452

463

Hisun Pfizer Pharmaceuticals Co. Ltd [Member] | Other Nonoperating Income (Expense) [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, recognized gain (loss)

$ (463)

Laboratorio Teuto Brasilero [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, ownership percentage

40.00%

40.00%

40.00%

Loss on disposal of equity method investment

$ 30

Equity method investment, other than temporary impairment

$ 50

Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]

Schedule of Equity Method Investments [Line Items]

Noncontrolling interest, ownership percentage by parent

60.00%

Laboratorio Teuto Brasilero [Member] | Other Nonoperating Income (Expense) [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment, other than temporary impairment

$ 50

AM Pharma BV [Member]

Schedule of Equity Method Investments [Line Items]

Cost-method investments, impairment

$ 43

$ 43

Long-term Investments [Member] | AM Pharma BV [Member]

Schedule of Equity Method Investments [Line Items]

Cost method investment, upfront and milestone payments

$ 87.5

Restructuring Charges and Oth57

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) - USD ($) $ in Millions		12 Months Ended			36 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 03, 2018
Restructuring Cost and Reserve [Line Items]
Integration costs	[1]	$ 305	$ 441	$ 219
Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred		137
Enterprise-wide Cost Reduction/Productivity Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred		348
Expected cost		$ 1,100
Percentage of non-cash restructuring charges expected		20.00%
Enterprise-wide Cost Reduction/Productivity Plan [Member] | Manufacturing Plant Network Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred to date		$ 197
Expected cost		800
Enterprise-wide Cost Reduction/Productivity Plan [Member] | Centralization of Corporate and Platform Functions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred to date		151
Expected cost		300
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Expected integration costs, period				3 years
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred				$ 215
Hospira [Member] | Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred		$ 319
Forecast [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Integration costs					$ 1,000
[1]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2017, integration costs primarily relate to our acquisitions of Hospira and Medivation, as well as a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 11). In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira.

Restructuring Charges and Oth58

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring charges:
Employee terminations	[1]	$ (34)	$ 940	$ 489
Asset impairments	[1],[2]	190	142	254
Exit costs	[1]	21	74	68
Total restructuring charges	[1]	178	1,156	811
Transaction costs	[3]	4	127	123
Integration costs	[4]	305	441	219
Restructuring charges and certain acquisition-related costs	[5]	487	1,724	1,152
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows:
Additional depreciation	[6]	91	207	122
Implementation costs recorded in our consolidated statements of income as follows:
Implementation costs	[7]	227	340	203
Total costs associated with acquisitions and cost-reduction/productivity initiatives		805	2,271	1,478
Cost of Sales [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows:
Additional depreciation	[6]	91	201	117
Implementation costs recorded in our consolidated statements of income as follows:
Implementation costs	[7]	118	230	102
Selling, Informational and Administrative Expenses [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows:
Additional depreciation	[6]	0	0	0
Implementation costs recorded in our consolidated statements of income as follows:
Implementation costs	[7]	71	81	82
Research and Development Expense [Member]
Additional depreciation––asset restructuring recorded in our consolidated statements of income as follows:
Additional depreciation	[6]	0	7	5
Implementation costs recorded in our consolidated statements of income as follows:
Implementation costs	[7]	38	25	14
Other (income)/deductions - net [Member]
Implementation costs recorded in our consolidated statements of income as follows:
Implementation costs	[7]	$ 0	$ 3	$ 5
[1]	In 2017, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In 2016, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In 2015, restructuring charges are largely associated with.cost-reduction and productivity initiatives not associated with acquisitions. In 2017, Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring activities in 2017 are associated with the following:•IH ($64 million income); EH ($4 million income); WRD/GPD ($80 million); manufacturing operations ($115 million); and Corporate ($51 million).The restructuring activities in 2016 are associated with the following:•IH ($272 million); EH ($158 million); WRD/GPD ($169 million); manufacturing operations ($368 million); and Corporate ($189 million), The restructuring activities in 2015, which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following:•IH ($85 million); EH ($402 million); WRD/GPD ($80 million); manufacturing operations ($80 million); and Corporate ($164 million). In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.
[2]	The asset impairment charges for 2017 are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for 2017 and 2016 are primarily associated with abandoned assets. The asset impairment charges for 2015 are primarily associated with our acquisition of Hospira. See (a) above for additional information.
[3]	Transaction costs represent external costs for banking, legal, accounting and other similar services, which in 2017 are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in 2016 are mostly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and the terminated transaction with Allergan and primarily include expenditures for banking, legal, accounting and other similar services.
[4]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2017, integration costs primarily relate to our acquisitions of Hospira and Medivation, as well as a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 11). In 2016, integration costs primarily relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira.
[5]	Amounts may not add due to rounding.
[6]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[7]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth59

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Provision	[1]		$ 178	$ 1,156	$ 811
Intangible asset impairments			337	869	323
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Provision			51	189	164
Worldwide Research and Development and Global Product Development [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Provision			80	169	80
Manufacturing Operations [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Provision			115	368	80
Innovative Health Segment [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Provision			(64)	272	85
Intangible asset impairments				29
Essential Health Segment [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Provision			(4)	158	402
Intangible asset impairments				840	294
Venezuela [Member]
Restructuring Cost and Reserve [Line Items]
Provision					$ 39
Reduction in labor force, percentage		36.00%			36.00%
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Write off of prepaid amounts					$ 25
Payments for the return of acquired rights					20
Hospira [Member] | In Process Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Intangible asset impairments					170
Return of Acquired Rights [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred					215
Pension Plan [Member] | United States [Member]
Restructuring Cost and Reserve [Line Items]
Gain related to settlement	[2]		(75)	$ (90)	$ (556)
Pension Plan [Member] | Qualified Plan [Member] | United States [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Gain related to settlement			$ 12
[1]	In 2017, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In 2016, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In 2015, restructuring charges are largely associated with.cost-reduction and productivity initiatives not associated with acquisitions. In 2017, Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring activities in 2017 are associated with the following:•IH ($64 million income); EH ($4 million income); WRD/GPD ($80 million); manufacturing operations ($115 million); and Corporate ($51 million).The restructuring activities in 2016 are associated with the following:•IH ($272 million); EH ($158 million); WRD/GPD ($169 million); manufacturing operations ($368 million); and Corporate ($189 million), The restructuring activities in 2015, which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following:•IH ($85 million); EH ($402 million); WRD/GPD ($80 million); manufacturing operations ($80 million); and Corporate ($164 million). In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.
[2]	In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3). In 2015, the net periodic benefit costs included settlement losses primarily related to participants accepting the lump-sum option made in an offer to certain plan participants to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or to elect an early annuity.

Restructuring Charges and Oth60

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Restructuring Reserve [Roll Forward]
Beginning balance		$ 1,583	[1]	$ 1,157
Provision	[2]	178		1,156		$ 811
Utilization and other	[3]	(656)		(730)
Ending balance		1,105	[4]	1,583	[1]	1,157
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		1,547	[1]	1,109
Provision		(34)		940
Utilization and other	[3]	(474)		(502)
Ending balance		1,039	[4]	1,547	[1]	1,109
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		0	[1]	0
Provision		190		142
Utilization and other	[3]	(190)		(142)
Ending balance		0	[4]	0	[1]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		36	[1]	48
Provision		21		74
Utilization and other	[3]	9		(86)
Ending balance		$ 66	[4]	$ 36	[1]	$ 48
[1]	Included in Other current liabilities ($863 million) and Other noncurrent liabilities ($720 million).
[2]	In 2017, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In 2016, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In 2015, restructuring charges are largely associated with.cost-reduction and productivity initiatives not associated with acquisitions. In 2017, Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring activities in 2017 are associated with the following:•IH ($64 million income); EH ($4 million income); WRD/GPD ($80 million); manufacturing operations ($115 million); and Corporate ($51 million).The restructuring activities in 2016 are associated with the following:•IH ($272 million); EH ($158 million); WRD/GPD ($169 million); manufacturing operations ($368 million); and Corporate ($189 million), The restructuring activities in 2015, which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following:•IH ($85 million); EH ($402 million); WRD/GPD ($80 million); manufacturing operations ($80 million); and Corporate ($164 million). In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015, we incurred charges of $215 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ($643 million) and Other noncurrent liabilities ($462 million).

Restructuring Charges and Oth61

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 1,105	[1]	$ 1,583	[2]	$ 1,157
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	643		863
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 462		$ 720
[1]	Included in Other current liabilities ($643 million) and Other noncurrent liabilities ($462 million).
[2]	Included in Other current liabilities ($863 million) and Other noncurrent liabilities ($720 million).

Other (Income)_Deductions - N62

Other (Income)/Deductions - Net (Details) - USD ($) $ in Millions		1 Months Ended		12 Months Ended
		Dec. 31, 2017	Nov. 30, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Other Income and Expenses [Abstract]
Interest income	[1]			$ (391)		$ (470)		$ (471)
Interest expense	[1]			1,270		1,186		1,199
Net interest expense				879		716		728
Foreign currency loss related to Venezuela	[2],[3]			0		0		806
Royalty-related income	[4]			(499)		(905)		(922)
Certain legal matters, net	[5]			240		510		975
Net gains on asset disposals	[6]			(343)		(171)		(232)
Loss on sale and impairment on remeasurement of HIS net assets	[2],[7]			55		1,712		0
Certain asset impairments	[8]			395		1,447		818
Business and legal entity alignment costs	[9]			71		261		282
Net losses on early retirement of debt		$ 999	$ 312	999	[10]	312	[10]	0	[10]
Other, net	[11]			(482)		(227)		403
Other (income)/deductions––net	[12]			$ 1,315		$ 3,655		$ 2,860
[1]	2017 v. 2016––Interest income decreased primarily driven by a lower investment balance. Interest expense increased, primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt. Capitalized interest expense totaled $72 million 2017, $61 million in 2016 and $32 million in 2015.
[2]	Amounts may not add due to rounding.
[3]	In 2015, represents a foreign currency loss related to conditions in Venezuela during 2015, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation were no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.3, but rather at the then SIMADI rate of 200, the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy.
[4]	Royalty-related income decreased in 2017 and 2016, primarily due to lower royalty income for Enbrel of $470 million in 2017, compared to 2016, and $54 million in 2016, compared to 2015, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by increases in Xtandi royalty-related income of $176 million in 2017, compared to 2016, and $63 million in 2016, compared to 2015.
[5]	In 2017, primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to court approval (for additional information, see Note 17A2), and a $79 million charge to reflect damages awarded by a jury in a patent matter. In 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, 2016 includes a settlement related to a patent matter. In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws.
[6]	In 2017, primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $451 million; (ii) gross realized losses on sales of available-for-sale debt securities of $281 million; (iii) gross realized gains on sales of available-for-sale equity securities of $75 million; (iv) a net loss of $120 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of $187 million; (vi) gains on sales of investments in private equity securities of $80 million; (vii) a gain on sale of property of $52 million; (viii) a net loss of $30 million related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest; and (ix) a loss of $81 million related to the sale of our 49% equity share in Hisun Pfizer. Proceeds from the sale of available-for-sale securities were $5.1 billion in 2017.In 2016, primarily includes (i) gross realized gains on sales of available-for-sale debt securities of $666 million; (ii) gross realized losses on sales of available-for-sale debt securities of $548 million; (iii) a net loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of $84 million; and (v) gains on sales of investments in private equity securities of $2 million. Proceeds from the sale of available-for-sale securities were $10.2 billion in 2016. In 2015, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $164 million; (ii) gross realized losses on sales of available-for-sale debt securities of $960 million; (iii) net gain of $937 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (iv) gains on sales/out-licensing of product and compound rights of $90 million; and (v) gains on sales of investments in private equity securities of $3 million. Proceeds from the sale of available-for-sale securities were $4.3 billion in 2015.
[7]	In 2017, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[8]	In 2017, primarily includes intangible asset impairment charges of $337 million, reflecting (i) $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) $124 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) $39 million related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) $26 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) $20 million related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with EH and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of $43 million for an impairment of our AM-Pharma B.V. long-term investment (see Note 2E).In 2016, primarily includes intangible asset impairment charges of $869 million, reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ($840 million) and IH ($29 million). In addition, 2016 includes an impairment loss of $452 million related to Pfizer’s then 49%-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40%-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a then recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.In 2015, primarily includes an impairment loss of $463 million related to Pfizer’s then 49%-owned equity-method investment in Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2D) and intangible asset impairment charges of $323 million, reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: EH ($294 million), WRD ($13 million); and Consumer Healthcare ($17 million).The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment.
[9]	Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[10]	In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in 2016.
[11]	In 2017, includes, among other things, dividend income of $266 million from our investment in ViiV, and income of $62 million from resolution of a contract disagreement. In 2016, includes among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A); and income of $116 million from resolution of a contract disagreement. In 2015, includes, among other things, (i) charges of $194 million related to the write-down of assets to net realizable value; (ii) charges of $159 million, reflecting the change in the fair value of contingent consideration liabilities; and (iii) income of $45 million associated with equity-method investees.
[12]	Amounts may not add due to rounding.

Other (Income)_Deductions - N63

Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Income and Expenses [Abstract]
Interest costs capitalized	$ 72	$ 61	$ 32

Other (Income)_Deductions - N64

Other (Income)/Deductions - Net - Footnotes - Foreign Currency and Royalty Income (Details) $ in Millions		1 Months Ended	3 Months Ended	12 Months Ended
		Oct. 31, 2016	Dec. 31, 2015VEB / $	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)VEB / $
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty income	[1]			$ 499	$ 905	$ 922
Xtandi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty income				176	63
Collaborative Arrangement, Co-promotion [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty revenue, term		36 months
Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Decrease in royalty revenue				$ 470	$ 54
Royalty revenue, term		36 months
Venezuela [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reduction in labor force, percentage			36.00%			36.00%
Venezuelan bolívar | Venezuela [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Official foreign exchange rate | VEB / $			6.3			6.3
Foreign exchange rate | VEB / $			200			200
[1]	Royalty-related income decreased in 2017 and 2016, primarily due to lower royalty income for Enbrel of $470 million in 2017, compared to 2016, and $54 million in 2016, compared to 2015, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by increases in Xtandi royalty-related income of $176 million in 2017, compared to 2016, and $63 million in 2016, compared to 2015.

Other (Income)_Deductions - N65

Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details) - USD ($) $ in Millions		1 Months Ended	12 Months Ended
		Nov. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Loss Contingencies [Line Items]
Litigation settlement income (loss)	[1]		$ (240)	$ (510)	$ (975)
Protonix / Pantoprazole [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)					$ (784.6)
Pending Litigation [Member] | Patent Matter [Member]
Loss Contingencies [Line Items]
Litigation settlement expense			79
Pending Litigation [Member] | Celebrex [Member]
Loss Contingencies [Line Items]
Litigation settlement expense			$ 94
Litigation settlement, amount awarded to other party		$ 94
Pending Litigation [Member] | Celebrex and Bextra [Member] | Product Safety Misrepresentation [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party				$ 486
[1]	In 2017, primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to court approval (for additional information, see Note 17A2), and a $79 million charge to reflect damages awarded by a jury in a patent matter. In 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, 2016 includes a settlement related to a patent matter. In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws.

Other (Income)_Deductions - N66

Other (Income)/Deductions - Net - Footnotes - Investments (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2017	Jul. 02, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 10, 2017	Jun. 30, 2017
Investment Holdings [Line Items]
Gain on sale of investments			$ 80
Gain on sale of property			52
Available-for-sale securities, gross realized gains (losses), sale proceeds			5,100	$ 10,200	$ 4,300
Debt Securities [Member]
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains			451	666
Available-for-sale securities, gross realized losses			281	548	960
Equity Securities [Member]
Investment Holdings [Line Items]
Available-for-sale securities, gross realized gains			75		164
Private Equity Funds [Member]
Investment Holdings [Line Items]
Gain on sale of investments				2	3
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Debt Securities [Member]
Investment Holdings [Line Items]
Gain (loss) on derivative instruments, net, pretax			(120)	(64)	937
Distribution Rights [Member]
Investment Holdings [Line Items]
Gain on disposition of intangible assets			$ 187	$ 84	$ 90
Laboratorio Teuto Brasilero [Member]
Investment Holdings [Line Items]
Equity method investment, ownership percentage				40.00%			40.00%
Loss on disposal of equity method investment		$ 30
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Investment Holdings [Line Items]
Equity method investment, ownership percentage				49.00%		49.00%
Loss on disposal of equity method investment	$ 81
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]
Investment Holdings [Line Items]
Noncontrolling interest, ownership percentage by parent							60.00%

Other (Income)_Deductions - N67

Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended				12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jul. 03, 2016	Apr. 03, 2016	Dec. 31, 2017		Dec. 31, 2016	Dec. 31, 2015	Nov. 10, 2017	Jun. 30, 2017
Schedule of Intangible Assets [Line Items]
Intangible asset impairments					$ 337		$ 869	$ 323
Impairment of intangible assets, finite-lived					337
Operating Segments [Member] | Essential Health Segment [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							840	294
Operating Segments [Member] | Innovative Health Segment [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							29
In Process Research and Development [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments								71
In Process Research and Development [Member] | Hospira [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							265
In Process Research and Development [Member] | InnoPharma [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							128
Other In Process Research and Development [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							110
Other In Process Research and Development [Member] | Hospira [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							81
Other In Process Research and Development [Member] | King [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							29
Trade Names [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments								132
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Schedule of Intangible Assets [Line Items]
Equity method investment, other than temporary impairment		$ 241	$ 130	$ 81			$ 452	463
Equity method investment, ownership percentage		49.00%					49.00%		49.00%
Laboratorio Teuto Brasilero [Member]
Schedule of Intangible Assets [Line Items]
Equity method investment, other than temporary impairment							$ 50
Equity method investment, ownership percentage		40.00%					40.00%			40.00%
AM Pharma BV [Member]
Schedule of Intangible Assets [Line Items]
Cost-method investments, impairment	$ 43				43
Developed Technology Rights [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments					20
Impairment of intangible assets, finite-lived					337	[1]		120
Developed Technology Rights [Member] | Hospira [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments							$ 366
Developed Technology Rights [Member] | Operating Segments [Member] | Essential Health Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments					127
Developed Technology Rights [Member] | Operating Segments [Member] | Essential Health Segment [Member] | Hospira [Member] | Sterile Injectable Pain Reliever [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments					124
Developed Technology Rights [Member] | Operating Segments [Member] | Essential Health Segment [Member] | Hospira [Member] | Generic Injectable Pain Reliever [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments					26
Developed Technology Rights [Member] | Operating Segments [Member] | Essential Health Segment [Member] | NextWave [Member] | Treatment Of Attention Hyperactivity Disorder [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments					$ 39
Pfizer's Worldwide Research and Development [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments								13
Consumer Healthcare [Member]
Schedule of Intangible Assets [Line Items]
Intangible asset impairments								$ 17
[1]	Reflects intangible assets written down to fair value in 2017. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Other (Income)_Deductions - N68

Other (Income)/Deductions - Net - Footnotes - Additional Information (Details) - USD ($) $ in Millions	Apr. 08, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Income from resolution of contract disagreement		$ 62	$ 116
Payments for merger termination costs	$ 150		$ 150
Writedown of assets to net realizable value				$ 194
Income (Loss) from equity method investments				45
ViiV Healthcare Limited [Member]
Business Acquisition [Line Items]
Change in fair value of fair value contingent consideration liabilities				$ 159
Operating Segments [Member] | Innovative Health Segment [Member] | ViiV Healthcare Limited [Member]
Business Acquisition [Line Items]
Dividend income		$ 266

Other (Income)_Deductions - N69

Other (Income)/Deductions - Net - Footnotes - Additional Information about Intangible Assets (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2015
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1]	$ 50
Impairment of intangible assets, finite-lived		337
Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	50
Impairment of intangible assets, finite-lived		337	[2]	$ 120
Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1]	0
Level 1 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	0
Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1]	0
Level 2 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	0
Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1]	50
Level 3 [Member] | Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Finite-lived intangible assets, fair value disclosure	[1],[2]	$ 50
[1]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
[2]	Reflects intangible assets written down to fair value in 2017. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters - Income from Conti

Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
United States		$ (6,879)	$ (8,534)	$ (6,809)
International		19,184	16,886	15,773
Income from continuing operations before provision/(benefit) for taxes on income	[1],[2],[3],[4]	$ 12,305	$ 8,351	$ 8,965
[1]	2016 v. 2015––The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs.
[2]	2017 v. 2016––The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower certain asset impairments and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in international income was primarily due to the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower restructuring charges and certain acquisition-related costs, and lower certain asset impairments.
[3]	Amounts may not add due to rounding.
[4]	Income from continuing operations before provision/(benefit) for taxes on income. IH’s earnings in 2017 include dividend income of $266 million from our investment in ViiV. For additional information, see Note 4.

Tax Matters - Provision for Tax

Tax Matters - Provision for Taxes on Income (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current income taxes:
Federal		$ 14,127	$ 342	$ 67
State and local		320	(52)	(8)
Deferred income taxes:
Federal		(25,964)	(419)	300
State and local		(268)	(106)	(36)
Total U.S. tax provision		(11,785)	(235)	323
International
Current income taxes		2,709	1,532	1,951
Deferred income taxes		28	(175)	(284)
Total international tax provision		2,737	1,358	1,667
Provision/(benefit) for taxes on income	[1]	$ (9,049)	$ 1,123	$ 1,990
[1]	Amounts may not add due to rounding.

Tax Matters - Provision for T72

Tax Matters - Provision for Taxes on Income (Narrative) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Repatriation tax liability		$ 15,200
Expense related to future taxes on global intangible low-taxed income		1,000
Tax Benefit from Tax Cuts and Jobs Act of 2017	[2],[3]	10,660	[1]	$ 0	$ 0
Tax benefit associated with remeasurement of U.S. deferred tax liabilities on remitted earnings of foreign subsidiaries		22,800
Tax benefit associated with remeasurement of U.S. deferred tax liabilities primarily intangibles		1,600
Expense related to repatriation tax on deemed repatriated accumulated pre-2017 earnings of foreign subsidiaries		12,900
Expense related to future taxes on global intangible low-taxed income		1,000
Tax benefit primarily associated with certain tax initiatives		100
Deferred income taxes on certain current-year funds earned outside of the U.S.		1,300		1,100	2,100
Tax benefit related to net losses on early retirement of debt		370
Tax benefits from resolution of certain tax positions		150		460	360
Selling, informational and administrative expenses		$ 307		312	$ 251
Tax benefit due to adoption of accounting standard				$ 89
[1]	2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A.
[2]	Amounts may not add due to rounding.
[3]	As a result of the enactment of the TCJA, Pfizer’s Provision/(benefit) for taxes on income was favorably impacted by approximately $10.7 billion, primarily reflecting the remeasurement of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information.

Tax Matters - Tax Rate Reconcil

Tax Matters - Tax Rate Reconciliation (Details)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate		35.00%	35.00%	35.00%
TCJA impact	[1]	(86.60%)	0.00%	0.00%
Taxation of non-U.S. operations	[2],[3],[4]	(17.00%)	(13.80%)	(9.60%)
Tax settlements and resolution of certain tax positions	[5]	(1.20%)	(5.50%)	(4.00%)
U.S. Healthcare Legislation	[5]	0.90%	1.30%	0.90%
U.S. R&D tax credit and manufacturing deduction	[5]	(0.70%)	(1.00%)	(1.00%)
Certain legal settlements and charges	[5]	0.10%	(2.90%)	3.10%
All other, net	[6]	(3.90%)	0.30%	(2.10%)
Effective tax rate for income from continuing operations		(73.50%)	13.40%	22.20%
[1]	For a discussion about the enactment of the TCJA, see Note 5A.
[2]	For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which includes the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries discussed in Note 5A, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income.
[3]	In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. 2015 and 2016 also include incentives in Costa Rica and the Dominican Republic related to the Hospira infusion systems business, which was sold to ICU Medical in February 2017. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations.
[4]	The favorable rate impact in 2017 also reflects lower repatriation costs associated with estimated current year income of our foreign subsidiaries. The favorable rate impact in 2016 also includes the non-recurrence of the non-deductibility of a foreign currency loss related to Venezuela. The rate impact in 2015 also includes the non-deductibility of a foreign currency loss related to Venezuela.
[5]	For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and manufacturing deduction and the impact of certain legal settlements and charges, see Note 5A.
[6]	All other, net in 2017 and 2015 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business.

Tax Matters - Deferred Taxes (D

Tax Matters - Deferred Taxes (Details) - USD ($) $ in Millions		Dec. 31, 2017		Dec. 31, 2016
Deferred Tax Assets
Prepaid/deferred items - Deferred tax assets		$ 1,588	[1]	$ 2,180
Inventories - Deferred tax assets		224	[1]	366
Intangible assets - Deferred tax assets	[2]	685	[1]	1,139
Property, plant and equipment - Deferred tax assets		123	[1]	92
Employee benefits - Deferred tax assets		2,219	[1]	3,356
Restructurings and other charges - Deferred tax assets		226	[1]	458
Legal and product liability reserves - Deferred tax assets		459	[1]	650
Net operating loss/credit carryforwards - Deferred tax assets	[3]	4,502	[1]	2,957
State and local tax adjustments - Deferred tax assets		218	[1]	301
All other - Deferred tax assets		488	[1]	306
Subtotal - Deferred tax assets		10,732		11,806
Valuation allowance		(2,203)	[1]	(1,949)
Total deferred taxes - Deferred tax assets		8,529	[1]	9,857
Deferred Tax Liabilities
Prepaid/deferred items - Deferred tax liabilities		(132)	[1]	(68)
Inventories - Deferred tax liabilities		(3)	[1]	(47)
Intangible assets - Deferred tax liabilities	[2]	(9,269)	[1]	(15,172)
Property, plant and equipment - Deferred tax liabilities		(755)	[1]	(982)
Employee benefits - Deferred tax liabilities		(109)	[1]	(74)
Restructurings and other charges - Deferred tax liabilities		(8)	[1]	(2)
Unremitted earnings - Deferred tax liabilities	[2],[4]	(1,067)	[1]	(23,108)
All other - Deferred tax liabilities		(424)	[1]	(503)
Deferred tax liabilities, gross		(11,767)	[1]	(39,956)
Net deferred tax liability	[5]	$ (3,238)	[1]	$ (30,099)
[1]	2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A.
[2]	The decrease in 2017 is primarily the result of the enactment of the TCJA, which includes the remeasurement of deferred tax liabilities primarily associated with intangible assets and unremitted earnings of foreign subsidiaries as well as amortization on intangible assets. For additional information, see Note 5A.
[3]	The amounts in 2017 and 2016 are reduced for unrecognized tax benefits of $3.4 billion and $3.0 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
[4]	The amount in 2017 primarily includes a provisional estimate on temporary differences associated with global intangible low-taxed income primarily related to basis differentials on intangibles. For additional information, see Note 5A.
[5]	In 2017, Noncurrent deferred tax assets and other noncurrent tax assets ($0.7 billion), and Noncurrent deferred tax liabilities ($3.9 billion). In 2016, Noncurrent deferred tax assets and other noncurrent tax assets ($654 million), and Noncurrent deferred tax liabilities ($30.8 billion).

Tax Matters - Deferred Taxes -

Tax Matters - Deferred Taxes - Footnotes (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016
Income Tax Examination [Line Items]
Reduction for unrecognized tax benefit		$ 3,400		$ 3,000
Net deferred tax liability	[2]	3,238	[1]	30,099
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Examination [Line Items]
Net deferred tax liability		700		654
Noncurrent Deferred Tax Liabilities [Member]
Income Tax Examination [Line Items]
Net deferred tax liability		$ 3,900		$ 30,800
[1]	2017 reflects the estimated remeasurement of U.S. deferred tax assets and liabilities as the result of the enactment of the TCJA. For additional information, see Note 5A.
[2]	In 2017, Noncurrent deferred tax assets and other noncurrent tax assets ($0.7 billion), and Noncurrent deferred tax liabilities ($3.9 billion). In 2016, Noncurrent deferred tax assets and other noncurrent tax assets ($654 million), and Noncurrent deferred tax liabilities ($30.8 billion).

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)jurisdiction	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Income Tax Contingency [Line Items]
Unrecognized tax benefits excluding associated interest	$ 5,400	$ 4,600
Number of tax jurisdiction associated with uncertain tax positions | jurisdiction	1
Deferred tax assets associated with unrecognized tax benefits	$ 1,200
Unrecognized tax benefits, interest on income taxes expense	208	72	$ 71
Unrecognized tax benefits, interest on income taxes accrued	975	771
Unrecognized accrued interest decrease as a result of cash payments	4	18
Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit	150
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Contingency [Line Items]
Deferred tax assets associated with unrecognized tax benefits	1,000	1,000
Deferred Tax Liabilities, Net, Noncurrent [Member]
Income Tax Contingency [Line Items]
Deferred tax assets associated with unrecognized tax benefits	118	201
Income Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued	$ 975	4
Current Tax Assets [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued		13
Other Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits, interest on income taxes accrued		$ 754

Tax Matters - Reconciliation of

Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning		$ (5,826)	[1]	$ (5,919)	[1]	$ (6,182)
Acquisitions	[2]	10
Acquisitions	[2]			(83)		(110)
Increases based on tax positions taken during a prior period	[3]	(49)		(11)		(31)
Decreases based on tax positions taken during a prior period	[3],[4]	28		409		496
Decreases based on settlements for a prior period	[5]	35		126		64
Increases based on tax positions taken during the current period	[3]	(753)		(489)		(675)
Impact of foreign exchange		(121)		(5)		319
Other, net	[3],[6]	118		146		199
Balance, ending	[1]	$ (6,558)		$ (5,826)		$ (5,919)
[1]	In 2017, included in Income taxes payable ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($123 million), Noncurrent deferred tax liabilities ($3.3 billion) and Other taxes payable ($3.2 billion). In 2016, included in Income taxes payable ($14 million), Current tax assets ($17 million), Noncurrent deferred tax assets and other noncurrent tax assets ($184 million), Noncurrent deferred tax liabilities ($2.8 billion) and Other taxes payable ($2.8 billion).
[2]	For 2017 and 2016, primarily related to the acquisitions of Medivation and Anacor. For 2015, primarily related to the acquisition of Hospira. See also Note 2A.
[3]	Primarily included in Provision/(benefit) for taxes on income.
[4]	Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A.
[5]	Primarily related to cash payments and reductions of tax attributes.
[6]	Primarily related to decreases as a result of a lapse of applicable statutes of limitations.

Tax Matters - Reconciliation 78

Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) - USD ($) $ in Millions	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015	[1]	Dec. 31, 2014
Income Tax Contingency [Line Items]
Unrecognized tax benefits	$ 6,558	[1]	$ 5,826	[1]	$ 5,919		$ 6,182
Income Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	1		14
Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	123		184
Current Tax Assets [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits			17
Noncurrent Deferred Tax Liabilities [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	3,300		2,800
Other Taxes Payable [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits	$ 3,200		$ 2,800
[1]	In 2017, included in Income taxes payable ($1 million), Noncurrent deferred tax assets and other noncurrent tax assets ($123 million), Noncurrent deferred tax liabilities ($3.3 billion) and Other taxes payable ($3.2 billion). In 2016, included in Income taxes payable ($14 million), Current tax assets ($17 million), Noncurrent deferred tax assets and other noncurrent tax assets ($184 million), Noncurrent deferred tax liabilities ($2.8 billion) and Other taxes payable ($2.8 billion).

Tax Matters - Taxes on Items of

Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)
Foreign currency translation adjustments, net	[1]	$ (215)	$ (15)	$ 90
Unrealized holding gains/(losses) on derivative financial instruments, net		72	(75)	(173)
Reclassification adjustments for (gains)/losses included in net income		(224)	158	104
Other comprehensive income (loss), derivatives qualifying as hedges, tax, total		(152)	83	(69)
Unrealized holding gains/(losses) on available-for-sale securities, net		102	49	(104)
Reclassification adjustments for (gains)/losses included in net income		(60)	(15)	59
Other comprehensive income (loss), available-for-sale securities, tax, total		42	34	(45)
Benefit plans: actuarial losses, net		(59)	(535)	(23)
Reclassification adjustments related to amortization		192	186	183
Reclassification adjustments related to settlements, net		42	45	237
Other		(39)	36	66
Defined benefit plan, amounts recognized in other comprehensive income (loss), net actuarial gain (loss), tax		137	(269)	462
Benefit plans: prior service (costs)/credits and other, net		0	67	160
Reclassification adjustments related to amortization		(67)	(64)	(59)
Reclassification adjustments related to curtailments, net		(7)	(10)	(12)
Other		0	(1)	0
Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax		(74)	(7)	89
Tax provision/(benefit) on other comprehensive income/(loss)	[2],[3]	$ (262)	$ (174)	$ 528
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.
[3]	See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

Accumulated Other Comprehensi80

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	[1]	$ 59,544
Other comprehensive income/(loss)	[2]	1,715	$ (1,514)	$ (2,206)
Ending balance	[1]	71,308	59,544
Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(11,036)	(9,522)	(7,316)
Ending balance		(9,321)	(11,036)	(9,522)
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(6,659)	(5,863)	(2,689)
Other comprehensive income/(loss)	[2]	1,479	(797)	(3,174)
Ending balance		(5,180)	(6,659)	(5,863)
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		348	421	517
Other comprehensive income/(loss)	[2]	(378)	(73)	(96)
Ending balance		(30)	348	421
Available-For-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(131)	(227)	(222)
Other comprehensive income/(loss)	[2]	532	96	(5)
Ending balance		401	(131)	(227)
Actuarial Gains/(Losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		(5,473)	(4,733)	(5,654)
Other comprehensive income/(loss)	[2]	211	(740)	921
Ending balance		(5,262)	(5,473)	(4,733)
Prior Service (Costs)/Credits and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance		879	880	733
Other comprehensive income/(loss)	[2]	(129)	(1)	148
Ending balance		$ 750	$ 879	$ 880
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $14 million income in 2017, $3 million loss in 2016 and $26 million loss in 2015.

Accumulated Other Comprehensi81

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Foreign currency translation income (loss) attributable to noncontrolling interests	$ 14	$ (3)	$ (26)

Accumulated Other Comprehensi82

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) to be reclassified in next twelve months	$ (81)
Actuarial Gains/(Losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) to be reclassified in next twelve months	(247)
Prior Service (Costs)/Credits and Other [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gain (loss) to be reclassified in next twelve months	$ 184

Financial Instruments - Financi

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Document Period End Date		Dec. 31, 2017
Trading securities		$ 19	$ 0
Available-for-sale securities, equity securities		3,304	1,985
Total assets	[1]	171,797	171,615
Total liabilities		691	1,665
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		24,937	22,197
Total liabilities		691	1,666
Equity securities held in trust		42	71
Government and agency debt - non-U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		12,629	8,179
Corporate debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities	[2]	6,938	7,089
Government debt - U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		747	2,718
Agency asset-backed debt - U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		24	39
Other asset-backed debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		114	605
Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		2,115	1,445
Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		1,190	540
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		1,523	794
Total liabilities		0	0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		23,414	21,403
Total liabilities		691	1,666
Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading securities	[3]	19	0
Available-for-sale securities		17,493	14,567
Short-term Investments Excluding Held-To-Maturity Securities		17,512	14,567
Short-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		12,242	7,317
Short-term Investments [Member] | Corporate debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		2,766	2,783
Short-term Investments [Member] | Government debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		252	2,630
Short-term Investments [Member] | Agency asset-backed debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		23	39
Short-term Investments [Member] | Other asset-backed debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		79	367
Short-term Investments [Member] | Money market funds [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		2,115	1,431
Short-term Investments [Member] | Equity [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		16	1
Short-term Investments [Member] | Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading securities	[3]	0	0
Available-for-sale securities		16	1
Short-term Investments Excluding Held-To-Maturity Securities		16	1
Short-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Short-term Investments [Member] | Level 1 [Member] | Corporate debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Short-term Investments [Member] | Level 1 [Member] | Government debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Short-term Investments [Member] | Level 1 [Member] | Agency asset-backed debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Short-term Investments [Member] | Level 1 [Member] | Other asset-backed debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Short-term Investments [Member] | Level 1 [Member] | Money market funds [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		0	0
Short-term Investments [Member] | Level 1 [Member] | Equity [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		16	1
Short-term Investments [Member] | Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading securities	[3]	19	0
Available-for-sale securities		17,477	14,566
Short-term Investments Excluding Held-To-Maturity Securities		17,496	14,566
Short-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		12,242	7,317
Short-term Investments [Member] | Level 2 [Member] | Corporate debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		2,766	2,783
Short-term Investments [Member] | Level 2 [Member] | Government debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		252	2,630
Short-term Investments [Member] | Level 2 [Member] | Agency asset-backed debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		23	39
Short-term Investments [Member] | Level 2 [Member] | Other asset-backed debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		79	367
Short-term Investments [Member] | Level 2 [Member] | Money market funds [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		2,115	1,431
Short-term Investments [Member] | Level 2 [Member] | Equity [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		0	0
Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		337	566
Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		104	26
Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		234	540
Other Current Assets [Member] | Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Other Current Assets [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Other Current Assets [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Other Current Assets [Member] | Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		337	566
Other Current Assets [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		104	26
Other Current Assets [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		234	540
Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading securities	[3]	266	236
Available-for-sale securities		6,264	6,049
Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments		6,603	6,374
Trading securities, debt		73	89
Trading securities		340	325
Long-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		387	863
Long-term Investments [Member] | Corporate debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		4,172	4,306
Long-term Investments [Member] | Government debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		495	88
Long-term Investments [Member] | Other asset-backed debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		35	239
Long-term Investments [Member] | Money market funds [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		0	14
Long-term Investments [Member] | Equity [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		1,174	539
Long-term Investments [Member] | Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading securities	[3]	224	165
Available-for-sale securities		1,210	539
Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments		1,507	793
Trading securities, debt		73	89
Trading securities		298	254
Long-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Long-term Investments [Member] | Level 1 [Member] | Corporate debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		36	0
Long-term Investments [Member] | Level 1 [Member] | Government debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Long-term Investments [Member] | Level 1 [Member] | Other asset-backed debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		0	0
Long-term Investments [Member] | Level 1 [Member] | Money market funds [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		0	0
Long-term Investments [Member] | Level 1 [Member] | Equity [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		1,174	539
Long-term Investments [Member] | Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading securities	[3]	42	71
Available-for-sale securities		5,054	5,510
Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments		5,096	5,581
Trading securities, debt		0	0
Trading securities		42	71
Long-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		387	863
Long-term Investments [Member] | Level 2 [Member] | Corporate debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		4,136	4,306
Long-term Investments [Member] | Level 2 [Member] | Government debt - U.S. [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		495	88
Long-term Investments [Member] | Level 2 [Member] | Other asset-backed debt [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, debt securities		35	239
Long-term Investments [Member] | Level 2 [Member] | Money market funds [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		0	14
Long-term Investments [Member] | Level 2 [Member] | Equity [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, equity securities		0	0
Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		484	689
Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		477	599
Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		7	90
Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		484	689
Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		477	599
Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		7	90
Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		201	444
Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		1	1
Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		201	443
Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		201	444
Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		1	1
Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		201	443
Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		490	1,222
Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		177	147
Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		313	1,075
Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		490	1,222
Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		177	147
Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		$ 313	$ 1,075
[1]	Amounts may not add due to rounding.
[2]	Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
[3]	As of December 31, 2017 and December 31, 2016, equity securities of $42 million and $71 million, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.

Financial Instruments - Assets

Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Document Period End Date	Dec. 31, 2017
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	$ 33,538	$ 31,398
Estimated Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	37,253	34,896
Level 2 [Member] | Estimated Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	$ 37,253	$ 34,896

Financial Instruments - Total S

Financial Instruments - Total Short-term and Long-term Investments (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Financial Instruments [Abstract]
Trading securities		$ 19	$ 0
Available-for-sale debt and equity securities		17,493	14,567
Held-to-maturity debt securities		1,138	688
Total Short-term investments	[1]	18,650	15,255
Trading securities		340	325
Available-for-sale debt and equity securities		6,264	6,049
Held-to-maturity debt securities		4	7
Private equity investments carried at equity-method or cost		408	735
Total Long-term investments	[1]	7,015	$ 7,116
Held-to-maturity cash equivalents		$ 719
[1]	Amounts may not add due to rounding.

Financial Instruments - Investm

Financial Instruments - Investments (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Held-to-maturity Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]
Debt securities, amortized cost		$ 22,337	$ 20,184
Debt securities, gross unrealized gains		77	29
Debt securities, gross unrealized losses		(100)	(339)
Available-for-sale Securities and Held-to-maturity Securities		22,313	19,873
Debt securities maturities, within 1 year, fair value		17,219
Debt securities maturities, over 1 to 5 years, fair value		3,544
Debt securities maturities, over 5 years, fair value		1,550
Available-for-sale Securities and Held-to-maturity Securities		22,313	19,873
Available-for-sale Equity Securities, Amortized Cost Basis [Abstract]
Available-for-sale equity securities, amortized cost		2,843	1,872
Available-for-sale equity securities, gross unrealized gain		586	239
Available-for-sale equity securities, gross unrealized losses		(124)	(126)
Available-for-sale securities, equity securities		3,304	1,985
Government and agency debt - non-U.S. [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract]
Available-for-sale debt securities, amortized cost		12,616	8,403
Available-for-sale debt securities, gross unrealized gain		61	11
Available-for-sale debt securities, gross unrealized loss		(48)	(235)
Available-for-sale securities, debt maturities		12,629	8,179
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		12,242
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		387
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale securities, debt maturities		12,629	8,179
Held-to-maturity Securities, Debt Maturities [Abstract]
Held-to-maturity securities, debt maturities, total		770	412
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		770	412
Held-to-maturity Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		770
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		0
Held-to-maturity securities, debt maturities, over 5 years, fair value		0
Corporate debt [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract]
Available-for-sale debt securities, amortized cost	[1]	6,955	7,162
Available-for-sale debt securities, gross unrealized gain	[1]	15	16
Available-for-sale debt securities, gross unrealized loss	[1]	(33)	(89)
Available-for-sale securities, debt maturities	[1]	6,938	7,089
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	[1]	2,766
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	[1]	2,630
Available-for-sale securities, debt maturities, over 5 years, fair value	[1]	1,542
Available-for-sale securities, debt maturities	[1]	6,938	7,089
Government debt - U.S. [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract]
Available-for-sale debt securities, amortized cost		765	2,729
Available-for-sale debt securities, gross unrealized gain		0	1
Available-for-sale debt securities, gross unrealized loss		(19)	(12)
Available-for-sale securities, debt maturities		747	2,718
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		252
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		495
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale securities, debt maturities		747	2,718
Agency asset-backed debt - U.S. [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract]
Available-for-sale debt securities, amortized cost		24	41
Available-for-sale debt securities, gross unrealized gain		0	0
Available-for-sale debt securities, gross unrealized loss		(1)	(1)
Available-for-sale securities, debt maturities		24	39
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		23
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		0
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale securities, debt maturities		24	39
Other asset-backed debt [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract]
Available-for-sale debt securities, amortized cost		114	607
Available-for-sale debt securities, gross unrealized gain		0	1
Available-for-sale debt securities, gross unrealized loss		0	(2)
Available-for-sale securities, debt maturities		114	605
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		79
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		32
Available-for-sale securities, debt maturities, over 5 years, fair value		3
Available-for-sale securities, debt maturities		114	605
Time deposits and other [Member]
Held-to-maturity Securities, Debt Maturities [Abstract]
Held-to-maturity securities, debt maturities, total		1,091	830
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		1,091	830
Held-to-maturity Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		1,087
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		0
Held-to-maturity securities, debt maturities, over 5 years, fair value		4
Money market funds [Member]
Available-for-sale Equity Securities, Amortized Cost Basis [Abstract]
Available-for-sale equity securities, amortized cost		2,115	1,446
Available-for-sale equity securities, gross unrealized gain		0	0
Available-for-sale equity securities, gross unrealized losses		0	(1)
Available-for-sale securities, equity securities		2,115	1,445
Equity [Member]
Available-for-sale Equity Securities, Amortized Cost Basis [Abstract]
Available-for-sale equity securities, amortized cost		728	426
Available-for-sale equity securities, gross unrealized gain		586	239
Available-for-sale equity securities, gross unrealized losses		(124)	(125)
Available-for-sale securities, equity securities		$ 1,190	$ 540
[1]	Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, and loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.

Financial Instruments - Short-T

Financial Instruments - Short-Term Borrowings (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016	Jun. 24, 2016
Short-term Debt [Line Items]
Commercial paper		$ 6,100	$ 5,800
Current portion of long-term debt, carried at historical proceeds (not included above (2.4% and 3.0%)	[1]	3,532	4,201
Other short-term borrowings	[2]	320	673
Total short-term borrowings, principal amount		9,951	10,674
Net fair value adjustments related to hedging and purchase accounting		14	24
Net unamortized discounts, premiums and debt issuance costs		(12)	(11)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted	[3]	$ 9,953	$ 10,688
Commercial Paper [Member]
Short-term Debt [Line Items]
Commercial paper, weighted average interest rate		1.36%	0.83%
Anacor [Member]
Short-term Debt [Line Items]
Debt assumed				$ 698
Line of Credit [Member] | Commercial Paper [Member]
Short-term Debt [Line Items]
Line of credit facility, remaining borrowing capacity		$ 7,000
[1]	For additional information, see Note 7D.
[2]	Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F.
[3]	Amounts may not add due to rounding.

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt, New Issuances (Details) - Senior Notes [Member] € in Millions, £ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)		Dec. 31, 2017EUR (€)		Dec. 31, 2017GBP (£)
Senior Unsecured Euro Debt, 3-month EURIBOR20% (0% floor) [Member]
Debt Instrument [Line Items]
Principal amount			€ 1,250
Senior Unsecured Euro Debt, 3-month EURIBOR20% (0% floor) [Member] | EURIBOR [Member]
Debt Instrument [Line Items]
Basis spread	0.20%
Floor interest rate	0.00%
Senior Unsecured Euro Debt, 0.00%, Due 2020 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	0.00%		0.00%		0.00%
Principal amount			€ 1,000
Senior Unsecured Euro Debt, 0.25%, Due 2022 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	0.25%		0.25%		0.25%
Principal amount			€ 1,000
Senior Unsecured Euro Debt, 1.00%, Due 2027 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	1.00%		1.00%		1.00%
Principal amount			€ 750
Euro Long-term Debt [Member]
Debt Instrument [Line Items]
Principal amount			€ 4,000	[1]
Senior Unsecured U.K. Pound Debt, 2.735%, Due 2043 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	2.735%		2.735%		2.735%
Principal amount | £					£ 1,376	[2]
Senior Unsecured Debt, 4.20%, Due 2047 [Member]
Debt Instrument [Line Items]
Interest rate, percentage	4.20%		4.20%		4.20%
Principal amount | $	$ 1,065	[3]
[1]	The weighted-average effective interest rate for the euro notes at issuance was 0.23%.
[2]	In December 2017, Pfizer exchanged approximately £833 million principal amount of the outstanding 6.50% debt due 2038 for £1.376 billion principal amount of 2.735% debt due 2043. This exchange constituted a debt extinguishment. See the following “Retirements” section for the income statement impact from the extinguishment.
[3]	The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.

Financial Instruments - Long-89

Financial Instruments - Long-Term Debt - Footnotes (Details)	1 Months Ended	12 Months Ended
	Dec. 31, 2017GBP (£)	Dec. 31, 2017USD ($)	Dec. 31, 2017GBP (£)
Debt Instrument [Line Items]
Weighted average interest rate		3.50%	3.50%
Euro Long-term Debt [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Weighted average interest rate		0.23%	0.23%
Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Amount of debt exchanged	£ 833,000,000	$ 1,100,000,000
Interest rate, percentage		6.50%	6.50%
Senior Unsecured U.K. Pound Debt, 2.735%, Due 2043 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate, percentage		2.735%	2.735%
Debt instrument, face amount		$ 1,800,000,000	£ 1,375,882,000

Financial Instruments - Long-90

Financial Instruments - Long-Term Debt Narrative (Details) € in Millions, £ in Millions	1 Months Ended			12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2017GBP (£)	Nov. 30, 2016USD ($)	Dec. 31, 2017USD ($)		Dec. 31, 2016USD ($)		Dec. 31, 2015USD ($)	[1]	Dec. 31, 2017EUR (€)	Dec. 31, 2017GBP (£)	Nov. 21, 2016USD ($)	Jun. 30, 2016USD ($)	Oct. 31, 2015USD ($)	Sep. 03, 2015USD ($)
Debt Instrument [Line Items]
Weighted average interest rate	3.50%			3.50%						3.50%	3.50%
Repurchased debt												$ 3,400,000,000
Redemption value												3,700,000,000
Loss on early retirement of debt	$ 999,000,000		$ 312,000,000	$ 999,000,000	[1]	$ 312,000,000	[1]	$ 0
Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]
Debt Instrument [Line Items]
Loss on early retirement of debt	846,000,000
Senior Unsecured Euro Debt,5.75%, Due 2021 [Member]
Debt Instrument [Line Items]
Loss on early retirement of debt	$ 153,000,000
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt instrument, face amount												$ 6,000,000,000	$ 5,000,000,000
Weighted average interest rate	2.40%			2.40%		3.00%				2.40%	2.40%	3.10%	2.09%
Principal amount	$ 1,900,000,000			$ 1,900,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount												$ 1,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount												1,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2026 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount												1,750,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2036 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount												1,000,000,000
Unsecured Debt [Member] | Senior Unsecured Notes, Due 2046 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount												1,250,000,000
Unsecured Debt [Member] | Senior Unsecured Debt, 6.20%, Due 2019 [Member]
Debt Instrument [Line Items]
Repurchased debt												$ 3,270,000,000
Interest rate, percentage	6.20%			6.20%						6.20%	6.20%
Senior Notes [Member] | Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]
Debt Instrument [Line Items]
Amount of debt exchanged		£ 833		$ 1,100,000,000
Repurchased debt | £											£ 197
Redemption value | £											1,700
Principal amount | £											£ 470
Interest rate, percentage	6.50%			6.50%						6.50%	6.50%
Senior Notes [Member] | Senior Unsecured Euro Debt,5.75%, Due 2021 [Member]
Debt Instrument [Line Items]
Repurchased debt | €										€ 834
Redemption value | €										€ 1,000
Principal amount | £											£ 1,200
Interest rate, percentage	5.75%			5.75%						5.75%	5.75%
Hospira [Member]
Debt Instrument [Line Items]
Fair value of debt acquired															$ 1,928,000,000
Hospira [Member] | Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt instrument, face amount														$ 1,700,000,000	$ 1,750,000,000
[1]	In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in 2016.

Financial Instruments - Long-91

Financial Instruments - Long-Term Debt (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016	Nov. 21, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Interest rate, percentage		3.50%
Net fair value adjustments related to hedging and purchase accounting		$ 14	$ 24
Net unamortized discounts, premiums and debt issuance costs		(12)	(11)
Total long-term borrowings, carried at historical proceeds, as adjusted	[1]	33,538	31,398
Current portion of long-term debt, carried at historical proceeds (not included above (2.4% and 3.0%)	[1]	$ 3,546	$ 4,225
Unsecured Debt [Member]
Debt Instrument [Line Items]
Interest rate, percentage		2.40%	3.00%	3.10%	2.09%
Total principal amount of long-term debt		$ 32,783	$ 30,520
Net fair value adjustments related to hedging and purchase accounting		872	998
Net unamortized discounts, premiums and debt issuance costs		(125)	(130)
Other long-term obligations		8	9
Total long-term borrowings, carried at historical proceeds, as adjusted		33,538	31,398
Current portion of long-term debt, carried at historical proceeds (not included above (2.4% and 3.0%)		3,546	$ 4,225
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2018 [Member]
Debt Instrument [Line Items]
Interest rate, percentage			2.30%
Total principal amount of long-term debt	[2]	$ 0	$ 3,532
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2019 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		1.30%	1.80%
Total principal amount of long-term debt		$ 4,848	$ 3,350
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2020 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		1.10%	5.20%
Total principal amount of long-term debt		$ 1,528	$ 330
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2021 [Member]
Debt Instrument [Line Items]
Interest rate, percentage			3.90%
Total principal amount of long-term debt		$ 3,550	$ 4,260
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2022 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		0.30%
Total principal amount of long-term debt		$ 1,199	$ 0
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2023 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		4.30%	4.30%
Total principal amount of long-term debt		$ 1,592	$ 1,592
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2024-2028 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		3.50%	3.90%
Total principal amount of long-term debt		$ 6,259	$ 5,360
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2034-2038 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		5.70%	5.90%
Total principal amount of long-term debt		$ 4,886	$ 6,102
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2039-2043 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		5.20%	6.40%
Total principal amount of long-term debt		$ 5,606	$ 3,745
Unsecured Debt [Member] | Senior Unsecured Debt, Due 2044-2047 [Member]
Debt Instrument [Line Items]
Interest rate, percentage		4.20%	4.20%
Total principal amount of long-term debt		$ 3,315	$ 2,250
[1]	Amounts may not add due to rounding.
[2]	At December 31, 2017, the debt issuances have been reclassified to the current portion of long-term debt.

Financial Instruments - Other N

Financial Instruments - Other Noncurrent Liabilities (Details) - USD ($) $ in Millions		1 Months Ended			12 Months Ended
		Dec. 31, 2017	Aug. 31, 2017	Jun. 30, 2017	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 36,562			$ 36,562			$ 35,664
Bosulif [Member]
Finite-Lived Intangible Assets [Line Items]
Research and development arrangement, aggregate payment obligation, term					10 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement		$ 416			$ 416
Bosulif [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Research and development arrangement, aggregate payment obligation, term		10 years
Besponsa [Member]
Finite-Lived Intangible Assets [Line Items]
Research and development arrangement, aggregate payment obligation, term					9 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement		$ 443			$ 443
Besponsa [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Research and development arrangement, aggregate payment obligation, term			9 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement			$ 296
Besponsa [Member] | European Union [Member]
Finite-Lived Intangible Assets [Line Items]
Research and development arrangement, aggregate payment obligation, term				9 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement				$ 148
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net	[1]	34,765			34,765			$ 33,740
Developed Technology Rights [Member] | Bosulif [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		364			364
Developed Technology Rights [Member] | Besponsa [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		371			371
Developed Technology Rights [Member] | Besponsa [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net						$ 248
Developed Technology Rights [Member] | Besponsa [Member] | European Union [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net							$ 123
Other Noncurrent Liabilities [Member] | Developed Technology Rights [Member] | Bosulif [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		281			281
Other Noncurrent Liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		236			236
Other Noncurrent Liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | European Union [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		119			119
Other Current Liabilities [Member] | Developed Technology Rights [Member] | Bosulif [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		83			83
Other Current Liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | United States [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		15			15
Other Current Liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | European Union [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 6			$ 6
[1]	The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E), (iv) the Developed technology rights of $364 million recorded in connection with the U.S. approval of Bosulif (see Note 7E) and (v) the Developed technology rights of $140 million recorded in connection with the approvals of Bavencio (see Note 2C) partially offset by (vi) measurement period adjustments related to Medivation (see Note 2A) and (vii) impairments of Developed technology rights (see Note 4).

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Derivative [Line Items]
Derivative asset		$ 822	$ 1,255
Derivative liability		691	1,665
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset		760	1,093
Derivative liability		637	1,283
Foreign exchange contracts [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, notional amount	[1]	18,723	14,424
Derivative asset	[1]	179	468
Derivative liability	[1]	459	1,135
Foreign exchange contracts [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, notional amount		14,300	13,100
Derivative asset		62	162
Derivative liability		54	382
Interest rate contracts [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, notional amount		12,430	15,991
Derivative asset		581	625
Derivative liability		$ 178	$ 148
[1]	As of December 31, 2017, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion.

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, net liability position, aggregate fair value		$ 336
Collateral already posted, aggregate fair value		346
Cash collateral received		226
Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(591)	$ (483)
Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	(93)	(107)
Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	520	(452)
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency short-term borrowings [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	(26)
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency short-term borrowings [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency short-term borrowings [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency long-term debt [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2],[4]	(580)	0
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency long-term debt [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency long-term debt [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2],[4]	0	0
All other, net [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	2	1
All other, net [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	0	0
All other, net [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	1	(1)
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2],[5]	(12)	(444)
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[5]	(6)	(4)
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2],[5]	520	(451)
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Foreign exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	(19)	(4)
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Interest rate contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Interest rate contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	(60)	(181)
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Interest rate contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Interest rate contracts, hedged item gain (loss) [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Interest rate contracts, hedged item gain (loss) [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	60	181
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Interest rate contracts, hedged item gain (loss) [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Foreign exchange contracts, hedged item gain (loss) [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Foreign exchange contracts, hedged item gain (loss) [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	19	4
Designated as Hedging Instrument [Member] | Fair Value Hedging [Member] | Foreign exchange contracts, hedged item gain (loss) [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0	0
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	(15)
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	0	1
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	0
Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0
Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3]	(87)	(105)
Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[1],[2]	$ 0	$ 0
[1]	For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net.
[2]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income. COS = Cost of Sales, included in Cost of Sales in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income.
[3]	There was no significant ineffectiveness for any period presented.
[4]	Long-term debt includes foreign currency long-term borrowings with carrying values of $4.8 billion as of December 31, 2017, which are used as hedging instruments.
[5]	Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $72 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.9 billion U.K. pound debt maturing in 2043.

Financial Instruments - Deriv95

Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) $ in Millions	Dec. 31, 2017USD ($)
Derivative [Line Items]
Amount of pre-tax loss to be reclassified	$ (72)
Foreign currency long-term debt [Member]
Derivative [Line Items]
Principal amount	4,800
Unsecured Debt [Member]
Derivative [Line Items]
Principal amount	$ 1,900

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods		$ 2,883	$ 2,293
Work in process		3,908	3,696
Raw materials and supplies		788	793
Inventories	[1],[2]	7,578	6,783
Noncurrent inventories not included above	[3]	$ 683	$ 683
[1]	Amounts may not add due to rounding.
[2]	The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, as well as an increase due to foreign exchange.
[3]	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Property, Plant and Equipment97

Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	$ 30,037		$ 28,125
Less: Accumulated depreciation	16,172		14,807
Property, plant and equipment	13,865	[1],[2]	13,318	[1],[2]	$ 13,766
Land [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	540		530
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	10,254		9,810
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	11,902		11,248
Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	4,661		4,410
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment before accumulated depreciation	$ 2,680		$ 2,127
Minimum [Member] | Buildings [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	33 years
Minimum [Member] | Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	8 years
Minimum [Member] | Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	3 years
Maximum [Member] | Buildings [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	50 years
Maximum [Member] | Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	20 years
Maximum [Member] | Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Useful lives (years)	12 years 6 months
[1]	Amounts may not add due to rounding.
[2]	The increase in total property, plant and equipment is primarily due to capital additions and the impact of foreign exchange, partially offset by depreciation, reductions due to restructuring efforts and disposals.

Identifiable Intangible Asset98

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		$ 93,595	$ 87,351
Finite-lived intangible assets, accumulated amortization	[1]	(57,033)	(51,687)
Finite-lived intangible assets, less accumulated amortization		36,562	35,664
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		12,179	16,984
Intangible assets, gross carrying amount	[1]	105,774	104,335
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	48,741	52,648
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		6,929	6,883
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	[3]	5,249	10,101
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	[3]	89,550	83,390
Finite-lived intangible assets, accumulated amortization	[3]	(54,785)	(49,650)
Finite-lived intangible assets, less accumulated amortization	[3]	34,765	33,740
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		2,134	2,092
Finite-lived intangible assets, accumulated amortization		(1,152)	(1,032)
Finite-lived intangible assets, less accumulated amortization		982	1,060
Licensing Agreements And Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		1,911	1,869
Finite-lived intangible assets, accumulated amortization		(1,096)	(1,005)
Finite-lived intangible assets, less accumulated amortization		$ 815	$ 864
[1]	The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to (i) amortization, (ii) measurement period adjustments related to Medivation (see Note 2A), as well as (iii) impairments of Developed technology rights (see Note 4), partially offset by (iv) assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (v) the assets recorded in connection with the EU and U.S. approvals of Besponsa and in connection with the U.S. approval of Bosulif (see Note 7E) and (vi) the assets recorded in connection with the approvals of Bavencio (see Note 2C).
[2]	Amounts may not add due to rounding.
[3]	The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E), (iv) the Developed technology rights of $364 million recorded in connection with the U.S. approval of Bosulif (see Note 7E) and (v) the Developed technology rights of $140 million recorded in connection with the approvals of Bavencio (see Note 2C) partially offset by (vi) measurement period adjustments related to Medivation (see Note 2A) and (vii) impairments of Developed technology rights (see Note 4).

Identifiable Intangible Asset99

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($) $ in Millions		Dec. 31, 2017	Oct. 01, 2017	Dec. 31, 2016
Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 36,562		$ 35,664
In Process Research and Development [Member] | Eucrisa [Member]
Schedule of Intangible Assets [Line Items]
Transfers in (out) of intangible asset class		(4,800)
Developed Technology Rights [Member]
Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, net	[1]	34,765		$ 33,740
Developed Technology Rights [Member] | Eucrisa [Member]
Schedule of Intangible Assets [Line Items]
Transfers in (out) of intangible asset class		4,800
Developed Technology Rights [Member] | Besponsa [Member]
Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, net		371
United States [Member] | Developed Technology Rights [Member] | Besponsa [Member]
Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, net			$ 248
United States [Member] | Developed Technology Rights [Member] | Bosulif [Member]
Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 364
[1]	The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E), (iv) the Developed technology rights of $364 million recorded in connection with the U.S. approval of Bosulif (see Note 7E) and (v) the Developed technology rights of $140 million recorded in connection with the approvals of Bavencio (see Note 2C) partially offset by (vi) measurement period adjustments related to Medivation (see Note 2A) and (vii) impairments of Developed technology rights (see Note 4).

Identifiable Intangible Asse100

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Dec. 31, 2017
Operating Segments [Member] | Innovative Health Segment [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	68.00%
Operating Segments [Member] | Innovative Health Segment [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	75.00%
Operating Segments [Member] | Essential Health Segment [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	31.00%
Operating Segments [Member] | Essential Health Segment [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	25.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of finite-lived intangible asset amortized cost by segment	0.00%

Identifiable Intangible Asse101

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Dec. 31, 2017
Operating Segments [Member] | Innovative Health Segment [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	71.00%
Operating Segments [Member] | Innovative Health Segment [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	81.00%
Operating Segments [Member] | Essential Health Segment [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	29.00%
Operating Segments [Member] | Essential Health Segment [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	12.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of indefinite-lived intangible asset unamortized costs by segment	7.00%

Identifiable Intangible Asse102

Identifiable Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets	$ 4.8	$ 4.1	$ 3.8
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years

Identifiable Intangible Asse103

Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details) $ in Millions	Dec. 31, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,018	$ 4,798
2,019	4,592
2,020	3,569
2,021	3,474
2,022	$ 3,223

Identifiable Intangible Asse104

Identifiable Intangible Assets and Goodwill - Goodwill (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016
Goodwill [Roll Forward]
Beginning balance		$ 54,449	[1]	$ 48,242
Additions		664	[2]	6,369	[3]
Other		840	[4]	(162)	[5]
Ending balance	[1]	55,952		54,449
Innovative Health Segment [Member]
Goodwill [Roll Forward]
Beginning balance		30,134		23,809
Additions		572	[2]	6,357	[3]
Other		435	[4]	(32)	[5]
Ending balance		31,141		30,134
Essential Health Segment [Member]
Goodwill [Roll Forward]
Beginning balance		24,315		24,433
Additions		92	[2]	12	[3]
Other		404	[4]	(130)	[5]
Ending balance		24,811		24,315
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]
Goodwill [Roll Forward]
Goodwill		$ 0		$ 119
[1]	Amounts may not add due to rounding.
[2]	IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A).
[3]	IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo (see Note 2A).
[4]	Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.
[5]	Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $119 million to Assets held for sale during 2016 (see Note 2B).

Pension and Postretirement B105

Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost		$ 42	[1],[2]	$ 41	[1],[2]	$ 55
Interest cost		90	[1],[2]	101	[1],[2]	117
Expected return on plan assets		(36)		(34)		(53)
Amortization of actuarial losses		31		32		38
Amortization of prior service credits		(182)		(174)		(146)
Curtailments		(19)		(26)		(31)
Settlements		0		0		0
Special termination benefits		0	[1],[2]	0	[1],[2]	0
Net periodic benefit costs/(income) reported in Income		(75)		(59)		(21)
(Income)/cost reported in Other comprehensive loss	[3]	(8)		3		(540)
(Income)/cost recognized in Comprehensive income		(83)		(56)		(560)
United States [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[4]	269	[1],[5]	257	[1],[5]	287
Interest cost	[4]	634	[1],[5]	646	[1],[5]	676
Expected return on plan assets	[4]	(1,005)		(958)		(1,089)
Amortization of actuarial losses	[4]	393		395		346
Amortization of prior service credits	[4]	3		5		(5)
Curtailments	[4]	13		10		3
Settlements	[4]	75		90		556
Special termination benefits	[4]	0	[1],[5]	0	[1],[5]	0
Net periodic benefit costs/(income) reported in Income	[4]	382		444		773
(Income)/cost reported in Other comprehensive loss	[3],[4]	141		253		(396)
(Income)/cost recognized in Comprehensive income	[4]	523		697		378
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost		24	[1]	18	[1]	22
Interest cost		54	[1]	53	[1]	54
Expected return on plan assets		0		0		0
Amortization of actuarial losses		50		37		44
Amortization of prior service credits		(1)		(1)		(2)
Curtailments		1		1		0
Settlements		39		28		34
Special termination benefits		0	[1]	0	[1]	0
Net periodic benefit costs/(income) reported in Income		166		137		153
(Income)/cost reported in Other comprehensive loss	[3]	23		121		(143)
(Income)/cost recognized in Comprehensive income		189		258		10
Foreign Plan [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost		171	[1],[6]	165	[1],[6]	186
Interest cost		204	[1],[6]	233	[1],[6]	307
Expected return on plan assets		(345)		(381)		(418)
Amortization of actuarial losses		116		93		122
Amortization of prior service credits		(4)		(3)		(7)
Curtailments		0		(2)		5
Settlements		4		9		81
Special termination benefits		1	[1],[6]	1	[1],[6]	1
Net periodic benefit costs/(income) reported in Income		147		115		277
(Income)/cost reported in Other comprehensive loss	[3]	(301)		640		(542)
(Income)/cost recognized in Comprehensive income		$ (154)		$ 755		$ (265)
[1]	For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $16.7 billion in 2017 and $15.4 billion in 2016. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.5 billion in 2017 and $1.4 billion in 2016. The ABO for our international pension plans was $10.1 billion in 2017 and $9.3 billion in 2016.
[2]	The favorable change in the funded status of our postretirement plans was primarily due to a change to reimbursements of certain benefits provided under the plan, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[3]	In 2017 and 2016, the changes to Other comprehensive (income)/loss for the international plans was impacted by foreign currency movements. For details of the changes in Other comprehensive (income)/loss, see the benefit plan activity in the consolidated statements of comprehensive income.
[4]	In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3). In 2015, the net periodic benefit costs included settlement losses primarily related to participants accepting the lump-sum option made in an offer to certain plan participants to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or to elect an early annuity.
[5]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[6]	The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements.

Pension and Postretirement B106

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Footnotes (Details) - Pension Plan [Member] - United States [Member] - USD ($) $ in Millions		1 Months Ended	12 Months Ended
		Apr. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Decrease in pension benefit obligation in connection with Hospira pension plan	[1],[2]		$ 842	$ 449
Hospira [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Pretax settlement gain		$ 41
Net pension benefit obligation		30
Qualified Plan [Member] | Hospira [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Decrease in pension benefit obligation in connection with Hospira pension plan		$ 156
[1]	For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $16.7 billion in 2017 and $15.4 billion in 2016. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.5 billion in 2017 and $1.4 billion in 2016. The ABO for our international pension plans was $10.1 billion in 2017 and $9.3 billion in 2016.
[2]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.

Pension and Postretirement B107

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ (9)	[1]
Prior service credits and other	181
Total	$ 172
Amortization period	9 years 8 months 12 days
United States [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ (121)	[1]
Prior service credits and other	(2)
Total	$ (123)
Amortization period	24 years 9 months 18 days
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ (16)	[1]
Prior service credits and other	1
Total	$ (15)
Amortization period	26 years 2 months 12 days
Foreign Plan [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ (101)	[1]
Prior service credits and other	4
Total	$ (97)
Amortization period	20 years
[1]	Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans will reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for 2018 are 24.8 years for our U.S. qualified plans, 26.2 years for our U.S. supplemental (non-qualified) plans, 20.0 years for our international plans, and 9.7 for our postretirement plans.

Pension and Postretirement B108

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Postretirement Benefits Plan [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		3.70%	4.20%	4.50%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate		4.20%	4.50%	4.20%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets		8.00%	8.00%	8.30%
United States [Member] | Pension Plan [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		3.80%	4.30%	4.50%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase		2.80%	2.80%	2.80%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate		4.30%	4.50%	4.20%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets		8.00%	8.00%	8.30%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase		2.80%	2.80%	2.80%
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		3.70%	4.20%	4.50%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase		2.80%	2.80%	2.80%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine net periodic benefit cost, Discount rate		4.20%	4.50%	4.00%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase		2.80%	2.80%	2.80%
Foreign Plan [Member] | Pension Plan [Member]
Weighted-average assumptions used to determine benefit obligations:
Weighted-average assumptions used to determine benefit obligations, Discount rate		2.30%	2.40%	3.10%
Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase		2.50%	2.60%	2.60%
Weighted-average assumptions used to determine net periodic benefit cost:
Weighted-average assumptions used to determine interest cost, Discount rate	[1]	2.10%	2.70%	3.00%
Weighted-average assumptions used to determine service cost, Discount rate	[1]	2.30%	3.00%	3.00%
Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets		4.70%	5.20%	5.50%
Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase		2.60%	2.60%	2.70%
[1]	Effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with this change, the effective rate for interest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans.

Pension and Postretirement B109

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) - Postretirement Benefits Plan [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Healthcare cost trend rate assumed for next year (up to age 65)	6.10%	6.30%
Healthcare cost trend rate assumed for next year (age 65 and older)	7.00%	7.40%
Rate to which the cost trend rate is assumed to decline	4.50%	4.50%

Pension and Postretirement B110

Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details) - Postretirement Benefits Plan [Member] $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Defined Benefit Plan Disclosure [Line Items]
Effect on total service and interest cost components, increase	$ 3
Effect on total service and interest cost components, decrease	(4)
Effect on postretirement benefit obligation, increase	47
Effect on postretirement benefit obligation, decrease	$ (26)

Pension and Postretirement B111

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Postretirement Benefits Plan [Member]
Change in benefit obligation
Benefit obligation, beginning	[1],[2]	$ 2,254		$ 2,463
Service cost		42	[1],[2]	41	[1],[2]	$ 55
Interest cost		90	[1],[2]	101	[1],[2]	117
Employee contributions	[1],[2]	94		85
Plan amendments	[1],[2]	0		(177)
Changes in actuarial assumptions and other	[1],[2]	(177)		22
Foreign exchange impact	[1],[2]	5		0
Acquisitions/divestitures/other, net	[1],[2]	1
Curtailments	[1],[2]	1		0
Settlements	[1],[2]	0		0
Special termination benefits		0	[1],[2]	0	[1],[2]	0
Benefits paid	[1],[2]	(280)		(282)
Benefit obligation, ending	[1],[2]	2,028		2,254		2,463
Change in plan assets
Fair value of plan assets, beginning	[2]	458	[3]	622
Actual gain/(loss) on plan assets	[2]	39		44
Company contributions	[2]	183		(12)
Employee contributions	[2]	94		85
Foreign exchange impact	[2]	0		0
Acquisitions/divestitures, net	[2]	0		0
Settlements	[2]	0		0
Benefits paid	[2]	(280)		(282)
Fair value of plan assets, ending	[2]	494	[3]	458	[3]	622
Funded status—Plan assets less than benefit obligation	[2]	(1,534)		(1,796)
United States [Member] | Pension Plan [Member]
Change in benefit obligation
Benefit obligation, beginning	[1],[4]	15,547		14,926
Service cost	[5]	269	[1],[4]	257	[1],[4]	287
Interest cost	[5]	634	[1],[4]	646	[1],[4]	676
Employee contributions	[1],[4]	0		0
Plan amendments	[1],[4]	0		0
Changes in actuarial assumptions and other	[1],[4]	1,614		725
Foreign exchange impact	[1],[4]	0		0
Acquisitions/divestitures/other, net	[1],[4]	0		0
Curtailments	[1],[4]	11		9
Settlements	[1],[4]	(842)		(449)
Special termination benefits	[5]	0	[1],[4]	0	[1],[4]	0
Benefits paid	[1],[4]	(530)		(568)
Benefit obligation, ending	[1],[4]	16,702		15,547		14,926
Change in plan assets
Fair value of plan assets, beginning	[4]	12,556		11,633
Actual gain/(loss) on plan assets	[4]	2,005		939
Company contributions	[4]	1,095		1,000
Employee contributions	[4]	0		0
Foreign exchange impact	[4]	0		0
Acquisitions/divestitures, net	[4]	0
Settlements	[4]	(842)		(449)
Benefits paid	[4]	(530)		(568)
Fair value of plan assets, ending	[4]	14,284		12,556		11,633
Funded status—Plan assets less than benefit obligation	[4]	(2,418)		(2,990)
Defined benefit plan, accumulated benefit obligation		16,700		15,400
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Change in benefit obligation
Benefit obligation, beginning	[1]	1,450		1,343
Service cost		24	[1]	18	[1]	22
Interest cost		54	[1]	53	[1]	54
Employee contributions	[1]	0		0
Plan amendments	[1]	0		0
Changes in actuarial assumptions and other	[1]	110		185
Foreign exchange impact	[1]	0		0
Acquisitions/divestitures/other, net	[1]	0		0
Curtailments	[1]	0		1
Settlements	[1]	(98)		(78)
Special termination benefits		0	[1]	0	[1]	0
Benefits paid	[1]	(45)		(72)
Benefit obligation, ending	[1]	1,495		1,450		1,343
Change in plan assets
Fair value of plan assets, beginning		0		0
Company contributions		143		151
Employee contributions		0		0
Foreign exchange impact		0		0
Settlements		(98)		(78)
Benefits paid		(45)		(72)
Fair value of plan assets, ending		0		0		0
Funded status—Plan assets less than benefit obligation		(1,495)		(1,450)
Defined benefit plan, accumulated benefit obligation		1,500		1,400
Foreign Plan [Member] | Pension Plan [Member]
Change in benefit obligation
Benefit obligation, beginning	[1],[6]	9,691		9,214
Service cost		171	[1],[6]	165	[1],[6]	186
Interest cost		204	[1],[6]	233	[1],[6]	307
Employee contributions	[1],[6]	6		7
Plan amendments	[1],[6]	2		(6)
Changes in actuarial assumptions and other	[1],[6]	135		1,273
Foreign exchange impact	[1],[6]	760		(781)
Acquisitions/divestitures/other, net	[1],[6]	26		1
Curtailments	[1],[6]	0		(14)
Settlements	[1],[6]	(31)		(45)
Special termination benefits		1	[1],[6]	1	[1],[6]	1
Benefits paid	[1],[6]	(357)		(358)
Benefit obligation, ending	[1],[6]	10,607		9,691		9,214
Change in plan assets
Fair value of plan assets, beginning	[6]	7,683		7,959
Actual gain/(loss) on plan assets	[6]	811		693
Company contributions	[6]	160		209
Employee contributions	[6]	6		7
Foreign exchange impact	[6]	561		(782)
Acquisitions/divestitures, net	[6]	30		(1)
Settlements	[6]	(31)		(45)
Benefits paid	[6]	(357)		(358)
Fair value of plan assets, ending	[6]	8,863		7,683		$ 7,959
Funded status—Plan assets less than benefit obligation	[6]	(1,745)		(2,008)
Defined benefit plan, accumulated benefit obligation		$ 10,100		$ 9,300
[1]	For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $16.7 billion in 2017 and $15.4 billion in 2016. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.5 billion in 2017 and $1.4 billion in 2016. The ABO for our international pension plans was $10.1 billion in 2017 and $9.3 billion in 2016.
[2]	The favorable change in the funded status of our postretirement plans was primarily due to a change to reimbursements of certain benefits provided under the plan, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[3]	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
[4]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[5]	In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3). In 2015, the net periodic benefit costs included settlement losses primarily related to participants accepting the lump-sum option made in an offer to certain plan participants to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or to elect an early annuity.
[6]	The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements.

Pension and Postretirement B112

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	$ 0	$ 0
Current liabilities	[2]	(31)	(30)
Noncurrent liabilities	[3]	(1,504)	(1,766)
Funded status		(1,534)	(1,796)
United States [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	0	0
Current liabilities	[2]	0	(160)
Noncurrent liabilities	[3]	(2,418)	(2,830)
Funded status		(2,418)	(2,990)
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	0	0
Current liabilities	[2]	(160)	(152)
Noncurrent liabilities	[3]	(1,336)	(1,297)
Funded status		(1,495)	(1,450)
Foreign Plan [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	[1]	454	300
Current liabilities	[2]	(26)	(28)
Noncurrent liabilities	[3]	(2,172)	(2,279)
Funded status		$ (1,745)	$ (2,008)
[1]	Included primarily in Other noncurrent assets.
[2]	Included in Accrued compensation and related items.
[3]	Included in Pension benefit obligations, net and Postretirement benefit obligations, net, as appropriate.

Pension and Postretirement B113

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($) $ in Millions		Dec. 31, 2017	Dec. 31, 2016
Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	$ (293)	$ (502)
Prior service (costs)/credits		1,190	1,392
Total		(897)	(889)
United States [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	(4,677)	(4,530)
Prior service (costs)/credits		(23)	(27)
Total		(4,699)	(4,558)
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	(561)	(538)
Prior service (costs)/credits		1	2
Total		(559)	(536)
Foreign Plan [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	[1]	(2,322)	(2,629)
Prior service (costs)/credits		34	40
Total		$ (2,288)	$ (2,589)
[1]	The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the expected life expectancy of plan participants for frozen plans, using the corridor approach.

Pension and Postretirement B114

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
United States [Member] | Pension Plan [Member]
Pension plans with an ABO in excess of plan assets:
Fair value of plan assets	$ 14,284	$ 12,556
ABO	16,702	15,422
Pension plans with a PBO in excess of plan assets:
Fair value of plan assets	14,284	12,556
PBO	16,702	15,547
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Pension plans with an ABO in excess of plan assets:
ABO	1,495	1,410
Pension plans with a PBO in excess of plan assets:
PBO	1,495	1,450
Foreign Plan [Member] | Pension Plan [Member]
Pension plans with an ABO in excess of plan assets:
Fair value of plan assets	882	4,625
ABO	2,724	6,558
Pension plans with a PBO in excess of plan assets:
Fair value of plan assets	1,626	4,936
PBO	$ 3,825	$ 7,244

Pension and Postretirement B115

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) - USD ($) $ in Millions		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[2]	$ 494	[1]	$ 458	[1]	$ 622
Assets Measured at NAV	[1],[3]			0
Postretirement Benefits Plan [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	494		458
Postretirement Benefits Plan [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	0		0
Postretirement Benefits Plan [Member] | Cash and Cash Equivalents [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Cash and Cash Equivalents [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]			0
Postretirement Benefits Plan [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	0		0
Postretirement Benefits Plan [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	0		0
Assets Measured at NAV	[1],[3]			0
Postretirement Benefits Plan [Member] | Equity Securities [Member] | Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Equity Securities [Member] | Level 1 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]			0
Postretirement Benefits Plan [Member] | Equity Securities [Member] | Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Equity Securities [Member] | Level 3 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	0		0
Postretirement Benefits Plan [Member] | Corporate debt [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]			0
Postretirement Benefits Plan [Member] | Corporate debt [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Corporate debt [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]			0
Postretirement Benefits Plan [Member] | Government and Agency Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	0		0
Postretirement Benefits Plan [Member] | Government and Agency Obligations [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Government and Agency Obligations [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Government and Agency Obligations [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0
Postretirement Benefits Plan [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	0		0
Assets Measured at NAV	[1],[3]			0
Postretirement Benefits Plan [Member] | Fixed Income Commingled Funds [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]			0
Postretirement Benefits Plan [Member] | Fixed Income Commingled Funds [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Fixed Income Commingled Funds [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0		0
Postretirement Benefits Plan [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[5]	0		0
Assets Measured at NAV	[1],[3],[5]			0
Postretirement Benefits Plan [Member] | Partnership Interest [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4],[5]	0		0
Postretirement Benefits Plan [Member] | Partnership Interest [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4],[5]	0		0
Postretirement Benefits Plan [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	494		458
Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0
Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	494		458
Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]			0
Postretirement Benefits Plan [Member] | Other Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]	0	[6]	0	[7]
Assets Measured at NAV	[1],[3],[7]			0
Postretirement Benefits Plan [Member] | Other Commingled Funds [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0	[6]	0	[7]
Postretirement Benefits Plan [Member] | Other Commingled Funds [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0	[6]	0	[7]
Postretirement Benefits Plan [Member] | Other Commingled Funds [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1],[4]	0	[6]	0	[7]
United States [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[8]	14,284		12,556		11,633
Assets Measured at NAV	[3]	2,889		2,615
United States [Member] | Pension Plan [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	4,238		4,049
United States [Member] | Pension Plan [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	7,153		5,891
United States [Member] | Pension Plan [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	4		1
United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		655		672
United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	115		92
United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	540		580
United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		253		144
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		4,157		3,970
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1,194		1,062
Assets Measured at NAV	[3]	392		290
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	4,118		3,943
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 1 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 2 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	38		27
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	802		772
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 3 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1	[4]	0
United States [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 3 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		4,250		3,232
United States [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	5		14
United States [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		4,242	[4]	3,217
United States [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	3		1
United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		1,316		1,060
United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	1,316		1,060
United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		94		92
Assets Measured at NAV	[3]	94		92
United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]			0
United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[5]	1,197		1,093
Assets Measured at NAV	[3],[5]	1,197		1,093
United States [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[5]	0		0
United States [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[5]			0
United States [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[5]	0		0
United States [Member] | Pension Plan [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		215		235
United States [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	215		235
United States [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
United States [Member] | Pension Plan [Member] | Other Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[7]	1,206		1,140
Assets Measured at NAV	[3],[7]	1,206		1,140
United States [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[7]	0		0
United States [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[7]	0		0
Foreign Plan [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[9]	8,863		7,683		7,959
Assets Measured at NAV	[3]	2,709		2,346
Foreign Plan [Member] | Pension Plan [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	194		201
Foreign Plan [Member] | Pension Plan [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	5,073		4,558
Foreign Plan [Member] | Pension Plan [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	887		578
Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		385		439
Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	48		38
Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	337		401
Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		154		174
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,897		2,490
Assets Measured at NAV	[3]	1,303		1,224
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 1 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	146		163
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 1 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 2 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	8		11
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 2 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	1,594		1,265
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 3 [Member] | Global Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Equity Securities [Member] | Level 3 [Member] | Equity Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		588		489
Assets Measured at NAV	[3]	0		15
Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	588		474
Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[10]	716		853
Assets Measured at NAV	[3],[10]	0		67
Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[10]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[10]	716		786
Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[10]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2,181		1,750
Assets Measured at NAV	[3]	841		576
Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	1,340		1,174
Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[5]	42		32
Assets Measured at NAV	[3],[5]	35		32
Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[5]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[5]	7		0
Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[5]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[11]	496		272
Assets Measured at NAV	[3],[11]	1		1
Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[11]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[11]	75		17
Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		420	[4],[11]	254	[4],[11]	219
Foreign Plan [Member] | Pension Plan [Member] | Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[7],[11]	1,404		1,185
Assets Measured at NAV	[3],[7],[11]	528		431
Foreign Plan [Member] | Pension Plan [Member] | Other [Member] | Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[7],[11]	0		0
Foreign Plan [Member] | Pension Plan [Member] | Other [Member] | Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[4],[7],[11]	408		430
Foreign Plan [Member] | Pension Plan [Member] | Other [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		$ 468	[4],[7],[11]	$ 324	[4],[7],[11]	$ 398
[1]	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
[2]	The favorable change in the funded status of our postretirement plans was primarily due to a change to reimbursements of certain benefits provided under the plan, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[3]	Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.
[4]	Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E).
[5]	Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.
[6]	Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
[7]	Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
[8]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[9]	The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements.
[10]	Government and agency obligations are inclusive of repurchase agreements.
[11]	See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.

Pension and Postretirement B116

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) - Foreign Plan [Member] - Pension Plan [Member] - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[1]	$ 7,683		$ 7,959
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) [Abstract]
Exchange rate changes	[1]	561		(782)
Fair value of plan assets, ending	[1]	8,863		7,683
Insurance Contracts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[2]	272
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) [Abstract]
Fair value of plan assets, ending	[2]	496		272
Other Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[2],[3]	1,185
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) [Abstract]
Fair value of plan assets, ending	[2],[3]	1,404		1,185
Level 3 [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning	[4]	578
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) [Abstract]
Fair value of plan assets, ending	[4]	887		578
Level 3 [Member] | Insurance Contracts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning		254	[2],[4]	219
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) [Abstract]
Assets held, ending		1		11
Assets sold during the period				0
Purchases, sales and settlements, net		138		20
Exchange rate changes		27		4
Fair value of plan assets, ending	[2],[4]	420		254
Level 3 [Member] | Other Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Fair value of plan assets, beginning		324	[2],[3],[4]	398
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) [Abstract]
Assets held, ending		18		(1)
Assets sold during the period		1		6
Purchases, sales and settlements, net		94		(18)
Exchange rate changes		30		(61)
Fair value of plan assets, ending	[2],[3],[4]	$ 468		$ 324
[1]	The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements.
[2]	See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.
[3]	Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
[4]	Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E).

Pension and Postretirement B117

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail) - USD ($) $ in Millions		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		100.00%
Equity and debt securities, percentage of plan assets		100.00%		100.00%
Plan assets	[2]	$ 494	[1]	$ 458	[1]	$ 622
Cash and Cash Equivalents [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		0.00%		0.00%
Plan assets	[1]	$ 0		$ 0
Equity Securities [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		0.00%
Equity and debt securities, percentage of plan assets		0.00%		0.00%
Fixed Income Securities [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		0.00%
Equity and debt securities, percentage of plan assets		0.00%		0.00%
Plan assets	[1]	$ 0		$ 0
Other Investments [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		100.00%		100.00%
Insurance Contracts [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets	[1]	$ 494		$ 458
United States [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		100.00%
Equity and debt securities, percentage of plan assets		100.00%		100.00%
Plan assets	[3]	$ 14,284		$ 12,556		11,633
United States [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		4.60%		5.30%
Plan assets		$ 655		$ 672
United States [Member] | Equity Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		37.50%		40.10%
Plan assets		$ 253		$ 144
United States [Member] | Fixed Income Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		39.60%		34.90%
Plan assets		$ 94		$ 92
United States [Member] | Other Investments [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets	[4]	18.30%		19.70%
United States [Member] | Insurance Contracts [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets		$ 215		$ 235
Foreign Plan [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		100.00%
Equity and debt securities, percentage of plan assets		100.00%		100.00%
Plan assets	[5]	$ 8,863		$ 7,683		$ 7,959
Foreign Plan [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		4.30%		5.70%
Plan assets		$ 385		$ 439
Foreign Plan [Member] | Equity Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		34.40%		34.70%
Foreign Plan [Member] | Fixed Income Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		39.30%		40.20%
Plan assets		$ 2,181		$ 1,750
Foreign Plan [Member] | Other Investments [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, percentage of plan assets		21.90%		19.40%
Foreign Plan [Member] | Insurance Contracts [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets	[6]	$ 496		$ 272
Minimum [Member] | Cash and Cash Equivalents [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		0.00%
Minimum [Member] | Other Investments [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		95.00%
Minimum [Member] | United States [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		0.00%
Minimum [Member] | United States [Member] | Equity Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		35.00%
Minimum [Member] | United States [Member] | Fixed Income Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		30.00%
Minimum [Member] | United States [Member] | Other Investments [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage	[4]	5.00%
Minimum [Member] | Foreign Plan [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		0.00%
Minimum [Member] | Foreign Plan [Member] | Equity Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		25.00%
Minimum [Member] | Foreign Plan [Member] | Fixed Income Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		30.00%
Minimum [Member] | Foreign Plan [Member] | Other Investments [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		10.00%
Maximum [Member] | Cash and Cash Equivalents [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		5.00%
Maximum [Member] | Other Investments [Member] | Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		100.00%
Maximum [Member] | United States [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		10.00%
Maximum [Member] | United States [Member] | Equity Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		55.00%
Maximum [Member] | United States [Member] | Fixed Income Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		55.00%
Maximum [Member] | United States [Member] | Other Investments [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage	[4]	17.50%
Maximum [Member] | Foreign Plan [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		10.00%
Maximum [Member] | Foreign Plan [Member] | Equity Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		50.00%
Maximum [Member] | Foreign Plan [Member] | Fixed Income Securities [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		55.00%
Maximum [Member] | Foreign Plan [Member] | Other Investments [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity and debt securities, target allocation percentage		30.00%
[1]	Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
[2]	The favorable change in the funded status of our postretirement plans was primarily due to a change to reimbursements of certain benefits provided under the plan, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[3]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[4]	Actual percentage of plan assets in Other investments for 2017 includes $215 million, as compared to $235 million in 2016, related to a group fixed annuity insurance contract that was executed by legacy Wyeth for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $253 million in 2017, as compared to $144 million in 2016, related to an investment in a partnership whose primary holdings are public equity securities.
[5]	The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements.
[6]	See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.

Pension and Postretirement B118

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details) - USD ($) $ in Millions		1 Months Ended	12 Months Ended
		Feb. 22, 2018	Dec. 31, 2017	Dec. 31, 2016
Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2018	[1]		$ 167
Expected benefit payments:
2,018			173
2,019			179
2,020			181
2,021			179
2,022			173
2023-2027			802
Company contributions	[2]		183	$ (12)
United States [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2018	[1]		500
Expected benefit payments:
2,018			1,225
2,019			1,071
2,020			1,087
2,021			1,059
2,022			1,032
2023-2027			4,865
Company contributions	[3]		1,095	1,000
United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2018	[1]		160
Expected benefit payments:
2,018			160
2,019			129
2,020			128
2,021			122
2,022			123
2023-2027			513
Company contributions			143	151
Foreign Plan [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in 2018	[1]		226
Expected benefit payments:
2,018			368
2,019			373
2,020			385
2,021			394
2,022			401
2023-2027			2,101
Company contributions	[4]		$ 160	$ 209
Subsequent Event [Member] | United States [Member] | Pension Plan [Member]
Expected benefit payments:
Company contributions		$ 500
[1]	For the U.S. qualified plans, a $500 million voluntary contribution was paid in February 2018.
[2]	The favorable change in the funded status of our postretirement plans was primarily due to a change to reimbursements of certain benefits provided under the plan, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[3]	The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the actual return on assets, partially offset by plan losses resulting from the decrease in the discount rate at the end of 2017.
[4]	The favorable change in the international plans’ funded status was primarily due to an increase in the actual return on plan assets, partially offset by plan losses related to a decrease in the discount rate and unfavorable currency movements.

Pension and Postretirement B119

Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jan. 01, 2018pension_plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, cost recognized | $	$ 380	$ 317	$ 287
Subsequent Event [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of pension plans frozen | pension_plan				2

Equity - Summary of Common Stoc

Equity - Summary of Common Stock Purchases (Details) - USD ($) shares in Millions, $ in Millions		Jun. 20, 2016	Mar. 10, 2016	Jul. 13, 2015	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Equity [Abstract]
Shares of common stock purchased		18	136	151	150	[1]	154	[2]	182	[3]
Cost of purchase	[4]				$ 5,000	[1]	$ 5,000	[2]	$ 6,160	[3]
Payments for repurchase of common stock				$ 5,200	$ 5,000	[5]	$ 5,000	[5]	$ 6,160	[5]
[1]	Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on February 2, 2017. See above for additional information.
[2]	Represents shares purchased pursuant to the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.
[3]	Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.

Equity - Narrative (Details)

Equity - Narrative (Details)

May 19, 2017shares

Feb. 06, 2017USD ($)$ / sharesshares

Feb. 02, 2017USD ($)

Jun. 20, 2016$ / sharesshares

Mar. 10, 2016USD ($)$ / sharesshares

Mar. 08, 2016USD ($)

May 19, 2017$ / shares

Jul. 13, 2015USD ($)$ / sharesshares

Dec. 31, 2017USD ($)employee_stock_ownership_plan$ / sharesshares

Dec. 31, 2016USD ($)shares

Dec. 31, 2015USD ($)shares

Feb. 11, 2015USD ($)

Oct. 23, 2014USD ($)

Jun. 27, 2013USD ($)

Equity, Class of Treasury Stock [Line Items]

Amount of shares authorized in stock purchase plan, value

$ 5,000,000,000

$ 10,000,000,000

Amount of additional shares authorized in stock purchase plan, value

$ 11,000,000,000

Amount of remaining shares authorized in stock purchase plan, value

$ 16,400,000,000

Accelerated share repurchases, cash paid

$ 5,000,000,000

$ 160,000,000

$ 5,000,000,000

Shares repurchased | shares

18,000,000

136,000,000

151,000,000

150,000,000

[1]

154,000,000

[2]

182,000,000

[3]

Payments for repurchase of common stock

$ 5,200,000,000

$ 5,000,000,000

[4]

$ 5,000,000,000

[4]

$ 6,160,000,000

[4]

Accelerated share repurchase, final average price paid (in dollars per share) | $ / shares

$ 32.38

$ 34.13

Shares repurchased, initial price per share (in dollars per share) | $ / shares

$ 29.36

Accelerated share repurchase, percentage of agreement

80.00%

Number of employee stock ownership plans | employee_stock_ownership_plan

2

Common ESOP Plan [Member]

Equity, Class of Treasury Stock [Line Items]

ESOP compensation expense

$ 11,000,000

$ 9,000,000

8,000,000

Preferred Stock [Member] | Series A, Convertible Preferred Stock [Member] | Preferred Employee Stock Ownership Plan [Member]

Equity, Class of Treasury Stock [Line Items]

Series A convertible perpetual preferred stock, dividends rate

6.25%

Series A convertible perpetual preferred stock, per share stated value (in dollars per share) | $ / shares

$ 40,300

Preferred stock, redemption price per share (in dollars per share) | $ / shares

$ 40,300

Common Stock [Member] | Preferred Employee Stock Ownership Plan [Member]

Equity, Class of Treasury Stock [Line Items]

Series A convertible perpetual preferred stock, common stock shares when converted | shares

2,574.87

Convertible preferred stock, number of shares convertible | shares

1,000,000

Common Stock [Member] | Common ESOP Plan [Member]

Equity, Class of Treasury Stock [Line Items]

Number of shares in ESOP | shares

51,000,000

December 2015 Stock Purchase Plan [Member]

Equity, Class of Treasury Stock [Line Items]

Amount of shares authorized in stock purchase plan, value

$ 11,000,000,000

Amount of remaining shares authorized in stock purchase plan, value

$ 6,400,000,000

December 2017 Stock Purchase Plan [Member]

Equity, Class of Treasury Stock [Line Items]

Amount of shares authorized in stock purchase plan, value

$ 10,000,000,000

Share Repurchase Agreement with Citibank [Member]

Equity, Class of Treasury Stock [Line Items]

Amount of shares authorized in stock purchase plan, value

$ 5,000,000,000

Accelerated share repurchases, cash paid

$ 5,000,000,000

Shares repurchased | shares

24,000,000

126,000,000

Shares repurchased, initial price per share (in dollars per share) | $ / shares

$ 31.73

Accelerated share repurchase, percentage of agreement

80.00%

Accelerated share repurchase, average price paid per share (in dollars per share) | $ / shares

$ 33.31

[1]

Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on February 2, 2017. See above for additional information.

[2]

Represents shares purchased pursuant to the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.

[3]

Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement entered into on February 9, 2015 (see above for additional information), as well as other share repurchases through year-end 2015.

[4]

Amounts may not add due to rounding.

Share-Based Payments - Narrativ

Share-Based Payments - Narrative (Detail)	12 Months Ended
	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for award	290,000,000
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized	520,000,000
Maximum shares available per individual during the plan period	20,000,000
2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares available per individual during the plan period	8,000,000
Restricted Stock Units (RSUs) [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Restricted Stock Units (RSUs) [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	2
Portfolio Performance Shares [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Performance Shares [Member] | 2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	3
Total Shareholder Return Units (TSRUs) [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1
Performance Total Shareholder Return Unit (PTSRUs) [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1
Employee Stock Option [Member] | 2004 Stock Plan, Amended and Restated [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares counted toward maximum	1

Share-Based Payments - Impact o

Share-Based Payments - Impact on Net Income (Detail) - 2004 Stock Plan, Amended and Restated [Member] - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense		$ 840	$ 691	$ 669
Tax benefit for share-based compensation expense	[1]	(163)	(205)	(198)
Share-based payment expense, net of tax		677	486	471
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense		301	299	306
Total Shareholder Return Units (TSRUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense		221	134	36
Portfolio Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense		209	135	147
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense		55	106	165
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense		47	13	11
Directors' compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment expense		$ 7	$ 4	$ 4
[1]	2017 includes the impact of the TCJA on income taxes.

Share-Based Payments - Restrict

Share-Based Payments - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)Employee$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	29,605
Granted, shares	9,669
Vested, shares	(16,677)	[1]
Reinvested dividend equivalents, shares	1,106
Forfeited, shares	(1,463)
Nonvested, end of period, shares	22,241
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.59
Granted, weighted-average grant-date fair value per share (in dollars per share) | $ / shares	34.05
Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares	33.41	[1]
Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share) | $ / shares	33.41
Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares	32.77
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.64
Number of shares modified to accelerate vesting	6,400
Number of employees affected by accelerated vesting | Employee	9,900
Number of shares scheduled for near-term vesting	6,600
Incremental compensation cost resulting from plan modification | $	$ 0
[1]	Includes the modification for a commitment to pay 6.4 million RSUs to approximately 9,900 employees, including senior and key management employees, for the 6.6 million RSUs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification.

Share-Based Payments - Data Rel

Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2017USD ($)Employeeshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	[1]	$ 584	$ 293	$ 371
Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax		$ 254	$ 262	$ 279
Weighted-average period over which RSU cost is expected to be recognized (years)		1 year 8 months 12 days	1 year 8 months 12 days	1 year 9 months 18 days
Number of shares modified to accelerate vesting | shares		6.4
Number of employees affected by accelerated vesting | Employee		9,900
Number of shares scheduled for near-term vesting | shares		6.6
Incremental compensation cost resulting from plan modification		$ 0
[1]	Includes the modification for a commitment to pay 6.4 million RSUs to approximately 9,900 employees, including senior and key management employees, for the 6.6 million RSUs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification.

Share-Based Payments - Stock Op

Share-Based Payments - Stock Option Narrative (Details)	12 Months Ended
	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares	1,375,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Contractual term (years)	10 years
Holding period	1 year
Exercise period in the event of a divestiture or restructuring	3 months
Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares	0

Share-Based Payments - Valuatio

Share-Based Payments - Valuation Assumptions of Stock Options (Detail) - Employee Stock Option [Member]		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	[1]	3.69%	3.85%	3.19%
Risk-free interest rate	[2]	2.23%	1.55%	1.89%
Expected stock price volatility	[3]	18.39%	21.64%	18.34%
Expected term (years)	[4]	6 years 9 months	6 years 9 months	6 years 9 months
[1]	Determined using a constant dividend yield during the expected term of the option.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility, after consideration of historical volatility.
[4]	Determined using historical exercise and post-vesting termination patterns.

Share-Based Payments - Stock128

Share-Based Payments - Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning of period, shares | shares	186,676
Granted, shares | shares	1,375
Exercised, shares | shares	(34,686)
Forfeited, shares | shares	(1,208)
Expired, shares | shares	(1,400)
Outstanding, end of period, shares | shares	150,757
Vested and expected to vest, end of period, shares | shares	150,368	[1]
Exercisable, end of period, shares | shares	108,747
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share) | $ / shares	$ 26.86
Granted, weighted-average exercise price per share (in dollars per share) | $ / shares	34.06
Exercised, weighted-average exercise price per share (in dollars per share) | $ / shares	24.94
Forfeited, weighted-average exercise price per share (in dollars per share) | $ / shares	34.26
Expired, weighted-average exercise price per share (in dollars per share) | $ / shares	30.78
Outstanding, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares	27.27
Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares	27.25	[1]
Exercisable, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares	$ 24.49
Outstanding, end of period, weighted-average remaining contractual term	5 years 1 month 6 days
Vested and expected to vest, end of period, weighted-average remaining contractual term	5 years 1 month 6 days	[1]
Exercisable, end of period, weighted-average remaining contractual term	4 years 3 months 18 days
Outstanding, end of period, aggregate intrinsic value | $	$ 1,350	[2]
Vested and expected to vest, end of period, aggregate intrinsic value | $	1,349	[1],[2]
Exercisable, end of period, aggregate intrinsic value | $	$ 1,276	[2]
[1]	The number of options expected to vest takes into account an estimate of expected forfeitures.
[2]	Market price of our underlying common stock less exercise price.

Share-Based Payments - Data 129

Share-Based Payments - Data Related to All Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per stock option (in dollars per share)		$ 4.01	$ 3.89	$ 4.30
Aggregate intrinsic value on exercise		$ 331	$ 389	$ 666
Cash received upon exercise	[1]	862	1,019	1,263
Tax benefits realized related to exercise		95	112	187
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost related to nonvested stock options not yet recognized, pre-tax		$ 10	$ 58	$ 159
Weighted-average period over which stock option compensation cost is expected to be recognized (years)		9 months 18 days	1 year 1 month 6 days	1 year 9 months 18 days
[1]	Amounts may not add due to rounding.

Share-Based Payments - Portfoli

Share-Based Payments - Portfolio Performance Shares Narrative (Details) - Portfolio Performance Shares [Member]	12 Months Ended
	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period	3 years
Award vesting period	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	200.00%

Share-Based Payments - Portf131

Share-Based Payments - Portfolio Performance Shares Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)Employee$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Vested and expected to vest, end of period, shares	150,368	[1]
Portfolio Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	22,266
Granted, shares	7,013
Vested, shares	(7,196)
Forfeited, shares	(1,110)
Nonvested, end of period, shares	20,973	[2]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.48
Granted, weighted-average grant date fair value per share (in dollars per share) | $ / shares	34.06
Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares	34.28
Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares	33.62
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 36.22	[2]
Vested and expected to vest, end of period, shares	35,000
Number of shares modified to accelerate vesting	5,700
Number of employees affected by accelerated vesting | Employee	2,800
Number of shares scheduled for near-term vesting	5,900
Incremental compensation cost resulting from plan modification | $	$ 0
[1]	The number of options expected to vest takes into account an estimate of expected forfeitures.
[2]	Vested and non-vested shares outstanding, but not paid as of December 31, 2017 were 35.0 million. Included in this amount is the modification for a commitment to pay 5.7 million PPSs to approximately 2,800 employees, including senior and key management employees, for the 5.9 million PPSs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification.The following table provides data related to all PPS activity:(MILLIONS OF DOLLARS) Year Ended December 31,2017 2016 2015Total fair value of shares vested $131 $118 $60Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax $94 $93 $102Weighted-average period over which PPS cost is expected to be recognized (years) 1.7 1.8 1.7

Share-Based Payments - Data 132

Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details) - Portfolio Performance Shares [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 131	$ 118	$ 60
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$ 94	$ 93	$ 102
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 8 months 12 days	1 year 9 months 18 days	1 year 8 months 12 days

Share-Based Payments - Total Sh

Share-Based Payments - Total Shareholder Return Units Narrative (Details) - Total Shareholder Return Units (TSRUs) [Member]	Oct. 26, 2016USD ($)Employeetrading_day	Dec. 31, 2017USD ($)Employeetrading_day
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Trading day average used to calculate the conversion | trading_day	20	20
Age of eligible unit holder which can elect to exercise and convert TSRUs when vested into PTUs	55 years
Award requisite service period	10 years
Number of employees affected by plan modification | Employee	2,900	150
Incremental compensation cost resulting from plan modification | $	$ 0	$ 0
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term (years)		5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term (years)		7 years

Share-Based Payments - Valua134

Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail) - Total Shareholder Return Units (TSRUs) [Member]		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	[1]	3.69%	3.85%	3.19%
Risk-free interest rate	[2]	1.98%	1.31%	1.76%
Expected stock price volatility	[3]	18.39%	21.64%	18.41%
Contractual term (years)		5 years 1 month 10 days	5 years 1 month 13 days	5 years 10 months 28 days
[1]	Determined using a constant dividend yield during the expected term of the TSRU.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility, after consideration of historical volatility.

Share-Based Payments - Total135

Share-Based Payments - Total Shareholder Return Units Activity (Details) - Total Shareholder Return Units (TSRUs) [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	62,007
Granted, shares	52,574
Vested, shares	(5,805)
Forfeited, shares	(4,870)
Nonvested, end of period, shares	103,906	62,007
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)	$ 5.97
Granted, weighted-average grant-date fair value per share (in dollars per share)	6.23	$ 5.83	$ 6.66
Vested, weighted-average grant date fair value per share (in dollars per share)	6.50
Forfeited, weighted-average grant date fair value per share (in dollars per share)	6.02
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)	6.07	5.97
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]
Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)	31.10
Granted, weighted-average exercise price per share (in dollars per share)	34.06
Forfeited, weighted-average exercise price per share (in dollars per share)	32.25
Expired, weighted-average exercise price per share (in dollars per share)	32.36
Outstanding, end of period, weighted-average exercise price per share (in dollars per share)	$ 32.47	$ 31.10

Share-Based Payments - Outstand

Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details)		Oct. 26, 2016USD ($)Employee	Dec. 31, 2017USD ($)Employee$ / sharesshares
Total Shareholder Return Units (TSRUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Share Units	[1],[2]		124,745,000
Outstanding, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares	[1],[2]		$ 31.37
Outstanding, Weighted-Average Remaining Contractual Term (Years)	[1],[2]		3 years 3 months 18 days
Outstanding, Aggregate Intrinsic Value | $	[1],[2]		$ 896,000,000
Vested, Share Units	[1],[2],[3]		20,839,000
Vested, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares	[1],[2],[3]		$ 25.89
Vested, Weighted-Average Remaining Contractual Term (Years)	[1],[2],[3]		1 year 2 months 12 days
Vested, Aggregate Intrinsic Value | $	[1],[2],[3]		$ 335,000,000
Expected to vest, Share Units	[1],[2],[4]		95,485,000
Expected to vest, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares	[1],[2],[4]		$ 32.45
Expected to vest, Weighted-Average Remaining Contractual Term (Years)	[1],[2],[4]		3 years 8 months 12 days
Expected to vest, Aggregate Intrinsic Value | $	[1],[2],[4]		$ 516,000,000
Settled, Share Units			11,327,156
Settled, Weighted-Average Grant Price Per Share Per Unit (in dollars per share) | $ / shares			$ 22.26
Exercised during period, Share Units			46,278
Exercised during period, Weighted-Average Grant Price (in dollars per share) | $ / shares			$ 22.65
Number of shares modified to accelerate vesting			7,000,000
Number of employees affected by accelerated vesting | Employee		2,900	150
Number of shares scheduled for near-term vesting			7,200,000
Incremental compensation cost resulting from plan modification | $		$ 0	$ 0
Profit Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Share Units	[1],[2],[5]		36,000
Outstanding, Weighted-Average Remaining Contractual Term (Years)	[1],[2],[5]		2 months 12 days
Outstanding, Aggregate Intrinsic Value | $	[1],[2],[5]		$ 1,000,000
Vested, Share Units	[1],[2],[3]		0
Expected to vest, Share Units	[1],[2],[4]		0
Converted awards			24,602
Number of shares modified to accelerate vesting			17,000
Number of shares scheduled for near-term vesting			17,000
Incremental compensation cost resulting from plan modification | $			$ 0
[1]	In 2017, 46,278 TSRUs with a weighted-average grant price of $22.65 per unit were converted into 24,602 PTUs.
[2]	In 2017, we settled 11,327,156 TSRUs with a weighted-average grant price of $22.26 per unit. This includes the modification for a commitment to pay 7.0 million TSRUs to approximately 150 employees, including senior and key management employees, for the 7.2 million TSRUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification.
[3]	This includes the modification for a commitment to pay 7.0 million TSRUs to approximately 150 employees, including senior and key management employees, for the 7.2 million TSRUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification.
[4]	The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.
[5]	Includes the modification for a commitment to pay 17,000 PTUs to a few employees, including senior and key management employees, for the 17,000 PTUs scheduled for near-term settlement. There was no material impact to compensation expense due to the modification.

Share-Based Payments - Data 137

Share-Based Payments - Data Related to All Total Shareholder Return Units (Details) - Total Shareholder Return Units (TSRUs) [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per stock option (in dollars per share)	$ 6.23	$ 5.83	$ 6.66
Total compensation cost related to nonvested awards not yet recognized, pre-tax	$ 232	$ 164	$ 29
Weighted-average period over which nonvested award cost is expected to be recognized (years)	1 year 8 months 12 days	1 year 10 months 24 days	1 year 9 months 18 days

Share-Based Payments - Performa

Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details) - Performance Shares [Member]	12 Months Ended
	Dec. 31, 2017measureperiod
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Number of measures used to determine share payout | measure	2
Share payout measures, operating income, number of periods | period	3
Share payout measures, operating income, duration of period	1 year
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares earned as a percentage of initial award	200.00%

Share-Based Payments - Perfo139

Share-Based Payments - Performance Share Awards (PSAs) Activity (Details) - Performance Shares [Member] $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)Employee$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning of period, shares	4,546
Granted, shares	1,753
Vested, shares	(1,639)	[1]
Forfeited, shares	(635)
Nonvested, end of period, shares	4,024
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 32.48
Granted, weighted-average grant date fair value per share (in dollars per share) | $ / shares	34.06
Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares	35.65	[1]
Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares	34.16
Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares	$ 36.22
Number of shares modified to accelerate vesting	1,100
Number of employees affected by accelerated vesting | Employee	90
Number of shares scheduled for near-term vesting	1,100
Incremental compensation cost resulting from plan modification | $	$ 0
[1]	Includes the modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and key management employees, for the 1.1 million PSAs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification.

Share-Based Payments - Data 140

Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details) - Performance Shares [Member] shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2017USD ($)Employeeshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	[1]	$ 58	$ 9	$ 14
Total compensation cost related to nonvested awards not yet recognized, pre-tax		$ 34	$ 30	$ 24
Weighted-average period over which nonvested award cost is expected to be recognized (years)		1 year 9 months 18 days	1 year 9 months 18 days	1 year 10 months 24 days
Number of shares modified to accelerate vesting | shares		1.1
Number of employees affected by accelerated vesting | Employee		90
Number of shares scheduled for near-term vesting | shares		1.1
Incremental compensation cost resulting from plan modification		$ 0
[1]	Includes the modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and key management employees, for the 1.1 million PSAs scheduled for near-term vesting. There was no material impact to compensation expense due to the modification.

Share-Based Payments - Perfo141

Share-Based Payments - Performance Total Shareholder Return Units Narrative (Details) - Performance Total Shareholder Return Unit (PTSRUs) [Member]	Dec. 29, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant price (in dollars per share) | $ / shares	$ 36.22
Grant-date fair value (in dollars per share) | $ / shares	$ 5.83
Board of Directors Chairman [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred compensation arrangement, shares issued | shares	1,372,213
Head Of Innovative Health [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred compensation arrangement, shares issued | shares	343,053

Share-Based Payments Share-Base

Share-Based Payments Share-Based Payments - Valuation Assumptions of Performance Total Shareholder Return Units (Details) - Performance Total Shareholder Return Unit (PTSRUs) [Member]	12 Months Ended
	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	3.69%	[1]
Risk-free interest rate	2.25%	[2]
Expected stock price volatility	16.12%	[3]
Contractual term (years)	5 years
[1]	Determined using a constant dividend yield during the expected term of the PTSRU.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility, after consideration of historical volatility.

Earnings Per Common Share At143

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details) - USD ($) shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016		Dec. 31, 2015
EPS Numerator-Basic
Income from continuing operations	[1]	$ 21,353	$ 7,229		$ 6,975
Less: Net income attributable to noncontrolling interests		47	31		26
Income from continuing operations attributable to Pfizer Inc.		21,306	7,198		6,949
Less: Preferred stock dividends––net of tax		1	1		1
Income from continuing operations attributable to Pfizer Inc. common shareholders		21,305	7,197		6,948
Discontinued operations––net of tax	[1]	2	17		11
Less: Discontinued operations––net of tax, attributable to noncontrolling interests		0	0		0
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders		2	17		11
Net income attributable to Pfizer Inc. common shareholders		21,307	7,214		6,959
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		21,306	7,197		6,948
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 21,308	$ 7,214		$ 6,960
EPS Denominator
Weighted-average number of common shares outstanding––Basic	[1],[2]	5,970	6,089		6,176
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements	[2]	89	70		81
Weighted-average number of common shares outstanding––Diluted	[1]	6,058	6,159	[2]	6,257	[2]
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans	[3]	36	63		50
Common Stock [Member]
EPS Denominator
Number of shares modified to accelerate vesting		15.2
[1]	Amounts may not add due to rounding.
[2]	2017 shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement.
[3]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Lease Commitments (Detail)

Lease Commitments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Leases [Abstract]
Operating leases, rent expense, net	$ 314	$ 292	$ 243
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,018	209
2,019	172
2,020	150
2,021	136
2,022	123
After 2,022	$ 891

Commitments and Contingencies (

Commitments and Contingencies (Action In Which We Are the Plaintiff) (Details) $ in Millions

Aug. 10, 2017Patents

Jan. 31, 2018Patents

Nov. 30, 2017USD ($)

Oct. 31, 2017Patents

Sep. 30, 2017Patents

Jul. 31, 2017Patents

Mar. 31, 2017Patents

Feb. 28, 2017Patents

Jan. 31, 2017Patents

Aug. 31, 2016Patents

Jul. 31, 2016Patents

Jan. 31, 2016Patents

Dec. 31, 2015Patents

Jul. 31, 2015Defendant

Jun. 30, 2015Patents

Jan. 31, 2015Patents

Jun. 30, 2013Patents

Jul. 31, 2015Defendant

Apr. 30, 2017DefendantPatents

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Celebrex [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Litigation settlement, amount awarded to other party | $

$ 94

Bosulif [Member]

Gain Contingencies [Line Items]

Research arrangement, fixed payment obligation, term

10 years

Research arrangement, fixed payment obligation | $

$ 416

Bosulif [Member] | Wyeth Versus Sun [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

4

Precedex Premix [Member] | Hospira Versus Fresenius [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

4

Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

4

Toviaz [Member] | Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

5

5

5

Number of patents infringed upon

5

Toviaz [Member] | Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] | Patent Infringement [Member] | Judicial Ruling [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

5

Number of patents infringed upon

5

5

Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of defendants | Defendant

4

Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of defendants | Defendant

4

Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

3

Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

3

Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Xeljanz [Member] | Pfizer Versus Zydus [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents allegedly infringed upon due to expire in December 2020

3

Number of patents allegedly infringed upon due to expire in December 2025

1

Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Number of defendants | Defendant

25

Patent Infringement [Member] | Bavencio [Member] | Pfizer Versus BMS, E.R. Squibb & Sons, Ono Pharmaceutical and Tasuku Honjo [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed

1

Forecast [Member] | Mylotarg [Member]

Gain Contingencies [Line Items]

Research arrangement, fixed payment obligation, term

10 years

Research arrangement, fixed payment obligation | $

$ 310

Subsequent Event [Member] | Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents found not infringed upon

3

Number of patents infringed upon

1

Commitments and Contingencie146

Commitments and Contingencies (Action In Which We Are The Defendant) (Details) £ in Millions, $ in Millions	1 Months Ended
	Nov. 30, 2017USD ($)	Oct. 31, 2017Patents	Mar. 31, 2015Patents	Mar. 31, 2013lagoon	Dec. 31, 2017Claim	Dec. 31, 2016GBP (£)
Celebrex [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party | $	$ 94
Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed			6
Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Number of claims dismissed			4
Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed			2
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of claims seeking damages | Claim					56,500
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of claims seeking damages | Claim					1
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Feasibility study, number of lagoons | lagoon				2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £						£ 84.2
Patent Infringement [Member] | Pfizer Versus Breckenridge [Member] | Xeljanz [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon due to expire in December 2025		1

Commitments and Contingencie147

Commitments and Contingencies (Certain Matters Resolved And Commitments) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Dec. 31, 2017
Loss Contingencies [Line Items]
Long-term purchase commitment, amount		$ 4,500
Repatriation tax liability		$ 15,200
Xtandi [Member] | Regents Versus Medivation [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Percentage of payments sought by plaintiff	10.00%
Besponsa [Member]
Loss Contingencies [Line Items]
Research and development arrangement, aggregate payment obligation, term		9 years
Research arrangement, fixed payment obligation		$ 443
Bosulif [Member]
Loss Contingencies [Line Items]
Research and development arrangement, aggregate payment obligation, term		10 years
Research arrangement, fixed payment obligation		$ 416

Segment, Geographic and Othe148

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		12 Months Ended
		Dec. 31, 2017USD ($)Operating_SegmentCountry	Dec. 31, 2016USD ($)	Dec. 31, 2015Country
Segment Reporting Information [Line Items]
Number of operating segments | Operating_Segment		2
Total assets | $	[1]	$ 171,797	$ 171,615
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Outside United States [Member]
Segment Reporting Information [Line Items]
Number of countries outside the U.S | Country		11		12
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | United States [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues		10.00%	10.00%	10.00%
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | JAPAN
Segment Reporting Information [Line Items]
Percentage of total revenues		8.00%	8.00%	8.00%
Geographic Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | CHINA
Segment Reporting Information [Line Items]
Percentage of total revenues		7.00%	6.00%	6.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler One [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues		16.00%	16.00%	14.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler Two [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues		12.00%	12.00%	11.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Domestic Wholesaler Three [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues		10.00%	10.00%	10.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest U.S. Wholesaler Customers [Member]
Segment Reporting Information [Line Items]
Percentage of total revenues		36.00%	29.00%	23.00%
[1]	Amounts may not add due to rounding.

Segment, Geographic and Othe149

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenues	[1]	$ 52,546	$ 52,824	$ 48,851
Earnings	[1],[2],[3],[4]	12,305	8,351	8,965
Depreciation and Amortization	[5]	6,269	5,757	5,157
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		52,546	52,824	48,851
Earnings	[4]	29,625	28,752	27,295
Depreciation and Amortization	[5]	1,113	1,183	998
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	0	0	0
Earnings	[4],[6]	(3,137)	(3,020)	(2,914)
Depreciation and Amortization	[5],[6]	90	85	76
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Revenues	[7]	0	0	0
Earnings	[4],[7]	(5,522)	(5,491)	(5,607)
Depreciation and Amortization	[5],[7]	337	356	355
Innovative Health Segment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		31,422	29,197	26,758
Earnings	[4]	18,341	15,854	14,581
Depreciation and Amortization	[5],[6]	534	583	552
Essential Health Segment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		21,124	23,627	22,094
Earnings	[4]	11,283	12,898	12,714
Depreciation and Amortization	[5],[7]	579	600	446
Purchase Accounting Adjustments [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[7]	0	0	0
Earnings	[4],[7]	(4,758)	(4,185)	(3,953)
Depreciation and Amortization	[5],[7]	4,565	3,890	3,573
Acquisition-Related Costs [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[7]	0	0	0
Earnings	[4],[7]	(456)	(785)	(894)
Depreciation and Amortization	[5],[7]	39	7	75
Certain Significant Items [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[8]	0	0	0
Earnings	[4],[8]	(2,647)	(5,888)	(4,321)
Depreciation and Amortization	[5],[8]	52	200	48
Other Unallocated [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	[7]	0	0	0
Earnings	[4],[7]	(799)	(1,032)	(642)
Depreciation and Amortization	[5],[7]	$ 72	$ 35	$ 33
[1]	Amounts may not add due to rounding.
[2]	2016 v. 2015––The increase in the domestic loss was primarily due to a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, higher asset impairments, and higher restructuring charges and certain acquisition-related costs, partially offset by the inclusion of a full year of legacy U.S. Hospira operations as compared to four months of U.S. operations in 2015, and lower charges for legal matters. The increase in international income is primarily due to the non-recurrence of a foreign currency loss related to Venezuela partially offset by a charge related to the write-down of HIS net assets to fair value less estimated costs to sell, and higher restructuring charges and certain acquisition-related costs.
[3]	2017 v. 2016––The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower certain asset impairments and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in international income was primarily due to the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower restructuring charges and certain acquisition-related costs, and lower certain asset impairments.
[4]	Income from continuing operations before provision/(benefit) for taxes on income. IH’s earnings in 2017 include dividend income of $266 million from our investment in ViiV. For additional information, see Note 4.
[5]	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
[6]	Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017, Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $165 million and $177 million of costs from Other Business Activities to Corporate in 2016 and 2015, respectively, to conform to the current period presentation.
[7]	For a description, see the “Other Costs and Business Activities” section above.
[8]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $348 million, (ii) charges for certain legal matters of $237 million, (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $55 million, (iv) certain asset impairment charges of $379 million, (v) charges for business and legal entity alignment of $71 million, (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $556 million. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.5 billion, (ii) charges for certain legal matters of $494 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion, (iv) certain asset impairment charges of $1.4 billion, (v) charges for business and legal entity alignment of $261 million, (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $197 million. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million, (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million, (iii) certain asset impairment charges of $787 million, (iv) a charge related to pension settlements of $491 million, (v) charges for business and legal entity alignment of $282 million, (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million. For additional information, see Note 3 and Note 4.

Segment, Geographic and Othe150

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		1 Months Ended		12 Months Ended
		Dec. 31, 2017	Nov. 30, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Segment Reporting Information [Line Items]
Charges for legal matters	[1]			$ 240		$ 510		$ 975
Loss on sale of HIS net assets	[2],[3]			55		1,712		0
Certain asset impairments	[4]			395		1,447		818
Business and legal entity alignment costs	[5]			71		261		282
Loss on early retirement of debt		$ 999	$ 312	999	[6]	312	[6]	0	[6]
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Restructuring charges and implementation costs				348		1,500		584
Charges for legal matters				237		494
Certain asset impairments				379
Business and legal entity alignment costs				71
Loss on early retirement of debt				999		312
Other charges				556		197		332
Certain asset impairments						1,400		787
Alignment costs						261		282
Settlements of pension obligations related to terminated employees								491
Other legal matters, net								968
Venezuela [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Foreign currency loss and inventory impairment								878
HIS [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Loss on sale of HIS net assets				55		1,700
Scenario, Adjustment [Member] | Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Costs reclassified						165		177
ViiV Healthcare Limited [Member] | Innovative Health Segment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Dividend income				$ 266
Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member] | Scenario, Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs reclassified						$ (165)		$ (177)
[1]	In 2017, primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to court approval (for additional information, see Note 17A2), and a $79 million charge to reflect damages awarded by a jury in a patent matter. In 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, 2016 includes a settlement related to a patent matter. In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 and finalized in April 2016 to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws.
[2]	Amounts may not add due to rounding.
[3]	In 2017, represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[4]	In 2017, primarily includes intangible asset impairment charges of $337 million, reflecting (i) $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) $124 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) $39 million related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) $26 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) $20 million related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with EH and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of $43 million for an impairment of our AM-Pharma B.V. long-term investment (see Note 2E).In 2016, primarily includes intangible asset impairment charges of $869 million, reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ($840 million) and IH ($29 million). In addition, 2016 includes an impairment loss of $452 million related to Pfizer’s then 49%-owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40%-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a then recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.In 2015, primarily includes an impairment loss of $463 million related to Pfizer’s then 49%-owned equity-method investment in Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2D) and intangible asset impairment charges of $323 million, reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: EH ($294 million), WRD ($13 million); and Consumer Healthcare ($17 million).The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment.
[5]	Represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[6]	In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in 2016.

Segment, Geographic and Othe151

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 52,546	$ 52,824	$ 48,851
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		26,026	26,369	21,704
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	8,508	9,306	9,714
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	6,612	6,729	6,298
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[4]	$ 11,399	$ 10,420	$ 11,136
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $6.8 billion in 2017, $7.2 billion in 2016 and $7.4 billion in 2015.
[3]	Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.

Segment, Geographic and Othe152

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 52,546	$ 52,824	$ 48,851
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	8,508	9,306	9,714
Euro Member Countries, Euro | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 6,800	$ 7,200	$ 7,400
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $6.8 billion in 2017, $7.2 billion in 2016 and $7.4 billion in 2015.

Segment, Geographic and Othe153

Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail) - USD ($) $ in Millions		Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net		$ 13,865	[1],[2]	$ 13,318	[1],[2]	$ 13,766
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net		6,971		6,649		7,072
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[3]	4,345		4,228		4,376
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[4]	632		643		660
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	[5]	$ 1,917		$ 1,797		$ 1,658
[1]	Amounts may not add due to rounding.
[2]	The increase in total property, plant and equipment is primarily due to capital additions and the impact of foreign exchange, partially offset by depreciation, reductions due to restructuring efforts and disposals.
[3]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.
[4]	Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.
[5]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.

Segment, Geographic and Othe154

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue from External Customer [Line Items]
Revenues	[1]	$ 52,546	$ 52,824	$ 48,851
Innovative Health and Essential Health [Member]
Revenue from External Customer [Line Items]
Revenues		52,546	52,824	48,851
Innovative Health and Essential Health [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	5,065	4,966	4,839
Innovative Health and Essential Health [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,204	1,564	1,708
Innovative Health and Essential Health [Member] | Alliance Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		2,927	1,746	1,312
Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	31,422	29,197	26,758
Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	21,124	23,627	22,094
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		9,684	8,858	7,611
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	4,511	4,165	3,655
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues		2,523	1,713	913
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Chantix Champix [Member]
Revenue from External Customer [Line Items]
Revenues		997	842	671
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	823	1,181	1,297
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues		261	251	232
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		257	258	267
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues		312	447	577
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		6,001	6,071	6,454
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Prevenar Family [Member]
Revenue from External Customer [Line Items]
Revenues		5,601	5,718	6,245
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | FSME-IMMUN/TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		134	114	104
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Other Vaccines Products [Member]
Revenue from External Customer [Line Items]
Revenues		266	239	104
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		6,056	4,563	2,955
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		3,126	2,135	723
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		1,081	1,095	1,120
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		594	561	488
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xtandi Alliance [Member]
Revenue from External Customer [Line Items]
Revenues		590	140	0
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		339	401	430
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		233	167	111
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Other Oncology Products [Member]
Revenue from External Customer [Line Items]
Revenues		93	63	83
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		3,968	3,928	3,918
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Enbrel [Member]
Revenue from External Customer [Line Items]
Revenues		2,452	2,909	3,333
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		1,345	927	523
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Eucrisa [Member]
Revenue from External Customer [Line Items]
Revenues		67	0	0
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		103	93	61
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		2,240	2,369	2,425
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		604	712	752
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | ReFacto AF Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		551	554	533
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		532	579	617
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		254	232	218
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Rare Disease Products [Member]
Revenue from External Customer [Line Items]
Revenues		300	292	306
Consumer Healthcare [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues		3,472	3,407	3,395
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	10,894	11,197	11,745
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		1,915	1,758	1,860
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Premarin Family [Member]
Revenue from External Customer [Line Items]
Revenues		977	1,017	1,018
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		926	962	991
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Xalatan Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		335	363	399
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		297	278	288
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		291	304	374
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Epi Pen [Member]
Revenue from External Customer [Line Items]
Revenues		290	386	339
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zithromax Zmax [Member]
Revenue from External Customer [Line Items]
Revenues		270	272	275
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues		236	323	352
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Xanax/Xanax XR [Member]
Revenue from External Customer [Line Items]
Revenues		225	222	224
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Sildenafil Citrate [Member]
Revenue from External Customer [Line Items]
Revenues		56	0	0
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		5,077	5,313	5,625
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	5,673	6,014	3,944
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		483	450	402
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		471	396	339
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		306	318	335
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		260	274	304
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Precedex [Member]
Revenue from External Customer [Line Items]
Revenues		243	264	76
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Tazosyn / Zosyn [Member]
Revenue from External Customer [Line Items]
Revenues		194	146	144
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		3,715	4,166	2,343
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	3,223	4,220	5,326
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	553	801	1,183
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	382	383	411
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		775	733	830
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		421	590	682
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		303	732	715
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		281	421	883
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		252	285	260
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		257	276	362
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	531	319	63
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues		419	192	30
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues		112	127	33
CentreOne [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	706	718	612
Hospira Infusion Systems [Member] | Essential Health Business [Member] | Essential Health Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	$ 97	$ 1,158	$ 403
[1]	Amounts may not add due to rounding.
[2]	Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3]	Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. Viagra lost exclusivity in the U.S. in December 2017. Beginning in the first quarter of 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through December 2017, will be reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore total Viagra worldwide revenues will be reported in EH from 2018 forward
[4]	The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.
[5]	The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017), and includes all legacy Hospira commercial operations.
[6]	Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above.
[7]	Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).
[8]	Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. Beginning in the first quarter of 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through December 2017, will be reported in EH. Therefore total Viagra worldwide revenues will be reported in EH from 2018 forward. See note (c) above.
[9]	Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
[10]	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc.
[11]	HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.